HEALTH

Per informazioni: Valentina Tegas tegas@apre.it

Reference n.: **HEALTH-PT-SMCP-1**

Deadline: **18/09/2007**

Programme: **COOPERATION- HEALTH**

Project Title: New express method of diagnostics of preeclampsia

Financial Scheme:

Description: Priorities' Main Research Areas:

Development of the new express method of diagnostics of preeclampsia on the basis of the platelets ability to the trypsin-induced aggregation.
The problem of preeclampsia is one of the most important in obstetrics. Preeclampsia develops after 20-th week of pregnancy and is the frequent reason of maternal and perinatal mortality. For improvement of antenatal and postnatal medical help, development of effective ways of preeclampsia diagnostics is of high importance. Because of the preeclampsia development connected with damages of a hemostasis and aggregative activity of platelets, creation of a new express method of diagnostics of this pathology on the basis of an estimation of aggregative activity of platelets under the action of activators can become perspective.
Using the standard stimuli of aggregation (ADP, adrenaline, arachidonic acid) for the diagnostic purposes is not advisable because of the absence of correlation between its possibility to induce the aggregation of platelets and preeclampsia. Possibility of using the serine protease trypsin in low concentration (1 – 50 mkg/ml) as stimuli of platelets aggregation for diagnostic of preeclampsia was shown in the Institute of biophysics and cell engineering of National academy of sciences of Belarus. As the preliminary results, the trypsin-induced aggregation of platelets of healthy pregnant women is characterized by parameters close to those of donors. Development of preeclampsia is linked to essential decrease in a degree and speed of the trypsin-induced aggregation of platelets. However the trypsin-induced aggregation of platelets at preeclampsia in details are not studied. The reasons of decreased ability of platelets to aggregate under the action of trypsin in low concentration are also not elucidated.
The purpose of the project is creation of a new express method of diagnostics of preeclampsia. The method will be based on measurement by means of automated aggregometer (after the manner of АР 2110 «SOLAR», Belarus) kinetics of trypsin-induced aggregation and subsequent definition of its parameters (degree, speed). It is supposed, that on the basis of the analysis of kinetic parameters of the trypsin-induced aggregation of platelets, statement of the preeclampsia and definition of its degree will be carried out. For achievement of an object it is planned to analyse the process of the trypsin-induced aggregation of platelets of women with normal pregnancy (1), risk factors of preeclampsia (2), preeclampsia without clinical displays (3), preeclampsia with clinical displays (4). The opportunity to use the other serine proteases – thrombin and a-chymotrypsin as stimulus of platelets aggregation for diagnostics of preeclampsia as will be studied.
With the purpose of elucidation of the mechanisms of aggregative activity of platelets at preeclampsia disturbance, it is planned to study by means of tryptophan phosphorescence at a room temperature method the structural and dynamic condition of membrane proteins of platelets of women with normal pregnancy (1), risk factors of preeclampsia (2), preeclampsia without clinical displays (3), preeclampsia with clinical displays (4). Carrying out of such researches expediently, considering importance of a membrane proteins in realization of functional activity of cells in norm and pathology.
Researches in the frame of the project will be carried out in Institute of biophysics and cell engineering of National academy of sciences of Belarus together with obstetrics department of the Belarus state medical university (Minsk). There are highly skilled experts and the corresponding equipment, necessary for successful performance of the work.

For the project objects achievement it is necessary to elucidate the mechanisms of decrease in ability of platelets to the trypsin-induced aggregation at preeclampsia. Such researches could be spent in directions of the analysis of damage at preeclampsia proteomic (1) and genomic (2) statuses of platelets, elucidation of biochemical (3) and morphological (4) changes of platelets, researches of shifts specificity occurring in platelets (5), studying of interrelation between damage of aggregative activity of platelets and clinical displays of preeclampsia (6).

Workprogramme Topic :

FP7 HEALTH
HEALTH-2007-3.5-4

Project description :

Development of a new express method of diagnostics of preeclampsia on the basis of the ability of platelets to the aggregation, induced by trypsin in low concentration.

Keywords:
Preeclampsia, aggregation, platelets, trypsin, diagnostics/

Organisation Type: Centro di Ricerca

Partner Sought: Profile of Partner sought:

Role
x technology development
x research
x training
x dissemination

Country /region:
Any country

Start of partnership:
x start-up phase
x mid-term

Reference n.: **HEALTH-PT-SMCP-2**

Deadline: **18/09/2007**

Programme:

Project Title: Alzheimer - AD pathophysiological mechanisms, early diagnosis & novel therapeutic strategies

Financial Scheme:

Description: Status:
planned for submission

Call references:
FP7-HEALTH-2007-B.

Priorities' Main Research Areas: 2.2.1. Brain and brain-related diseases

Workprogramme Topic:
2.2.1-7: Restorative approaches for therapy of neurodegenerative diseases

Project description:
Providing fundamental knowledge on pathophysiological mechanisms of AD, developing MRI-based methodologies for early diagnosis of AD, developing novel therapeutic strategies, demonstrating the ability of metal-chelators-cyclic peptide conjugates and nanoparticles bearing b-sheet breakers to cross the BBB, evaluating the efficacy of the novel therapeutic agents in protecting neuron cells from neurodegenerative damages using selected cells and various animal models.

Keywords:
brain plasticity, animal models, neurodegenerative diseases, MRI, toxicology

Organisation Type: Altro

Partner Sought: Profile of Partner sought:

Role: technology development, research

Start of partnership: mid-term

Expertise required: brain plasticity, animal models, neurodegenerative diseases, MRI expert, toxicology

Reference n.: **HEALTH-PT-SMCP-3**

Deadline: **18/09/2007**

Programme:

Project Title: Obesity - Alternative novel Te-based organic compounds towards the treatment and/or prevention of obesity

Financial Scheme:

Description: Status: planned for submission

Call references: FP7-HEALTH-2007-B

Priorities' Main Research Areas: 2.4.3. Diabetes and obesity

Workprogramme Topic: HEALTH-2007-2.4.3-6: Nutritional signals and the development of new diabetes/obesity therapeutic agents

Project description: Development of novel oral therapeutics based on Tellurium alternative Compounds. The mechanism of action of these compounds related to modifying body weight. These small alternative tellurium compounds will be tested in vivo for both their affect on delaying and preventing genetically and diet-induced obesity.
Assessment of the Toxicology and Pharmacokinetics of the Tellurium alternative Compounds following oral administration.

Keywords: Obesity, modifying body weight, animal model, toxicology, formulation, SAR, QSAR, Pharmacokinetics, Safety

Organisation Type: Altro

Partner Sought: Role: research

Start of partnership: mid-term

Expertise required: mechanism of action in Obesity, modifying body weight, animal model, toxicology, formulation, SAR, QSAR, Pharmacokinetics, Safety of oral

Reference n.: **HEALTH-PT-SMCP-4**

Deadline: **18/09/2007**

Programme:

Project Title: EasyPark - Novel non invasive oral therapeutic approach development for Parkinson’s disease treatment based on the mechanism of brain repair study, e.g. dopaminergic effects

Financial Scheme:

Description: Status: planned for submission

Call references: FP7-HEALTH-2007-B

Priorities’ Main Research Areas: 2.2.1. Brain and brain-related diseases

Workprogramme Topic: 2.2.1-7: Restorative approaches for therapy of neurodegenerative diseases

Project description: Development of non invasive oral therapeutic approach for Parkinson’s disease treatment based on an intensive study of the mechanism of brain repair in this neurodegenerative disease. The new therapeutics will be based on Tellurium Compounds which supposed to be protective and also restorative to dopaminergic neurons
Keywords: neurodegenerative disease, imaging techniques, PET, SPECT, animal model, toxicology, formulation, SAR, QSAR

Organisation Type: Altro

Partner Sought: Role: technology development

Start of partnership: mid-term

Expertise required: neurodegenerative disease, imaging techniques, PET or SPECT, animal models for PD, toxicology, formulation, SAR, QSAR, evaluation of Safety in animal models

Per informazioni: Valentina Tegas *tegas@apre.it*

Reference n.: **HEALTH-EU-LCP-5**

Deadline: **18/09/2007**

Programme: COOPEARATION

Project Title: TIBODI: TIck-BOrne DIseases

Description: Goals of the Project:

So we could prevent the tick-borne quenches and chronic inflammatory diseases and we could prevent them with entomopathogenic fungi there is a need for further researches to make sure it is harmless, and to choose the correct formula and to choose the storegment. There is a need to emphasise the efficiency of the product, and further experiments on field and also we have to try out the entomopathogenic fungi on larger surfaces. Supporting of such researching methods that helps to show the infection right after the tick bite. Also to handel the already existing chronic inflammatory diseases spread by tick, and to heal with much more efficient methods.

Term of the research: 60 months

General Information about the Project:

According to the topic (HEALTH-2007-2.4.5-12) the Project has to contain the new possibilities of the prevention of chronic inflammatory diseases.
We worked out a method to prevent tick born diseases. The Method: there are many fungis that are entomopathogenic which kills insects, sometimes do it like an epidemic. During a 10 year old process we could develop such a technology with the help of entomopathogenic fungi which can wipe out totally or rarefy them significantly in 7-14 days at their living place without hurting the environment.
In the other part of the Project our goal is to improve methods to show the presence of tick born diseases and also to review the effective treatments of those that are already affected.

Organisation Type: Impresa

Partner Sought: We are looking for partners for such duties:

We are looking for such researching groups (immunologists, cell biologists, molecular biologists, bioinformaticians) from member countries or joined countries who are researching the new way handling of tick-borne chronic inflammatory diseases. Or has any information about how to show the appearance fo the disease.

1. Bacteria:

- Lyme- Borreliosis
- Febris Recurrens
- Leptospirosis (Reaping fever)
- Q fever
- Rickettsiosis
- Tularemia

2. Parasite:

- Babesiosis
- Ehrlichiosis

3. Virus:

- Tick-Encephalitis
- Louping Ill

Per informazioni: Valentina Tegas *tegas@apre.it*

Reference n.: **HEALTH-EU-LCP-6**

Deadline: **18/09/2007**

Programme: **HEALTH**

Project Title: MOODEST- Mood Disorders European Study. Genetic vulnerability and environmental effects in pathogenesis and pharmacotherapy of mood disorders.

Financial Scheme:

Description: The scientific objectives of the project are

- The assessment of gene-environment interactions in the pathogenesis of mood disorders using new animal models, the genome wide association approach, endophentoypes and imaging genetics
- The identification of psychosocial and neurobiological surrogate markers for major depression and for prediction of antidepressant treatment outcome
- The assessment of functional and structural alterations in neuronal activation patterns and brain connectivity in depressed patients using neuroimaging
- The integration of molecular, preclinical and clinical data to a comprehensive pathophysiological perspective on mood disorders and antidepressant treatment outcome.

TOPIC:

- HEALTH-2007-2.2.1-8: From mood disorders to experimental models.

Organisation Type: Università>

Partner Sought: Role:
- research

Country /region:
- Europe

Start of partnership:
- start-up phase

Expertise required:
- Bioinformatics; integration of large scale data (neuroimaging, genetics, biomarkers)

Per informazioni: Valentina Tegas tegas@apre.it

Reference n.: **HEALTH-EU-SMCP-9**

Deadline: **18/09/2007**

Programme: **COOPERATION**

Project Title: **Cardiac malformations in CHD.**

Financial Scheme:

Description: Cardiac malformations in CHD remain a major public health problem despite the dramatic advances that have been made in surgical repair, and they account for a large proportion of the infant mortality rate. Nonetheless, the molecular causes are unknown. Since 2001, I serve as principal investigator to a project in pursuit of molecular mechanisms leading to cardiac malformations. We are interested in broader investigations in the interplay between cardiac transcription components, mutations, somatic hypermutability and environmental factors in CHD.
We have investigated in the past a panel of cardiac-specific transcription factor genes in a rare collection of hearts from patients with complex malformations, including 31 hearts with HLHS. Most of these patients died at birth or early infancy. Sequence analysis revealed mutations in diseased tissues, which were absent in matched normal heart samples. Common occurring mutations were identified, especially in the binding domains of transcription factors, which could affect DNA-protein or protein-protein interactions leading to CHD. While certain transcription factor genes (NKX2-5, GATA4) exhibited a high rate of mutations, others were not affected (HEY2, MEF2C). Results of these studies enabled us to put forward a hypothesis of somatic mutations as a novel molecular cause of CHD.
Through a collaborative study that utilized a yeast-based system to address human transcription factors, we established that many of the individual mutations altered transcription from specific human target sequences. Although the pattern of mutations is unusual, we propose environmental exposures to industrial chemicals as likely culprits, to result in hypermutability of cardiac transcription factor genes.
I have also been involved in heart-related studies pertaining to cardiac function and physiology, and have 25 PUBMED cited publications credited to my name in this area of research. Notably, among these studies were those published in the Lancet, the FASEB Journal, Circulation Research, and Molecular Pharmacology.
Furthermore, a key member in my department, Dr. Stella Marie Reamon-Buettner, leads a group of technicians and students in the lab in pursuit of understanding the molecular causes of CHD.
Equipment: Aside from those technology platform pertaining to genomics and proteomics studies described above, we are well-equipped to undertake genetic and/or epigenetic analysis including cell-based notably yeast-based assays to determine effects of sequence alterations on transcriptional activities, DNA-protein and protein-protein interactions. Detection or confirmation of genetic alterations can be carried out through Affymetrix microarray systems (e.g. GeneChip® Mapping 100K Set), denaturing high-performance liquid chromatography (dHPLC, Transgenomic), Applied Biosystems 3100 capillary genetic analyzer, Taq Man assays (Applied Biosystems 7500), fluorescence resonance energy transfer (FRET, Light Cycler), and PCR-RFLP assays. Furthermore, comparative sequencing analysis can be undertaken by the following softwares: Lasergene 7.0, Vector NTI 10, and SeqScape 2.0.

TOPIC: Health-2007-2.4.2-4 Congenital pathologies affecting the heart

Organisation Type: Centro di Ricerca

Partner Sought: Keywords specifying your expertise:
molecular mechanisms in cardiac malformations, yeast-based functional assays, molecular markers, DNA diagnostic assays.

Expected Commitment: research
Country /region: Germany, Italy, UK, Belgium

Per informazioni: Valentina Tegas -tegas@apre.it

Riferimento: HEALTH-EU-LCP-3

Data Scadenza: **19/09/2007**

Programma: **HEALTH**

Titolo: Early processes in the pathogenesis of chronic inflammatory diseases

Tipo Progetto: Large Scale integrating collaborative project>

Descrizione: Priorities' Main Research Areas:
-2.4.5. Other chronic diseases
The focus will be on non-lethal diseases with a high impact on the quality of life at old age such as functional and sensory impairment and other chronic diseases (e.g. arthritis, rheumatic and musculo-skeletal diseases and respiratory diseases including those induced by allergies). Expected impact: Collaborative research in this area will develop improved diagnostics and/or intervention strategies with the expected impact of delaying the onset of chronic diseases and improving quality of life.

Workprogramme Topic (according to each priority workprogramme):
-HEALTH-2007-2.4.5-12:
Early processes in the pathogenesis of chronic inflammatory diseases. Translational research to obtain mechanistic insights into the early processes underlying chronic inflammatory diseases, such as asthma, rheumatoid arthritis and autoimmune conditions. Emphasis should be placed on identifying and validating molecular networks involved in the establishment and persistence of the chronic nflammatory reaction, with the aim of developing novel and specific anti-inflammatory treatments. A multidisciplinary approach (immunologists, cell biologists, molecular biologists, bioinformaticians) and the use of animal models amenable to genetic testing and manipulation are required. Funding scheme:
Collaborative project (Large-scale integrating project).

Project description:
Chronic immune-mediated diseases constitute a group of non-lethal disorders that have high impact on life quality. Allergic and autoimmune diseases manifested as chronic inflammation are progressive and can lead to end organ damage. It is, therefore, important to elucidate the mechanisms early in disease pathogenesis of chronic inflammatory conditions before irreversible tissue and organ destruction ensues.

Our aims have been to investigate the factors governing the initiation and perpetuation of allergic asthma. Afflicted individuals have intermittent and recurrent or chronic-unremitting exacerbations of asthma associated with allergen exposure. These exacerbations progressively destroy the respiratory tract, leaving individuals in their later years chronically disabled. We have established mouse models of allergic asthma in which the focus is on acute-remission-exacerbation phases of disease. We discovered that mice recovered from an initial acute episode of allergic asthma harbor memory CD4+ Th2 lymphocytes within lung infiltrates for their lifetime. These pathogenic cells respond rapidly to allergen exposure and induce disease exacerbation. We hypothesize that lung Th2 memory lymphocytes play a central role in the initiation and perpetuation of exacerbations of allergic asthma and propose to further explore this central hypothesis and build upon our results thus far on the involvement of memory Th2 cells in the lung during remission, allergen-induced exacerbation, during resolution of active inflammation, and unrelenting chronic inflammation. Our goals for this project are to identify and validate molecular networks that define early disease pathogenesis before persistent, chronic inflammation causes irreversible tissue damage and reduced life quality as well as the development of novel and specific anti-inflammatory treatments for allergic asthma.
Allergic asthma constitutes just one of many chronic inflammatory disorders that are connected to one another by overzealous immune reactions to harmless antigens. We would like to include partners in this project who study chronic immune-mediated inflammatory diseases with the intention of discovering basic mechanisms underlying

and linking dysfunctional chronic immune-inflammatory responses in a variety of diseases.

KEYWORDS: chronic inflammation, allergy, asthma, autoimmunity

Tipo Ente: Università>

Partner richiesto: Role:
technology development, research, dissemination

Country /region:
member and associated states

Expertise required:
We are looking for immunologists, cell biologists, molecular biologists, bioinformaticians, and scientists who use of animal models amenable to genetic testing and manipulation and who are involved with studies in chronic inflammation, allergy, and autoimmunity.

Per informazioni: Valentina Tegas -tegas@apre.it>

Riferimento: HEALTH-EU-LCP-2

Data Scadenza: **18/09/2007**

Programma: HEALTH

Titolo: Etiopathology of hepatic encephalopathy: behavioural, neuroendocrine, and immune interrelations

Tipo Progetto: Large Scale integrating collaborative project

Descrizione: Inflammatory chemical mediators play a key role in the development of hepatic insufficency and associated encephalopathy. However, the complex interactions among neural, immune and endocrine factors leading to systemic inflammation involved in the neurological, endocrine and immune alterations typical of hepatic encephalopathy are not well known. Using different animal models of hepatic insufficency we aim to characterize in detail the early pathophysiological changes leading to mininum hepatic encephalopathy. We also expect to develop specific behavioural and neuropsychological tests to diagnose and characterize the early manifestations of hepatic encephalopathy in human patients.

KEYWORDS:
inflammation, liver cirrhosis, hepatic insufficiency, portal hypertension, minimum hepatic encephalopathy, animal models, chemokines, neuroendocrine system, immune system, digestive system, behaviour, brain function, neuropsychological tests
topic : HEALTH-2.4.5-12

Tipo Ente: Università

Partner richiesto: Partners already involved:
Maybe two research centres from London and Italy and two companies from Spain (in converstations).

PARTNER SOUGHT
Role of partner technology development:
research , training, Dissemination, demonstration.
Any Country.

Type of organisation:
Industria, PMI, Università.

Per informazioni: Valentina Tegas - tegas@apre.it

Riferimento: HEALTH-PT-LCP-1

Data Scadenza: **18/09/2007**

Programma: **HEALTH**

Titolo: Impact of tumor hypoxia on bone marrow microenvironment and the development of minimal residual disease in patients with gastric and pancreatic cancer

Descrizione: Idea:
to test the hypothesis that hypoxia-associated signal pathway in primary tumor are the key factors in the malignant progression, in particular by the modification of bone marrow function that results in “premetastatic niche” formation.

Aim: to evaluate the impact of hypoxia-associated microenvironment of primary tumor and bone marrow on the development of minimal residual disease and create the test-system for prognosis of clinical outcome.

Methods: biochemical, molecular-biological, immunocyto- and immunohistochemical methods (zymography, western-blotting, RT-PCR, etc.), FACs, NMR spectroscopy.

Milestones:
– influence of hypoxia and hypoxia-regulated proteins on the appearance of tumor cells in bone marrow and lymphatic nodes;
– relationship between VEGFR-1 (Flt-1) expression, MMP-2 and -9 activity in bone marrow mononuclears, and their phospholipide composition and hypoxia-associated events in primary tumor;
– basis for the escape of disseminated tumor cell of the cytotoxic action of lymphocytes, in particular memory T-cells;
– hypoxia-associated molecular characteristics of bone marrow and primary tumor cells that their impact on the appearance and behavior of disseminated tumor cells;
- prognostic factors for the evaluation of risk development of minimal residual disease.

Expected results:
1. The mechanisms of impact of hypoxia-associated molecular profile of primary tumor and bone marrow microenvironment on the development of minimal residual disease will be clarified.
2. The potential biomarkers for detection of risk of minimal residual disease development will be proposed for the application in Ukrainian as well as European hospitals and clinics.

HEALTH-2007-B-2.4.1-12: Translating the hypoxic tumour microenvironment.

Tipo Ente: Centro di Ricerca

Partner richiesto: Key words: tumor, bone marrow, hypoxia, microenvironment, metastasis, prognosis.

Reference n.: **HEALTH-PT-LCP-3**

Deadline: **18/09/2007**

Programme: **COOPERATION**

Project Title: The study of extrinsic embryonic and mesenchymal stem cells transplantation into Rheumatoid arthritis joints of experimental animals under model conditions to elaborate the new approaches for the treatment of model disease

Financial Scheme:

Description: Priorities' Main Research Areas:
(Topics from Workprogramme) Regenerative medicine. Health-2007-1.4.-6:
Stem cells lines for cell-based therapies on knowledge and technologies in the field of Life sciences, genomics and biotechnology of health, focussing on the recent advances in mesenchymal stem cell (MSC) research, gene transfer and tissue engineering for the treatment of connective tissue diseases.

Idea of the project

Background:
Propose is to develop new knowledge, new technology, new products (stem cells) through research activities. Study will be conducted using embrionic stem cells (ESCs) and mesenchimal stem cells (MSCs) obtained or produced in the IBCENASB for Rheumatoid arthritis (RA).
RA is a chronic system inflammatory disease of connective tissues with predominant destructive-erosive affection. At present, many facts indicate that RA is a disease with disordered motor functions resulting very often in death. Statistics data show that mortality rates are increased with simultaneous decreasing in average life interval of RA patients by 10-15 years. It clearly means that this disease is dangerous for life. RA is associated with changes in humoral (rheumatoid factor) and cellular immunities. This is accompanied by active synoviacyte proliferation comparable with that of malignant cells. The assessment of functional state of locomotor apparatus is an important diagnostic criterion of RA severity.
The intra-articular inflammation in RA is induced and supported by a number of cytokines such as IL-1, TNF, IL-6, TGF-β etc. These factors are known to be crucial for the regulation of proliferation activity of stem cells. Besides, they provide cell viability and keep the cell in "stemness" state. They themselves exert a pathologic action on the cell component of joints when joint inflammation is induced.
In the frame of the Health-2007-1.4.-6 the following experiment will be done:
1. study of the influence of the growth factors such as LIF, SCF, or L-6 and their combinations with the TGF-β on growth, proliferation, colony formation, vital capacity of MSCs obtained or produced in the IBCENASB;
2. creation the RA model in mice and rats;
3. evaluate the state of locomotor apparatus and the expression level of inflammatory process in model animals;
4. characterize the structural and metabolic states of the cells of the immune system;
5. analysis of the regulatory action of cytokines on the maintenance of pluripotency of MSCs ex vivo;
6. study of the influence of MSC transplantation on the development of RA;
7. analysis of the efficacy of cellular therapy using .
This work is in HEALTH framework in order to elaborate the approaches for the treatment of RA under the model conditions using MSCs that can be useful for therapeutic intervention in human.
The IBCENASB role consists in obtaining the new data on the influence of various inductors such as LIF, SCF, and IL-6 in combination with TGF-β on growth, proliferation, formation of colony, and also intrinsic growth factors (LIF) using RT-PCR, and vital capacity of MSCs. The objectives of IBCENASB proposal – to elaborate the methods of MSC utilization for arthritis treatment. The importance of IBCENASB contribution is to establish of relationship between local joint inflammation and system inflammatory process in organism and also with the structure-function changes in the cells of immune system.
The proposed investigations will be performed using RA model that provides for the complementarity between original participants and IBCENASB.
Development of experimental RA model.

RA can be induced by the injection of Freund’s complete adjuvant (FCA) containing heat-inactivated Mycobacterium tuberculosis. Two groups of experimental animals will be investigated. Evaluation of inflammatory process expression during the experimental RA will be done using different determinations as follows:
1. serum acid glycoproteins;
2. serum TNF;
3. C-reactive protein (CPR);
4. content of tyrosine-containing and hydrophobic peptides in serum and synovia;
5. biophysical parameters of synovia;
6. ROS under lipid peroxidation and activity of phospholipases in synovia.

Evaluation of functional state of locomotor apparatus in experimental animals.
This study includes elucidation of presence of osteoporosis, constriction of joint slit, degree of joint erosion. Progression of adjuvant arthritis will be clinically evaluated for their characteristic signs and symptoms by employing an arthritis score. Besides, the pigmentation of skin in joint region will be tested by luminescence method and evaluation of joint morphology will be done using light microscopy. For that, tissue sections on the glass slides stained with hematoxilin and eosin will be prepared.
Characterization of metabolic state of immune system.
Adjuvant arthritis is a typical autoimmune disease accompanied by the disturbance of T-cell immunity. Therefore, the analysis of their immune status including energy cell status, structure-function state of membranes, parameters of antioxidant system gives a valuable information on the expression of inflammatory process.
Analysis of regulatory influence of cytokines on MSC development ex vivo.
The experiments will pursue the following objectives:
1. To select the conditions for the cultivation of GENOSTEM MSCs in presence of regulatory growth factors such as LIF, SCF or IL-3, TGF-β; the determination of optimal cell/factor ratio in cultural medium. Collection of MSC biomass for analysis of proliferation potential of the cells, determination of their spectroscopic and microscopic parameters.
The determine the dose and time course dependencies of apoptosis manifestation of MSCs in presence of growth factors (LIF, SCF, IL-6).
The study of influence of MSC transplantation into RA damaged knee-joints of experimental animals under model conditions. The efficiency of MSC therapy.
The experiments will include: the determination of expression of inflammatory process (Task 2); the evaluation of the state of the locomotor apparatus; the characterization of the metabolic state of the cells of immune system.

Keywords:
Rheumatoid arthritis, chronic system inflammatory diseases, cytokines, growth factors, in mesenchymal stem cells, tissue engineering.

Organization Type: Centro di Ricerca

Partner Sought: Commitment/Work to be offered:
The given project will be performed in our Laboratories by the research team consisting of biochemists, biophysicists, morphologists, cytologists under supervision of the director of our Institute. We are a leading research organisation in Belarus in the field of biophysics, proteomics, and genomics of cells including stem cells. This Institute is known by virtue of its researches on structure and dynamics of cellular membranes under the action of regulatory molecules (hormones, lectines, secondary messengers etc.). It has also experience in cell researches under pathological processes in organism (rheumatoid arthritis, disseminated sclerosis, lupus erythromatosis, cancer, etc.).

Profile of Partner Sought

Role:
technology development; research; training; dissemination; demonstration.
Country /region: - All country

Start of partnership
- start-up phase

Expertise required:
Molecular genetic field specially for congenital heart disease
Epidemiologist interested in the field of pediatric cardiology

Per informazioni: Valentina Tegas - *tegas@apre.it*

Riferimento: HEALTH-EU-SMCP-5

Data Scadenza: **18/09/2007**

Programma: **HEALTH**

Titolo: Thalassaemia

Tipo Progetto:

Descrizione: For this project we will develop Thalassaemia panels (i.e. Haemoglobinopathies) matching the ethnicities of the populations within the EU.

Main Research Topics :
HEALTH-2007-1.2-6: High-throughput molecular diagnostics in individual patients for genetic diseases with heterogeneous clinical presentation.

Keywords:
Thalassaemia, Haemoglobinopathies, SNPs, molecular diagnostics.>

Tipo Ente: Università>

Partner richiesto: Role of Partner sought:

Research, dissemination, demonstration,
other : sales/distribution.

Expertise required :
Understanding of molecular genetics, molecular diagnostic market and preventative medicine, ability to influence key opinion formers,

Per informazioni: Valentina Tegas *tegas@apre.it*

Reference n.: **HEALTH-EU-SMCP-8**

Deadline: **18/09/2007**

Programme: **COOPERATION- HEALTH**

Project Title: Sociocultural determinants in childhood obesity

Financial Scheme:

Description: Priorities' Main Research Areas:
nutrition, macro and micronutrient, obesity, rare diseases phenilcetonuria

Project description:
Obesity is one of the major treath in Europe. More and more children are becoming overweight. We intend to develop a study to identify the factors which are acting as risk factors in developing overweight. We will evaluate the impact and the effectivness of different prevention programs developed in different countries across Europe

Keywords:
obesity, childhood, socio-cultural determinants

Research topics:
- HEALTH-2007-3.3-1: Promoting healthy behaviour in children and adolescents.
- HEALTH-2007-3.3-3: Public health interventions addressing the abuse of alcohol.

Organisation Type: Centro di Ricerca>

Partner Sought: Profile of SME sought

Role:
research, training, dissemination

Country /region:
Romania

Start of partnership:
start-up phase

Expertise required:
epidemiology, qualitative studies (focus group discussions, Delphy method, in depth interviews) surveys, statistics,

Reference n.: **HEALTH-EU-SMCP-11**

Deadline: **18/09/2007**

Programme:

Project Title: De Autism in Fragile X: Microarray Identification of FMRP Associated Mrnas and Altered Profiles Related With Methylation Status of FMR1 Gene

Financial Scheme:

Description: Work Programme Topic: 2.2.1-10 Childhood and adolescent mental disorders (SICA)

Aim: A number of clinical features including epilepsy, MR, hypersensitivity to tactile stimuli, social deficits, and even loose stools have been hypothesized to be related to enhanced mGluR5 activity and LTD in FXS. This is important for clinicians to understand because these findings have direct therapeutic implications. Both mGluR5 antagonists and ampakines that stimulate the AMPA receptors are in investigational stages of development and they have potential to be specific treatments for FXS in the future. Both the genetic and the neural properties of FXS point out the importance of considering the network level, not just the level of individual genes or individual neurons.
Although FXS is in one sense a single-gene disorder, it is more proximally the result of disruption in regulatory networks via the many genes whose transcripts FMRP binds, and probably in many cellular processes. This very complexity is what gives FXS the power to disrupt brain development.
Similarly, as a single-gene disorder whose analysis illuminates networks of interacting genes and networks of interacting neurons, FXS opens for us a route to understanding the complexity of autistic development and a possibility of producing targeted therapies.
Recent reported data suggested that elevated FMR1 mRNA, but not CGG repeat size or reduced FMRP (as measured by immunocytochemistry), was significantly associated with increased autistic development such as the other psychological symptoms in Fragile X syndrome. In this project, it was aimed to draw a profile of mRNAs that are previously reported as selectively associated with FMRP-mRNP complexes to identify a subset of FMRP associated messages that play role in autism.

Organisation Type: Università

Partner Sought: Partners are welcome from all EU, Eastern Europe, Western Balkans and Central Asia (SICA)

- Experienced in applications of microoarray and molecular genetics.

OR

- Experienced in bioinformatics, population genetics, and microarray data analysis

OR

- Clinicians (pediatric neurologist, neurologist, pediatric psychiatrist or psychologist) experienced in clinical practices of mental retardation and autism developmental disorder in children with high patient circulation having these criteria.

Per informazioni: Valentina Tegas *tegas@apre.it*

Reference n.: **HEALTH-EU-SMCP-10**

Deadline: **18/09/2007**

Programme: **COOPERATION**

Project Title: REACTIVATION: Stem cell stimulation by endogenous activation

Financial Scheme:

Description: Priorities' Main Research Areas Molecular mechanisms guiding cardiomyogenesis Differentiation of embryonic stem cell sto cardiomyocytes
Charactersiation of somatic stem cells of the heart Development of cell free and serum free culture conditions for somatic stem cells.
Project description
Somatic stem cells are supposed to reside dormant in the tissue. We propose to identify cardiac progenitor and stem cells, their niches and to study the cellular and molecular conditions of these niches in tissues of different species and in embryonic stem cell derived embryoid bodies.
Defining parameters allowing maintaining the pluripotent phenotype of stem cells, their self renewal capacity and their potential to differentiate will lead to a better understanding of developmental processes during embryogenesis and the molecular foundation of pathology and ageing related phenomenon in stem cell maintenance and depletion in various tissues.

Keywords:
somatic and embryonic stem cells, progenitor cells, growth factors, transcription factors, maintenance, differentiation and dedifferentiation

TOPIC:
HEALTH-2007-1.4-7: Development of stem cell culture conditions.

Organisation Type: Università

Partner Sought: Role technology development, research, demonstration

Country /region
entire EU

Start of partnership
start-up phase

Expertise required
Provision and development of cell free culture substrates for embryonic and somatic stem cells of the heart.
Development of new culture subtrates based on existing basic science results provided by the academic partners.
Development and provision of serum free culture media for embryonic and somatic stem cells of the heart.
Development of new culture aditives based on existing basic science results provided by the academic partners.

We need as partner a SME developing cell free substrates for the culture of somatic and embryonic stem cells aiming at the in vitro maintenance of cardioblasts, cardiac progenitor cells or somatic stem cells of the adult myocardium. We can provide candidate substrates and growth factors for cardiac stem cells which might be explored towards patenting and commercial exploitation.

Per informazioni: Valentina Tegas *tegas@apre.it*

Riferimento: HEALTH-EU-LCP-4

Data Scadenza: **10/09/2007**

Programma: **HEALTH**

Titolo: Enzymes CYP2E1 (P450)

Tipo Progetto: Collaborative Project (Large-Scale integrating project)

Descrizione: Research Thematic line: HEALTH-2007-1.2-5

The studied enzymes are CYP2E1 (P450) which is the cause of bioactivation of certain drugs and membrane bound glutathione transferase which can protect from toxic chemicals and oxidative stress by its glutathione transferase or peroxidase activity. We seek to contribute the role of reactive intermediates generated by CYP2E1 as a possible regulator of glutathione transferase activity by developing a biosensor to study drug interactions. We are able to conduct research involving biomimetic,
reconstitution of membranous protein and interaction of biomolecules with inorganic surfaces. Our group comprises researchers with different background (such as biochemistry, biology and nanotechnology).

Tipo Ente: Università

Partner richiesto: Our group is looking for a partner organization (research institution or SME can qualify) to jointly write a proposal for a Cooperation Programme, in the context of the FP7 framework who have expertise in the field of biochemical toxicology of reactive oxygen species (ROS) with a focus on

Expertise Required:
Biochemistry/biophysics of free radicals (electron paramagnetic resonance), NMR, antioxidant, oxidative stress, protein oxidation and oxidative damage, purification of membranous protein. the enzymology of membrane proteins.

Partner Profile Form
7th Framework Programme (2007-2013)
Health Theme of the Specific Programme *Cooperation*

Date : yyyy mm dd

Note for attention: further details on the Partner Profile Form (PPF) can be found in the Topic PPF_FP7_T1.8 (page 4/4).

PPF_FP7_T1.1 Details of the organization and of the main researcher					
Contact person details					
Name, Title	Nuno Pereira Leite, Survey Engineer			Gender (M/F):	Male
Tel.:	+351 212945900	Fax.	+351212945999	E-mail:	nuno.leite@edisoft.pt
Personnel website:	http://www.edisoft.pt				
Organization/Research Group details					
Name:	EDISOFT S.A.				
Street name and number:	Rua Quinta dos Medronheiros - Apartado 382 Monte de Caparica Lazarim				
City, Postal address:	2826-801 Caparica	P.O Box		Country	Portugal
Website					
Organization activity type[1]	☐ HES	☒ IND	☐ REC	☐ N/A	☐ OTH _____
Organization legal status type	☐ Public	☒ Private	☐ Non-profit	☐ OTH _____	

PPF_FP7_T1.2 Personal profile and work history of the research group/organization (brief description - max 12 lines)
EDISOFT is With 20 years of Experience, EDISOFT belongs in equal shares of 30% to Empordef, NAV and Thales, with the remaining 10% belonging to the Co-founders. EDISOFT has gained a wide recognition for the excellence of its services, namely regarding software design, development, integration and maintenance. EDISOFT is the leading Portuguese company in the domains of integrated system solutions for Defense, Collective Security, Space and Location Intelligence. Thus going beyond the state-of-the-art in these sensitive areas as well as on interoperability, network enabled capabilities and environmental monitoring systems that uphold the network-based paradigm. EDISOFT provides specialized know-how, innovative technology, integrates open systems and standards, commercial-off-the-shelf applications, certified and standardized processes and protocols. EDISOFT has been working on a permanent basis with international organizations such as European Commission, NATO, European Defense Agency, European Space Agency, Joint Research Centre and European Meteorology Agency.

[1] **Organization activity type (fill all that apply): HES** - Higher Education (i. e. organisations only or mainly established for higher education/training, e. g. universities, colleges); **IND** - Industry (i. e. industrial organisations private and public, both manufacturing and industrial services such as industrial software, design, control, repair, maintenance); **REC** – Research organization (i. e. "research organisation" means a legal entity established as a non-profit organisation which carries out research or technological development as one of its main objectives); **OTH –** Others; **N/A** – Undefined.

Partner Profile Form
7th Framework Programme (2007-2013)
Health Theme of the Specific Programme *Cooperation*

PPF_FP7_T1.3 Areas of expertise and interest of the Research Group [activities and areas under the 2007 Work Programme for the Health Theme: Calls FP7-HEALTH-2007-A (2007-A) & FP7-HEALTH-2007-B (2007-B)]

	Activity / Area		2007-A	2007-B
	1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH		√	√
☐	1.1. High-throughput research		√	√
☐	1.2. Detection, diagnosis and monitoring		√	√
☐	1.3. Predicting suitability, safety and efficacy of therapies		√	-
☐	1.4. Innovative therapeutic approaches and interventions		√	√
	2. TRANSLATING RESEARCH FOR HUMAN HEALTH		√	
	2.1. Integrating biological data and processes: Large-scale data gathering, systems biology		√	√
☐		2.1.1. Large scale data gathering	√	-
☐		2.1.2. Systems biology	√	√
	2.2. Research on the brain and related diseases, human development and ageing		√	√
☐		2.2.1. Brain and brain-related diseases	√	√
☐		2.2.2. Human development and ageing	√	-
	2.3. Translational research in major infectious diseases: to confront major threats to public health		√	√
☐		2.3.1 Anti-microbial drug resistance including fungal pathogens	-	√
☐		2.3.2. HIV/AIDS, malaria and tuberculosis	√	√
☐		2.3.3. Potentially new and re-emerging epidemics	√	√
☐		2.3.4. Neglected infectious diseases	-	√
	2.4. Translational research in other major diseases		√	√
☐		2.4.1. Cancer	√	√
☐		2.4.2. Cardiovascular disease	√	√
☐		2.4.3. Diabetes and obesity	√	√
☐		2.4.4. Rare diseases	√	-
☐		2.4.5. Other chronic diseases	√	√
	3. OPTIMISING THE DELIVERY OF HEALTH CARE TO EUROPEAN CITIZENS		-	√
☒	3.1. Translating the results of clinical research outcome into clinical practice including better use of medicines, and appropriate use of behavioural and organisational interventions and new health therapies and technologies		-	√
☒	3.2. Quality, efficiency and solidarity of health care systems including transitional health systems		-	√
☒	3.3. Enhanced health promotion and disease prevention		-	√
☒	3.4. Horizontal coordination and support actions across "optimising the delivery of health care to European citizens"		-	√
	4. OTHER ACTIONS ACROSS THE HEALTH THEME		√	√
☐	4.1. Coordination and support actions across the Theme		√	√
☒	4.2. Responding to EU policy needs		√	√

Partner Profile Form
7th Framework Programme (2007-2013)
Health Theme of the Specific Programme *Cooperation*

PPF_FP7_T1.4 Description of previous and present experience in International Cooperation (max. 10 lines)	
EDISOFT is actively committed with several international research and standardization activities. The company has an extensive experience in national and international R&D activities, evolving from early collaboration to lately management and coordination of integrated projects within the EC's Framework Programme. Its R&D activities regard developing technology to go beyond the state of the art in sensitive areas such as defense, security, interoperability, network enabled capabilities, environmental monitoring, mobility and spatial data infrastructures.	
PPF_FP7_T1.4.1 Participation in EU Framework Programmes (FP) projects	
	☒ YES ☐ NO
If yes:	
Project 1 Title / Acronym (Activities performed)	
Project 2 Title / Acronym (Activities performed)	

Partner Profile Form
7th Framework Programme (2007-2013)
Health Theme of the Specific Programme *Cooperation*

PPF_FP7_T1.5. Topics of interest in the Health Theme Work Programme (WP)	
Call reference	HEALTH-2007-3.1-3, HEALTH-2007-3.1-4, HEALTH-2007-3.1-7, HEALTH-2007-3.2-1, HEALTH-2007-3.2-5, HEALTH-2007-3.3-1, HEALTH-2007-3.4-3, HEALTH-2007-4.2-5
WP Topic	
Project Type	☒ Large Collaborative Project ☒ Small or Medium Collaborative Project ☐ Network of Excellence ☐ Coordination and Support Action ☐ OTH _____

PPF_FP7_T1.5.1 Expertise/ Commitment offered	
Keywords specifying the expertise:	Sensor networks and embedded software Data Fusion Semantic Web and Interoperability Network-enabled operations Information Integrator Systems Location Intelligence Spatial data infra-structures Mobility Solutions Command and Control Systems Emergency and Crisis Management Integrated Logistic Systems
Description of the expertise:	EDISOFT's commitment to excellence is made reality in every high tech solution we provide. To meet our customers' needs the Company continually invests in R&D activities to keep providing competitive and innovative technology, integrating open systems and standards. The Health sector, being a key sensitive activity, clearly demands the application of such expertise. The above mentioned areas are our true areas of expertise, having EDISOFT the intention to apply them to this sector as it has been doing so in other sensitive areas - like defense, space or security as well as on other less sensitive sectors such as environment, logistics or tourism.
Role/Commitment offered	☒ Technology development ☒ Research ☒ Demonstration ☐ Training ☐ Dissemination ☐ OTH _____

PPF_FP7_T1.6 Interests on other Themes of the 7FP Specific Programme "Cooperation"	
	☐ No ☒ YES
If yes:	
	☐ Food, Agriculture, Fisheries and Biotechnology ☒ Information and Communication Technologies ☐ Nanosciences, Nanotechnologies, Materials and new Production Technologies ☐ Energy ☒ Environment (including Climate Change) ☒ Transport (Including Aeronautics) ☐ Socio-Economic Sciences and the Humanities ☒ Space ☒ Security

PPF_FP7.T1_7 I agree with the publication of my/our data:	
	☐ NO ☒ YES

Partner Profile Form
7th Framework Programme (2007-2013)
Health Theme of the Specific Programme *Cooperation*

PPF_FP7.8 Short guidelines on filling this Partner Profile Form	
The present form aims to help the researchers in disseminating their activities and interests as potential partners within the Health Theme of the FP7 by assisting the process of partner search.	
PPF_FP7.1	The fields should be filled in order to allow the identification as a partner proponent and further contact by possible coordinators or other entities.
PPF_FP7.2	A short description on the research team will allow the acknowledgement of the past and present activities.
PPF_FP7.3	The activities and areas of interest in the "Health" calls for 2007 should be indicated. Note that not all the areas or activities are open for submission of proposals in the 2007 Health Work Programme (WP).
PPF_FP7.4	Description of previous and present experience in International Cooperation (e.g. projects and partners involved).
PPF_FP7.5	If the interest of the organization regards several topics under the same area, or different areas, additional lines can be introduced in order to cover all the information considered relevant.
PPF_FP7.6	Information on activities and interest on areas of other Themes allows the identification of potential synergies – multidisciplinary projects/approaches.
PPF_FP7.7	In order to best fulfil the goals intended, this form should be circulated to the international community of National Contact Points, and also among potentially interested parties. Note that also the online publication of the present information could be of great help in the process of consortium search for a submission of a proposal.

Please fill in the Partner Profile Form (PPF) and return it to:	
NCP for "Health" Theme	Joana Camilo
Organisation	GRICES - Office for International Relations in Science and Higher Education Portuguese Ministry for Science, Technology and Higher Education
Tel.	(+351) 21 782 83 09
E-mail	joana.camilo@grices.mctes.pt

Partner Profile Form
7th Framework Programme (2007-2013)
Health Theme of the Specific Programme *Cooperation*

Date : 2007 08 24

Note for attention: further details on the Partner Profile Form (PPF) can be found in the Topic PPF_FP7_T1.8 (page 4/4).

PPF_FP7_T1.1 Details of the organization and of the main researcher					
Contact person details					
Name, Title	Maria Antonia Rebelo Botelho, PhD			Gender (M/F):	FEM
Tel.:	217913449	Fax.	217954729	E-mail:	uide@esenfcgl.pt
Personnel website:	http://www.esenfcgl.pt				
Organization/Research Group details					
Name:	Nursing Research and Development Unit (ui&de)				
Street name and number:	Escola Superior de Enfermagem Calouste Gulbenkian de Lisboa				
City, Postal address:	Lisboa	P.O Box	1600-190	Country	Portugal
Website					
Organization activity type[2]	☐ HES	☐ IND	☒ REC	☐ N/A	☐ OTH _____
Organization legal status type	☒ Public	☐ Private	☐ Non-profit	☐ OTH _____	

PPF_FP7_T1.2 Personal profile and work history of the research group/organization (brief description - max 12 lines)

The nursing research and development unit (ui&de) created in 2001 has the following objectives: to incentive policies that will allow development and evidence of nursing knowledge invested in care practices; clarification of nursing interventions in health promotion and community development; and innovations through partnership studies between the unit and health organisations that will contribute to new ways of envision health. To promote networking between Unit's projects, schools and organisations ant national and international levels.
At this moment the Unit has a huge programme called "caring and capacitating through life" and two sub-programmes : "knowledge and practice" and " health and development". Each subprogramme has different projects and studies, for instance the subprogramme "knowledge and practice contains three projects: !) therapeutic nursing instruments; Epistemology or nursing practice and lived experience. The other subprogramme is organised in four projects: - (re)habilitation and citizenship; Mental health ; education and relationship and surviving in our society.
Presently the Unit has 90 researchers, coming from different scientific disciplines as well practicing nurses, involved in 41 studies. Eleven of those researchers have a PhD and thirty seven have a Master's Degree, most of them preparing for their Doctoral Degree.
In last year the number of researchers working as clinical nurses in hospitals and health centers has increased.
The unit is a resource for nursing departments in health organisations and has been consulted regarding development of nursing research in hospitals ant the use of research outcomes in everyday practice.
Since 2004, the Unit supports the Lisbon University Doctoral Programme in Nursing.

[2] **Organization activity type (fill all that apply): HES** - Higher Education (i. e. organisations only or mainly established for higher education/training, e. g. universities, colleges); **IND** - Industry (i. e. industrial organisations private and public, both manufacturing and industrial services such as industrial software, design, control, repair, maintenance); **REC** – Research organization (i. e. "research organisation" means a legal entity established as a non-profit organisation which carries out research or technological development as one of its main objectives); **OTH –** Others; **N/A** – Undefined.

Partner Profile Form
7th Framework Programme (2007-2013)
Health Theme of the Specific Programme *Cooperation*

PPF_FP7_T1.3 Areas of expertise and interest of the Research Group [activities and areas under the 2007 Work Programme for the Health Theme: Calls FP7-HEALTH-2007-A (2007-A) & FP7-HEALTH-2007-B (2007-B)]				
Activity / Area			2007-A	2007-B
1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH			√	√
☐	1.1. High-throughput research		√	√
☐	1.2. Detection, diagnosis and monitoring		√	√
☐	1.3. Predicting suitability, safety and efficacy of therapies		√	-
☐	1.4. Innovative therapeutic approaches and interventions		√	√
2. TRANSLATING RESEARCH FOR HUMAN HEALTH			√	
	2.1. Integrating biological data and processes: Large-scale data gathering, systems biology		√	√
☐		2.1.1. Large scale data gathering	√	-
☐		2.1.2. Systems biology	√	√
	2.2. Research on the brain and related diseases, human development and ageing		√	√
☐		2.2.1. Brain and brain-related diseases	√	√
☒		2.2.2. Human development and ageing	√	-
	2.3. Translational research in major infectious diseases: to confront major threats to public health		√	√
☐		2.3.1 Anti-microbial drug resistance including fungal pathogens	-	√
☐		2.3.2. HIV/AIDS, malaria and tuberculosis	√	√
☐		2.3.3. Potentially new and re-emerging epidemics	√	√
☐		2.3.4. Neglected infectious diseases	-	√
	2.4. Translational research in other major diseases		√	√
☐		2.4.1. Cancer	√	√
☐		2.4.2. Cardiovascular disease	√	√
☐		2.4.3. Diabetes and obesity	√	√
☐		2.4.4. Rare diseases	√	-
☐		2.4.5. Other chronic diseases	√	√
3. OPTIMISING THE DELIVERY OF HEALTH CARE TO EUROPEAN CITIZENS			-	√
☒	3.1. Translating the results of clinical research outcome into clinical practice including better use of medicines, and appropriate use of behavioural and organisational interventions and new health therapies and technologies		-	√
☒	3.2. Quality, efficiency and solidarity of health care systems including transitional health systems		-	√
☒	3.3. Enhanced health promotion and disease prevention		-	√
☒	3.4. Horizontal coordination and support actions across "optimising the delivery of health care to European citizens"		-	√
4. OTHER ACTIONS ACROSS THE HEALTH THEME			√	√
☐	4.1. Coordination and support actions across the Theme		√	√
☐	4.2. Responding to EU policy needs		√	√

Partner Profile Form
7th Framework Programme (2007-2013)
Health Theme of the Specific Programme *Cooperation*

PPF_FP7_T1.4 Description of previous and present experience in International Cooperation (max. 10 lines)
Our team has been involved in the following projects: **ePsychNurse.net** Research project financed by *Leonardo da Vinci)* involving Finland, Ireland, Italy, Lithuania, United Kingdom and Portugal **The Girl Child Project: mobilising nurses for the health of urban girls** Research project proposed by the International Council of Nurses through the Portuguese national nurses organization (Ordem dos Enfermeiros). The same study has been done previously in Sweden and Botswana.

PPF_FP7_T1.4.1 Participation in EU Framework Programmes (FP) projects		
	☐ YES	☒ NO
If yes:		
Project 1 Title / Acronym (Activities performed)		
Project 2 Title / Acronym (Activities performed)		

Partner Profile Form
7th Framework Programme (2007-2013)
Health Theme of the Specific Programme *Cooperation*

PPF_FP7_T1.5. Topics of interest in the Health Theme Work Programme (WP)	
Call reference	FP7-HEALTH-2007-B
WP Topic	3.1-1: Implementation of research into healthcare practice 3.1-2: Self-medication and patient safety 3.1-7: Patient self-management or chronic disease 3.2-2: Health systems and long term care of the elderly 3.2-4: Health care human resource planning in nursing 3.3-4: Evaluation of suicide prevention strategies across and within European Countries
Project Type	☐ Large Collaborative Project ☒ Small or Medium Collaborative Project ☐ Network of Excellence ☐ Coordination and Support Action ☐ OTH _____

PPF_FP7_T1.5.1 Expertise/ Commitment offered	
Keywords specifying the expertise:	Nursing care and capacitating through life , elderly, patient self-management of chronic diseases, health and development, life-long education
Description of the expertise:	We are working as a team, integrating personal and social development, health education and rehabilitation, caring for individuals and groups and promoting autonomy along the life span with emphasis on chronic situations and dying
Role/Commitment offered	☐ Technology development ☒ Research ☐ Demonstration ☒ Training ☒ Dissemination ☐ OTH _____

PPF_FP7_T1.6 Interests on other Themes of the 7FP Specific Programme "Cooperation"	
	☐ No ☐ YES
If yes:	
	☐ Food, Agriculture, Fisheries and Biotechnology ☐ Information and Communication Technologies ☐ Nanosciences, Nanotechnologies, Materials and new Production Technologies ☐ Energy ☐ Environment (including Climate Change) ☐ Transport (Including Aeronautics) ☒ Socio-Economic Sciences and the Humanities ☐ Space ☐ Security

PPF_FP7.T1_7 I agree with the publication of my/our data:	
	☐ NO ☒ YES

Partner Profile Form
7th Framework Programme (2007-2013)
Health Theme of the Specific Programme *Cooperation*

PPF_FP7.8 Short guidelines on filling this Partner Profile Form	
The present form aims to help the researchers in disseminating their activities and interests as potential partners within the Health Theme of the FP7 by assisting the process of partner search.	
PPF_FP7.1	The fields should be filled in order to allow the identification as a partner proponent and further contact by possible coordinators or other entities.
PPF_FP7.2	A short description on the research team will allow the acknowledgement of the past and present activities.
PPF_FP7.3	The activities and areas of interest in the "Health" calls for 2007 should be indicated. Note that not all the areas or activities are open for submission of proposals in the 2007 Health Work Programme (WP).
PPF_FP7.4	Description of previous and present experience in International Cooperation (e.g. projects and partners involved).
PPF_FP7.5	If the interest of the organization regards several topics under the same area, or different areas, additional lines can be introduced in order to cover all the information considered relevant.
PPF_FP7.6	Information on activities and interest on areas of other Themes allows the identification of potential synergies – multidisciplinary projects/approaches.
PPF_FP7.7	In order to best fulfil the goals intended, this form should be circulated to the international community of National Contact Points, and also among potentially interested parties. Note that also the online publication of the present information could be of great help in the process of consortium search for a submission of a proposal.

Please fill in the Partner Profile Form (PPF) and return it to:	
NCP for "Health" Theme	Joana Camilo
Organisation	GRICES - Office for International Relations in Science and Higher Education Portuguese Ministry for Science, Technology and Higher Education
Tel.	(+351) 21 782 83 09
E-mail	joana.camilo@grices.mctes.pt

Partner Search Form: South Africa

CONTACT DETAILS

Organisation	**University of Kwazulu-Natal**
Department	**Pharmacy**
Address	**Private Bag X54001, Durban**
City/area code	**4000**
Country	**South Africa**
Contact person	**Professor Sabiha Essack**
e-mail	**essacks@ukzn.ac.za**
Phone	**+2731 260 8048**
Fax	**+2731 260 7872**

PROJECT DETAILS

Project type:	☐ **Large scale integrating collaborative project**	☐ **Networks of Excellence**	☐ **CA or SSA**
	x **Small or medium scale focussed research project**	☐ **SME**	
Planned to participate as:	x **Partner**	☐ **Coordinator**	
Call identifier : **Topic:**	**HEALTH-2007-2.3.1-5** Evidence-Based Strategies for the Containment of Antibiotic Resistance		
Your own research interests in relation to this project	I am Y-rated by the NRF, have established the Antimicrobial Resistance Research Unit in the School of Pharmacy and Pharmacology and have supervised/am currently supervising 3 PhD and 6 Masters students. I have secured several research grants for Essential National Health Research, from the World Health Organization, the Wellcome Trust, the Medical Research Council and the National Research Foundation investigating strategies for the prevention and containment of antibiotic resistance. I am the leader of the South African Chapter of the Alliance for the Prudent Use of Antibiotics and member of the National Antibiotic Surveillance Forum and the Federation of Infectious Diseases Societies of South Africa. **Research:** • Strategies for Prevention and Containment based on Surveillance, Risk Factors, Clinical Significance, Infection Control, Pharmaco-economics and Drug Pharmacokinetics and Pharmacodynamics • Molecular Biology/Genetics of Bacterial Resistance to Antibiotics (specifically beta-lactam antibiotics - penicillins, cephalosporins and related compounds) in *Acinetobacter spp., Citrobacter spp., Enterobacter spp., Escherichia coli, Haemophilis influenzae, Klebsiella spp., Proteus mirabilis, Salmonella spp., Staphylococcus aureus* and *Streptococcus spp.* • Extended-Spectrum Beta-lactamase (ESBL)-Mediated Resistance • Antibiotic Use and Resistance • Nosocomiology and Infection Control • Antibiotic Resistance Determinants in Agriculture		

Expertise that you have to offer in this call	I have hands-on expertise and experience in investigating the molecular biology and biochemistry of antibiotic resistance by virtue of my Wellcome Trust Research Training Fellowship to St Bartholomew's and the Royal London School of Medicine and Dentistry in the UK. I have been trained in epidemiology (Intensive Course in Epidemiology and Medical Statistics run by the London School of Hygiene and Tropical Medicine) and have undertaken epidemiological research. I have received several prestigious scholarships and bursaries from the Wellcome Trust, Medical Research Council (MRC) and National Research Foundation (NRF) and the University of Durban-Westville during the course of her Masters and PhD studies and my work has been published in several journals and has been presented at a number of national and international conferences.

Profile

Austria

Date: 2007/08/30	Deadline: 2010/01/31

Contact

Organisation	JOANNEUM RESEARCH Forschungsges.mbH	**Department**	Institute of Medical Technologies and Health Management
Contact person	Beck, MSc Peter		
Email	peter.beck@joanneum.at		
Address	Elisabethstraße 11a		
Postcode	8010	**City**	Graz
Country	Austria		
Telephone	+43(0)316 876 2136	**Fax**	+43(0)316 876 92136
Website	www.joanneum.at/msg		

Organisation

Type:	Research Organisation & Universities
Is a Small and Medium Sized Enterprise (SME)? NO	
Number of Employees	400
Description of research activity:	Our research activity spectrum reaches from organizational and public health concepts to software development for the healthcare system: The basis for providing optimum health services to as many people as possible is analysis, monitoring and improvement of the mechanisms underlying the complex, expensive health care systems. In close cooperation with local health authorities we work on the improvement of administrative and clinical processes in medical care, the optimisation of data management, patient-oriented care, and we perform cost analyses and project evaluations. We are currently involved in several real-life healthcare projects in Austria as well as in international research projects. Current activities include: - Evaluation of (integrated) health care projects - Chronic disease management - Patient education and patient empowerment - Clinical documentation and quality management - Evidence Based Medicine and clinical decision making and support

Former participation in an FP European project? YES	
Project title / Acronym:	BIRO
Activities performed::	Clinical Review - Literature review to identify diabetes health indicators Software design and development: Secure data transmission module Design and specification: Data dictionary, reporting, system architecture

Research topics

• HEALTH-2007-3.1-2: Self-medication and patient safety.
• HEALTH-2007-3.1-4: Improving clinical decision making.
• HEALTH-2007-3.1-6: Continuity of clinical care.
• HEALTH-2007-3.1-7: Patient self-management of chronic disease.
• HEALTH-2007-3.2-1: Evaluation of disease management programmes.

Expertise/commitment offered

Keywords specifying the expertise:	chronic disease management, quality management, information systems, decision support, clinical decision making, information retrieval, workflow modelling, cost analysis, cost effectiveness, patient education, patient empowerment
Description of the expertise:	We have strong experience and research interest in the following domains: - chronic disease management - quality management in the care of chronically ill patients - implementation of information systems in healthcare for administration and clinical care - decision support and clinical decision making - information retrieval - workflow modelling - patient education and patient empowerment - cost analyses, cost-effectiveness, economic evaluation Joanneum Research has provided the necessary know-how and manpower for setting up and running national competence centres as well as numerous large international projects including R&D activities on a European level, co-ordinating and participating in several IST projects in FP4, FP5 and FP6.
Commitment offered	Research,Technology

Expectations

Term commitment:	Long (> 3 years)
Expected results for your organisation:	Our contributing in FP7 collaborative research projects aims at quality of care improvements for cronically ill patients. We are interested in international networking to identify best practices for direct implemetation in wide-scale regional and national programs as well as scientific publication of the results.

Profile

Date:	2007 09 03
Deadline:	-
Call identifier:	FP7-KBBE, FP7-HEALTH, FP7-ICT, FP7-NMP, FP7-ENERGY, FP7-INFRASTRUCTURES, FP7-SME
Topic title (from the Work Programme):	(FP7-KBBE KBBE-2007-2.2) Nutrition (FP7-HEALTH HEALTH-2007-1.2) Detection, diagnosis and monitoring (FP7-HEALTH HEALTH-2007-2.4.2) Cardiovascular disease (FP7-ICT ICT-2007.3.1) Next-generation nanoelectronic components and electronics integration (FP7-ICT ICT-2007.3.5) Photonic components and subsystems (FP7-ICT ICT-2007.3.6) Micro/nanosystems (FP7-ICT ICT-2007.5.1) Personal health systems for monitoring and point-of-care diagnostics (FP7-NMP NMP-1.1) Nanosciences and converging sciences (FP7-NMP NMP-1.2) Nanotechnologies and converging technologies (FP7-NMP NMP-2.1) Mastering nano-scale complexity in materials (FP7-NMP NMP-2.2) Knowledge-based smart materials with tailored properties (FP7-NMP NMP-2.5) Using engineering to develop high performance knowledge-based materials (FP7-NMP NMP-4) Integration of technologies for industrial applications (FP7-ENERGY ENERGY-1) Hydrogen and fuel cells (FP7-ENERGY ENERGY-4.1) Low/medium temperature solar thermal energy (FP7-INFRASTRUCTURES INFRA-2) Support to new research infrastructures (FP7-SME SME-1) Research for SMEs

EXPERTISE OFFERED	
Keywords specifying the field of expertise:	Femtosecond laser microfabrication; Surface microstructuring; Laser scanning microscopy; Microchip laser; High speed shutter; Pattern recognition system; Fs lasers pulses controller for micromachining systems;
Expertise of the research group:	Young and creative R&D team of Altechna Co. Ltd. is ready to assist in custom automation solutions for synchronized laser beam control in energy, space and time domain. Our competences and experiences could be helpful in the following areas: - automation of femtosecond laser microfabrication, micromachining;

	- surface microstructuring, laser marking, engraving; - laser cutting, drilling, custom pattern scribing; - scanning microscopy, two photon fluorescence microscopy; - non invasive optical imaging; - 3D multi-photon polymerization; - optical micro-manipulation; - development and manufacturing of solar elements; Our teem also expertise in creation and development of passive Q-switched microchip lasers generating high peak power pulses at high repetition rate for various applications like: - Physics (time resolved luminescence measurements, ranging); - Biology and biomedicine (flow-cytometry, laser induced fluorescence); - Chemistry (spectroscopy); - Material processing (marking); - Pumping source for supercontinuum generation in Photonic Crystal Fibers.
International projects and partnerships: (last 5 years - Title of project, source of funds, duration) Please, indicate if you were/are coordinator, partner or subcontractor	"Next Generation Photonic Crystal Fibres" (NextGenPCF), FP6, 3 years, partner. „Galvanic Mirrors/Counter Rotating Scanners micro machining system“, Internal + partner (Laser Systems Inc., Japan) resources, 1 year, coordinator.

CONTACT INFORMATION			
Type of organization:	☐ Research institute ☐ University ☒ **SME*** ☐ Industry ☐ Other		
Organization Name:	UAB Altechna	Department:	
Contact person:	Gintas Šlekys	Telephone:	+370 5 272 5738
Address:	Konstitucijos ave. 23C LT-08105 Vilnius Lithuania	Fax:	+370 5 272 3704
Web site:	www.altechna.com	E-mail:	info@altechna.com

1.

PARTNER PROFILE FORM
(PARTNER is looking for a Project)

Date:	2007-07-19
Deadline:	2007-09-18
Call identifier:	FP7-HEALTH-2007-B
Topic title (from the Work Programme):	Health 2007 2.4.1-13 **ERA-NET on optimisation of the use of cancer registries for cancer research purposes**

EXPERTISE OFFERED	
Keywords specifying the field of expertise:	Cancer registry; population based cancer registration; descriptive, analytical and clinical cancer epidemiology; cancer incidence mortality and survival; cancer risk
Expertise of the research group:	The researchers at the cancer registry have the experience in conducting the population and clinical based studies and have participated in numerous local and several international projects. The registry keeps close collaboration with the researchers from university hospitals in Lithuania and is actively working with the primary health care institutions. The researchers have experience in conducting the occupational cohort studies and passive follow-up of cancer patients with the aim to estimate the survival and the treatment outcome. The cancer registry data is published in the vol.8 Cancer incidence in Five continents and will appear in the vol 9. The registry also participated in several cancer mortality atlas studies covering the northern Europe and EU-25. Recently the registry is involved in the cervical and breast cancer prevention programmes. The registry manages the population-based cancer indidence and mortality database that covers records since 1978.
International projects and partnerships: (last 5 years - Title of project, source of funds, duration) Please, indicate if you were/are coordinator, partner or subcontractor	- Collaborative Group on Observational Studies of Breast Cancer Survivors , since 2007, Oxford - European Cancer Health Indicator Project-II, agreement n° 2003115 - Cancer mortality Atlas in Europe, IACR

CONTACT INFORMATION			
Type of organization:	☐ Research institute ☒ University ☐ **SME*** ☐ Industry ☐ Other		
Organization Name:	Institute of Oncology, Vilnius university	Department:	Center of cancer prevention and control
Contact person:	Juozas Kurtinaitis	Telephone:	+370 5 2 614130

Address:	Santariškių 1, Vilnius, Lithuania	Fax:	+370 5 2 720164
Web site:	http:/kancerreg.ten.lt	E-mail:	juozas.kurtinaitis @loc.lt

2.

FP7-COOPERATION WORK PROGRAMME:HEALTH.

CLINICAL BIOCHEMISTRY RESEARCH CENTER
C/O KYRIAKOS PISPIRIGOS PhD
TAD/FAX: +30 – 2610 - 273 277
pispirigos@yahoo.com

RESEARCHER - ENTERPRICE

SAMPLE PROFILE FORM.

EXPERTISE – COMMITMENT OFFERED.

Keywords specifying the expertise:

INDIVIDUALIZED: BLOOD ANALYSIS;→
INDIVIDUALIZED BLOOD ANALYSIS FOR THERAPEUTIC PROTOCOLS;
LIPIDAIMIC PROFILE;→ CARDIAC PROFILE; → LIVER & KIDNEY PROFILE;
POST MARKET STUDIES – A NOVEL TECHNIQUE FOR SAFETY & EFFICACY.
Blood banking; Animal husbandry; Sample security; Extensive experience in individualized measurements:→ True Positive/True Negative-TP/TN & False Positive/ False Negative FP/FN Lab.Results; Liquid nitrogen; cold storage; networked sample monitoring; predictive failure; sample security; data integrity.
DNA-pc:Development of Biochemical –Biological microarrays;

Bioavailability and Biosensitivity Advanced Studies of Safety and Efficacy.

Commitment offered:

1) Research, 2) Training, 3) Demonstration, 4) Tutoring new Technology, 4) Well established Medical Device approved company.

Interest for participation in project types:
1) Large-scale interacting collaborative project, 2) Small or Medium-scale focused Research collaborative project, 3) Coordination and Support Action.

Main Research Topics:

For first call & For second call.

1) **HEALTH-2007-1.2-5 Standardisation and improvement of pre-analytical procedures for in vitro diagnostics.**
2) **HEALTH-2007-4.2-2 Relative safety of non-steroidal anti-inflammantory drugs (NSAIDs).**

EXPACTATIONS:
Term of commitment: Short <1 year OK!, Medium 1-3 years OK! Etc.

KP/ZP.

3.

Dept. of Pathology, Belarusian State Medical University

Role of cytoskeleton rearrangement in colon cancer and inflammatory diseases

Contact Person

PORTYANKO, Anna (M.D., Ph. D.)
Associate professor
Dept. of Pathology, Belarusian State Medical University

Contact aportyanko@yahoo.com
Telephone: +375 29 3680779

Collaboration

Project Proposal

Title: Role of cytoskeleton rearrangement in colon cancer and inflammatory bowel diseases

Type Details:

The treatment of colorectal cancer is a worldwide problem. The understanding of mechanisms of tumor growth and progression is critical for the anticancer drugs development. It is well known that colorectal cancer is often associated with inflammation. From the one hand colorectal cancer develops in patients with inflammatory bowel disease, such as ulcerative colitis and Crohn's disease, from the other hand, tumor associated inflammation is not a rear finding. Tumor progression and inflammation are both closely linked to cell locomotion, which provide cancer cell invasion in the first case and ulcer epithelization in the second one. Cell locomotion depends on the dynamics of cytoskeletal structures. Many anticancer drugs are based on targeting cytoskeleton molecules. Nevertheless the treatment results are far from desired. Thus further investigations in this direction are needed.

We are going to reveal the spectrum of changes of the cytoskeleton in invading tumor cells and in superficial epithelium in IBD and to investigate the difference between them. Our preliminary results indicate that certain cytoskeleton changes should be critical in acquiring migrating phenotype and that cytoskeletal rearrangement is strongly related to extracellular remodeling both in inflammatory and tumor diseases. We believe that results from this research project could open new perspectives of therapeutic approaches in cancer treatment

Our team includes specialists in clinical gastroenterology and oncology, endoscopy, gastrointestinal and oncological pathology (histology). We closely collaborate with oncological and gastroenterological clinics and have got systematic clinical database and morphological samples bank of patients with bowel diseases. Clinical data and sample collection, diagnosing and histopathological grading will be provided by our team. Also we have expertise in immunohistochemistry and confocal microscopy.

Programme (Collaboration EU R&D): *FP7-HEALTH* (2007-2.4.1-10)

Target Partner

We are seeking

- for coordinator for the project described above. Also we would like to find partners with expertise in:
- gene expression profiling,
- laser microdissection,
- proteomic and biochemical approaches in studying extracellular remodeling,

- cancer cellular models and migration assays,
- cytoskeleton in vitro studying,
- designing and developing new molecules with anticancer properties.

or

- for the proposal under preparation in *FP7-HEALTH* (2007-2.4.1-10) to be included in.

Organisation Details

Name: Belarusian State Medical University

Department: Dept. of Pathology

Region: MINSK
Address: Dzerjinskogo Ave., 83

Minsk, 220116, Belarus

Type: Research; Education

Number of Employees: > 500

Keywords: Cancer, Cytoskeleton, Colon, Ulcerative colitis, Crohn's disease

4.

Date 17 07 07 Deadline 15 08 07

CONTACT

Organisation	**Biomedical Research Foundation of the Academy of Athens**	**Department**	**Pharmacology-Pharmacotechnology Laboratory**
Contact person	**Dr Constantin Tamvakopoulos & Dr Spiros Garbis**	**Male/female**	**Males**
Address	**Soranou Efesiou 4 street**	**Email**	**ctamvakop@bioacademy.gr; sgarbis@bioacademy.gr (PLEASE REPLY BY MAIL)**
Postcode	**11527**	**Fax**	**+30-2106597545**
City	**Athens**	**Telephone**	**+30-2106597475**
Country	**Greece**	**Website**	**www.bioacademy.gr**

Are you familiar with the European Framework Programme?

☒ **YES**	☐ NO

PROJECT

Title **Standardisation and improvement of pre-analytical procedures for in vitro diagnostics**	**Acronym**

Project type

☒ Large Collaborative Project	☐ Network of Excellence	☐ Small Collaborative Research	☐ Other:

Status	☒ **Planned for submission**	☐ **running EU project**
Call references	FP7-HEALTH-2007-B	

Priorities' Main Research Areas	**HEALTH**
Workprogramme Topic	**HEALTH-2007-1.2-5**

Project description	The main objective of the planned proposal is to generate pan-European quality assurance schemes and guidelines for **pre-analytical procedures** such as sample collection, handling, transportation, processing and storing of clinical samples. The project will focus both on the standardisation of existing pre-analytical procedures and on the identification of critical steps in the pre-analytical procedure which need further development and improvement. Training aspects will be considered.
Keywords	pre-analytical procedures, quality assurance, standardisation
Partners already involved	**The Greek partner combines the expertise of two different collaborating laboratories: One in the area of Proteomics (P1A) and one in the area of Pharmacology - Pharmacotechnology (P1B).** **CONTRIBUTION OF THE GREEK PARTNER** **Analytical experience and infrastructures** (mainly LC-MS systems) to support a variety of studies addressing sample stability and integrity in various complex biological matrices and solvent systems. The molecules with which the teams are involved in include **small molecules, peptides, proteins and oligonucleotides.** Emphasis on bottom-up Protein Analysis – **Quantitative Proteomics – Mechanism of drug action** Emphasis on **Validation** of findings – **Absolute Quantification** of Proteins and Peptides in biological fluids By Mass Spectrometry Emphasis on the **discovery of new therapeutic approaches** for the treatment of cancer especially in pre-clinical stages **Please note that the Greek participant is not willing to act as Coordinator but will be actively involved in the writing up of the planned proposal.** **P1A: The Proteomics group** is engaged in multidisciplinary research, including several projects on biomarker discovery. The major goal is technology development and transfer to the application of novel approaches in the investigation of human disorders and biological systems. Our group has extensive experience in the **protein profiling and relative protein expression analysis** of biological samples (tissues, cell culture and body fluids) by two-dimensional gel-electrophoresis (2DGE), multi-dimensional liquid-chromatography (MDLC) and advanced **mass spectrometry** (TOF-TOF, QqTOF and Quadrupole Ion Trap) based proteomics technologies. Areas of interest in the field of cancer specifically include: I) Identification of biomarkers for urogenital cancers (prostate, bladder), II) The proteomic characterization of novel chemotherapeutic/chemopreventive agents.

The current Proteomics research efforts incorporate the use of advanced mass spectrometric and sample preparation approaches (sub-cellular fractionation, laser capture microdissection, stable isotope labeling, multi-dimensional liquid chromatography) to assess qualitative (i.e. identity, detection of post-translational modications, determination of protein-protein interactions) and quantitative (i.e. relative expression analysis, protein kinetics, temporal protein changes) attributes within the context of the above on-going projects.

P1B: The Pharmacology group is currently focused on the discovery of bioactive compounds (small molecules or peptides) and their efficacy for the treatment of cancer. More recently emphasis has been placed on the role of oligonucleotides for the treatment of cancer. Mass spectrometry plays a key role in our objectives with projects focusing on quantification of small molecules, peptides, and oligonucleotides, questions on metabolism of drugs and mechanisms of drug action. The Pharmacology laboratory is in the process of obtaining ISO17025, with emphasis on the quantitative determination of drugs or biomarkers in biological fluids.
The group of Pharmacology has focused on two areas that are relevant to this project: a) The development and validation of sensitive and selective mass spectrometry based methods for the quantification of peptides and proteins by mass spectrometry, b) The discovery and evaluation of novel compounds or improvement of existing therapies for the treatment of cancer. Collaborative studies with groups that have significant accomplishments in the field of synthesis of bioactive peptides (University of Patras) give our teams access to a wide array of pure peptides that can be used as tools for our research efforts. The role of metabolically stable GnRH agonists for the treatment of cancer is currently being investigated. Answering basic questions related to signaling pathways associated with GnRH agonism or antagonism including inflammation may yield improved therapies for the treatment of prostate cancer.

RELEVANT RESEARCH COLLABORATIONS:

Relevant project experience: The described team from BRFAA has been on a collaborative project with the Department of Urology and the Department of Pathology, of the Athens University Medical School (Athens, Greece), the Department of Pathology of the Eastern Virginia Medical School (Virginia, USA) and the Chicago Biomedical Consortium (CBC, Illinois, USA) in which clinically traceable tissues and plasma samples have been collected from prostate cancer patients and from patients with benign prostate hyperplasia and are subjected to proteomic assessment in search of biomarkers with greater prognostic and diagnostic specificity and sensitivity relative to the current plasma PSA assay. Additionally, in collaboration with the University of Cyprus, Department of Biological Sciences (Nicosia, Cyprus), molecular biology and proteomic studies are underway to evaluate novel chemotherapeutic-chemopreventive agents in prostate and epithelial cell cultures. The role of such chemopreventive agents in inflammation is of key interest to our lab.

The two investigators involved in this effort, Dr. S. Garbis and Dr. C. Tamvakopoulos are confident that the infrastructures and experience of personnel involved are focused and complementary and could yield maximum benefits for this call. This effort would combine four different mass spectrometers (platforms), with distinct niches in proteomics or small molecule research, other infrastructures (see below) and a significant number of technical personnel and trained postdoctoral fellows that could contribute.

RESEARCH INFRASTRUCTURE AVAILABLE FOR THE PROJECT

Resources - Equipment and Facilities

- **ISO 17025** and experience/ability to **validate** and run assays under **GLP guidelines**.

- **Animal facility** that allows the evaluation of drugs or mechanistic studies in models of cancer research (rodents). The facility is also suitable for other animal models such as rabbits or pigs.

Formulation of compounds for in vivo dosing.

A bank of more than 30 human cancer cell lines originated from different panels of tumors covering the most frequent forms of the disease allowing the screening of bioactive leads and establishment of xenografts in animal models using NOD/SCID mice.

Flow cytometry facility equipped with an FC500 (Beckman-Coulter) FACS with one 488 argon laser and a PARTEC PAs with an HBO lamp and a 488 Argon laser (PArtec GMBh) FACS and a FACSAria cell sorter (Beckton-Dickinson) with a 488 and a 407 solid state laser.

- Mass Spectrometry

1. Matrix-assisted laser desorption-ionization tandem time-of-flight mass spectrometer (**MALDI-TOF-TOF**) with high-throughput and protein sequencing capabilities
2. Liquid chromatography- high resolution quadrupole ion trap tandem mass spectrometry with nano electrospray interface (**LC-nESI-QIT MSN**).
3. Liquid chromatography- Quadrupole time-of-flight tandem mass spectrometry with a nano-electrospray interface (**LC-nESI-QqTOF MS-MS**).
4. Liquid chromatography- Tandem mass spectrometry (**triple quadruple hybrid with linear ion trap**) with Ion Spray interface (**LC-MS-MS**) ideal for **quantitative** measurements, small molecule and peptide analysis in **biological fluids.**

All LC-MS systems are ideally suited for **sensitive/selective peptide sequencing** and identification of **post translation modifications**.
Software for spot detection and quantification (Melanie-Pharmacia, PD-Quest-Biorad)·

- **Sample preparation systems:**

Systems for laser capture microdissection **(LCM)**
Systems for **two-dimensional electrophoresis**.
Systems for liquid chromatography **(HPLC, FPLC)**
Systems for semi- preparative **protein electrophoresis** (isoelectric focusing and preparative poly-acrylamide gel electrophoresis)
Gel scanners
Systems for **ultracentrifugation**

SHORT CVs & RELEVANT PUBLICATIONS OF MAININVESTIGATORS (GREEK PARTNER)

PARTNER 1A. PROTEOMICS GROUP

Dr. Constantin Tamvakopoulos received his B.A. in Chemistry from the University of Chicago in 1986. He continued his studies in the United States and received a Ph.D. in Chemistry/Biochemistry from Brown University in 1992. Following his graduate studies he joined the department of Pharmacokinetics and Drug Metabolism at Purdue Pharma LP (a private pharmaceutical company specializing in drug delivery forms) as a Senior Scientist and then as a Principal Scientist in the same department until 1997. From 1997 until 2004 he held positions at Merck Research Laboratories as a Senior Research Chemist and a Research Fellow in the department of Basic Chemistry. In 2004 he accepted a tenure track position at the Department of Pharmacology, Foundation for Biomedical Research of the Academy of Athens, Athens, Greece. Dr. Tamvakopoulos' main focus of research revolves around the development and application of novel mass spectrometric techniques with significance in biomedical research, including the discovery and development of new drugs, pharmacokinetics, drug metabolism, quantification of bioactive peptides and bioequivalence studies. By placing emphasis on pharmacokinetic and drug metabolism questions, pharmacologic action can be better understood with beneficial consequences to the design of future therapies. Some of his main scientific contributions as a graduate student at Brown included the development of novel mass spectrometric approaches for the quantification of the intermediates of fatty acid metabolism. The methodology was applied towards the establishment of Acyl-CoA profiles in patient fibroblasts with inherited metabolic diseases, in collaborative studies with the Children's Hospital in the University of Pennsylvania.During his seven years at Merck Dr. Tamvakopoulos collaborated with synthetic chemists, biologists, pharmacologists in many new drug discovery programs in the therapeutic areas of metabolic disorders (obesity, diabetes), inflammation (arthritis) and atherosclerosis and actively participated towards the advancement of new leads in the various drug discovery programs. Some of those leads have now advanced to phases of clinical development by Merck. In the pharmaceutical industry, Dr. Tamvakopoulos, his group and colleagues contributed to the research and development work (execution of clinical pharmacokinetic and drug metabolism studies) that lead to the approval of successful new drugs to the market for the treatment of pain and type-II diabetes.

Selected publications/presentations

1.) Trivedi P, Jiang M, **Tamvakopoulos C**, Shen X, Yu H, Mock S, Fenyk-Melody J, Van der Ploeg LH, Guan XM. (2003) Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain Res. 977, 221-230.
2.) Zhu L, **Tamvakopoulos C**, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, Schmidt K, Bagchi A, Griffin PR, Thornberry NA, Sinha Roy R. (2003) The role of dipeptidyl peptidase IV (DP-IV) in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide [1-38]. J Biol Chem. 278 (25), 22418-23.
3.) **Tamvakopoulos C**, Dimas K, Sophianos ZD, Han Z, Wyche JH, Pantazis P. The Curcumin Analogue, Dimethoxycurcumin: Apoptosis Induction of Cultured Human Colon Cancer Cells, Metabolism in Liver Microsomes, Stability in Cultured Cells, and Plasma Concentrations in Mice. Clin Cancer Res. 13(4):1269-77.
4.) **Tamvakopoulos C.** (2007) Mass spectrometry for the quantification of bioactive peptides in biological fluids. Mass Spectrom Reviews, 26 (3): 389-402.
5.) Hatziieremia S, Kostomitsopoulos N, Balafas V, **Tamvakopoulos C.** (2007) A liquid chromatographic/tandem mass spectroscopic method for quantification of the cyclic peptide melanotan-II. Plasma and brain tissue concentrations following administration in mice. Rapid Commun Mass Spectrom. 21, 2431-2438.

PARTNER 1B. PHARMACOLOGY GROUP

Dr. Spiros D. Garbis received his BSc degree in Chemistry from the University of Illinois in 1989. As a research chemist he worked at Honeywell Zellweger Analytics in the area of environmental toxicology using remote sensing molecular spectroscopy technologies from 1990-1995. He later worked as a forensic scientist at the Animal Forensic Toxicology Laboratory of the University of Illinois, Department of Biopharmaceutical Sciences from 1994 – 1998 where he developed and applied methodologies based on bioanalytical mass spectrometry (MS) techniques in the determination of xenobiotic substances and their metabolites in biological fluids and tissues. His exposure in the area analytical toxicology prompted him to pursue doctoral training under the mentorship of Prof. Dr. Richard B. van Breemen at the University of Illinois, Department of Medicinal Chemistry and Pharmacognosy from 1998 – 2003 where he received his PhD in 2003 in the area of Molecular and Biochemical Toxicology. His studies involved the use of MS based proteomic and metabonomic approaches to the study of the bioavailability, biotransformation and bioequivalence properties of folate species in humans. As a tenure track research chemist at IIBEAA, Center for Basic Research, Biotechnology Division, Dr. Spiros D. Garbis is involved in the development and application of novel liquid chromatography – tandem mass spectrometry (LC-MS) techniques in the characterization of peptides and proteins in biological samples. In order to accurately address complex biological processes, he is currently involved in the method development and application of methods combining the use of multiplex stable isotope labeling techniques (i.e. iTRAQ, SILAC, and others) and multi-dimensional LC-MS platforms in the discovery and characterization of novel, mechanism-based protein biomarkers with prognostic and diagnostic potential in prostate cancer treatment (including the proteomic evaluation of natural product chemical analogs both as chemotherapeutic-chemopreventive agents and as «chemical probes» for biomarker effectiveness). As such, he has established in-house capabilities for the preparation of custom capillary columns utilizing advanced chromatographic chemistries to be used in combination with various MS architectures including nano-electrospray-quadrupole time-of-flight, ion trap and matrix assisted laser desorption tandem time-of-flight instrumentation. In addition, he is currently involved in the design and application of integrated lab-on-a-chip devices in collaboration with Democritos. Such devices hold promise in increasing analysis throughput and sensitivity for the MS based determination of low abundance biomolecules in complex biological matrices.

Selected Publications

1. **Garbis S**., Lubec G., Fountoulakis M. (2005). Limitations of current proteomics technologies. J. of Chromatogr. A 1077, 1-18.
2. Kouyianou K., **Garbis S.D**., Boulias K., Dimitraki P., Talianidis I., Fountoulakis M., Tsiotis G. (2006) Proteomic analysis of liver from transgenic mice overexpressing small heterodimer partner. Cancer Genomics and Proteomics.
3, 119-126.
3. Tsangaris G.T., Karamessinis P., Kolialexi A., **Garbis S.D**., Antsaklis A., Mavrou A., Fountoulakis M. (2006) Proteomic analysis of amniotic fluid in pregnancies with Down syndrome. Proteomics. 6, 4410-4419.
4. Giannopoulou E.G., **Garbis S.D**., Vlahou A., Kossida S., Lepouras G., Manolakos I. (2007) Proteomics Feature Maps Using Spheres. Proteomics. Submitted-manuscript: proteo-2007-00352.
5. **Garbis S.D.** et al (2007). Quantitative proteomic determination of potential cancer biomarkers in prostate tissue derived from a human pilot clinical study. J. of Prot. Res. Manuscript in preparation.

Project budget (for the running projects)		**Budget reserved for SMEs**	

Profile of Partner sought

Role	☒ technology development	☒ research	☒ training
	☐ dissemination	☐ demonstration	☐ other:
Country /region	All countries except Greece		
Start of partnership	☒ start-up phase	☐ mid-term	☐ end-phase

Expertise required	**Academia, industry and SMEs with relevant expertise in pre-analytical procedures for in vitro-diagnostics.**

5.

Date 17 07 07 **Deadline** 15 08 07

CONTACT

Organisation	**Biomedical Research Foundation of the Academy of Athens**	**Department**	**Pharmacology-Pharmacotechnology Laboratory**
Contact person	**Dr Constantin Tamvakopoulos, Dr Spiros Garbis & Dr Evangelos Andreakos**	**Male/female**	**Males**
Address	**Soranou Efesiou 4 street**	**Email**	**ctamvakop@bioacademy.gr; sgarbis@bioacademy.gr; vandreakos@bioacademy.gr (PLEASE REPLY BY MAIL)**
Postcode	**11527**	**Fax**	**+30-2106597545**
City	**Athens**	**Telephone**	**+30-2106597475**
Country	**Greece**	**Website**	**www.bioacademy.gr**

Are you familiar with the European Framework Programme?

☒ **YES**	☐ NO

PROJECT

Title Role of inflammation in tumour initiation & progression	**Acronym**

Project type	☒ **Large Collaborative Project**	☐ Network of Excellence	☐ Small Collaborative Research	☐ Other:
Status	☒ **Planned for submission**	☐ **running EU project**		
Call references	**FP7-HEALTH-2007-B**			

Priorities' Main Research Areas	**HEALTH**
Workprogramme Topic	**HEALTH-2007-2.4.1-10**

Project description	The main objective of the planned proposal will focus on translating knowledge on the molecular machinery underpinning **inflammatory processes driving tumour initiation and progression in various cancers**, into functional, validated therapeutic anti-cancer approaches.
Keywords	**inflammation, tumour initiation, tumour progression, cancer**
Partners already involved	**The Greek partner combines the expertise of three different collaborating laboratories: One in the area of Proteomics (P1A) and one in the area of Pharmacology - Pharmacotechnology (P1B) and one in the area of Immunology (P1C).** **<u>CONTRIBUTION OF THE GREEK PARTNER:</u>** **Emphasis on bottom-up Protein Analysis – Quantitative Proteomics – Mechanism of drug action** **Emphasis on Validation of findings – Absolute Quantification of Proteins and Peptides in biological fluids By Mass Spectrometry following pharmacologic intervention.** **Emphasis on the discovery of new therapeutic approaches for the treatment of cancer especially in pre-clinical stages** **Please note that the Greek participant is not willing to act as Coordinator but will be actively involved in the writing up of the planned proposal.** **P1A: The Proteomics group** is engaged in multidisciplinary research, including several projects on biomarker discovery. The major goal is technology development and transfer to the application of novel approaches in the investigation of human disorders and biological systems. Our group has extensive experience in the protein profiling and relative protein expression analysis of biological samples (tissues, cell culture and body fluids) by two-dimensional gel-electrophoresis (2DGE), multi-dimensional liquid-chromatography (MDLC) and advanced mass spectrometry (TOF-TOF, QqTOF and Quadrupole Ion Trap) based proteomics technologies. Areas of interest in the field of cancer specifically include: I) Identification of biomarkers for urogenital cancers (prostate, bladder), II) The proteomic characterization of novel chemotherapeutic/chemopreventive agents. The current Proteomics research efforts incorporate the use of advanced mass spectrometric and sample preparation approaches (sub-cellular fractionation, laser capture microdissection, stable isotope labeling, multi-dimensional liquid chromatography) to assess qualitative (i.e. identity, detection of post-translational modications, determination of protein-protein interactions) and quantitative (i.e. relative expression analysis, protein kinetics, temporal protein changes) attributes within the context of the above on-going projects. **P1B: The Pharmacology group** is currently focused on the discovery of bioactive compounds (small molecules or peptides) and their efficacy for the treatment of cancer. More recently emphasis has been placed on the role of oligonucleotides for the treatment of cancer. Mass spectrometry plays a key role in our objectives with projects focusing on quantification of small molecules, peptides, and oligonucleotides, questions on metabolism of drugs and mechanisms of drug action. The Pharmacology laboratory is in the process of obtaining ISO17025, with emphasis on the quantitative determination of drugs or biomarkers in biological fluids. The group of Pharmacology has focused on two areas that are relevant to this project: a) The development and validation of sensitive and selective mass spectrometry based methods for the quantification of peptides and proteins by mass spectrometry, b) The discovery and evaluation of novel compounds or improvement of existing therapies for the treatment of cancer. Collaborative studies with groups that have significant accomplishments in the field of synthesis of bioactive peptides (University of Patras) give our teams access to a wide array of pure peptides that can be used as tools for our research efforts. The role of metabolically stable GnRH agonists for the treatment of cancer is currently being investigated. Answering basic questions related to signaling pathways associated with GnRH agonism or antagonism including inflammation may yield improved therapies for the treatment of prostate cancer. **P1C: The Immunology group** covers the areas of target identification and validation in relevant animal models and human disease tissue. It can contribute to this project by studying the role of inflammatory processes in the development of lung cancer in animal models and humans using cutting edge technologies that include in vivo oligonucleotide (siRNA and antisense) delivery and Laser Capture Microdissection of disease tissue for Proteomics analysis.

RELEVANT RESEARCH COLLABORATIONS

Relevant project experience: The described team from BRFAA has been on a collaborative project with the Department of Urology and the Department of Pathology, of the Athens University Medical School (Athens, Greece), the Department of Pathology of the Eastern Virginia Medical School (Virginia, USA) and the Chicago Biomedical Consortium (CBC, Illinois, USA) in which clinically traceable tissues and plasma samples have been collected from prostate cancer patients and from patients with benign prostate hyperplasia and are subjected to proteomic assessment in search of biomarkers with greater prognostic and diagnostic specificity and sensitivity relative to the current plasma PSA assay. Additionally, in collaboration with the University of Cyprus, Department of Biological Sciences (Nicosia, Cyprus), molecular biology and proteomic studies are underway to evaluate novel chemotherapeutic-chemopreventive agents in prostate and epithelial cell cultures. The role of such chemopreventive agents in inflammation is of key interest to our lab.

The three main investigators involved in this effort, Dr. S. Garbis , Dr. C. Tamvakopoulos and Dr E. Andreakos are confident that the infrastructures and experience of personnel involved are focused and complementary and could yield maximum benefits for this call.

This effort would combine four different mass spectrometers (platforms), with distinct niches in proteomics or small molecule research, other infrastructures (see below) and a significant number of technical personnel and trained postdoctoral fellows.

RESEARCH INFRASTRUCTURE AVAILABLE FOR THE PROJECT

Resources - Equipment and Facilities

▪**ISO 17025** and experience/ability to **validate** and run assays under **GLP guidelines**.

▪ **Animal facility** that allows the evaluation of drugs or mechanistic studies in models of cancer research (rodents). The facility is also suitable for other animal models such as rabbits or pigs.

Formulation of compounds for in vivo dosing.

A bank of more than 30 human cancer cell lines originated from different panels of tumors covering the most frequent forms of the disease allowing the screening of bioactive leads and establishment of xenografts in animal models using NOD/SCID mice.

Flow cytometry facility equipped with an FC500 (Beckman-Coulter) FACS with one 488 argon laser and a PARTEC PAs with an HBO lamp and a 488 Argon laser (PArtec GMBh) FACS and a FACSAria cell sorter (Beckton-Dickinson) with a 488 and a 407 solid state laser.

▪ Mass Spectrometry

1. Matrix-assisted laser desorption-ionization tandem time-of-flight mass spectrometer (**MALDI-TOF-TOF**) with high-throughput and protein sequencing capabilities
2. Liquid chromatography- high resolution quadrupole ion trap tandem mass spectrometry with nano electrospray interface (**LC-nESI-QIT MSN**).
3. Liquid chromatography- Quadrupole time-of-flight tandem mass spectrometry with a nano-electrospray interface (**LC-nESI-QqTOF MS-MS**).
4. Liquid chromatography- Tandem mass spectrometry (**triple quadruple hybrid with linear ion trap**) with Ion Spray interface (**LC-MS-MS**) ideal for **quantitative** measurements, small molecule and peptide analysis in **biological fluids.**

All LC-MS systems are ideally suited for **sensitive/selective peptide sequencing** and identification of **post translation modifications**.
Software for spot detection and quantification (Melanie-Pharmacia, PD-Quest-Biorad)·

▪ **Sample preparation systems:**

Systems for laser capture microdissection **(LCM)**
Systems for **two-dimensional electrophoresis**.
Systems for liquid chromatography **(HPLC, FPLC)**
Systems for semi- preparative **protein electrophoresis** (isoelectric focusing and preparative poly-acrylamide gel electrophoresis)
Gel scanners
Systems for **ultracentrifugation**

SHORT CVs & RELEVANT PUBLICATIONS OF THE GREEK PARTNER

PARTNER 1A. PROTEOMICS GROUP

Dr. Constantin Tamvakopoulos received his B.A. in Chemistry from the University of

Chicago in 1986. He continued his studies in the United States and received a Ph.D. in Chemistry/Biochemistry from Brown University in 1992. Following his graduate studies he joined the department of Pharmacokinetics and Drug Metabolism at Purdue Pharma LP (a private pharmaceutical company specializing in drug delivery forms) as a Senior Scientist and then as a Principal Scientist in the same department until 1997. From 1997 until 2004 he held positions at Merck Research Laboratories as a Senior Research Chemist and a Research Fellow in the department of Basic Chemistry. In 2004 he accepted a tenure track position at the Department of Pharmacology, Foundation for Biomedical Research of the Academy of Athens, Athens, Greece. Dr. Tamvakopoulos' main focus of research revolves around the development and application of novel mass spectrometric techniques with significance in biomedical research, including the discovery and development of new drugs, pharmacokinetics, drug metabolism, quantification of bioactive peptides and bioequivalence studies. By placing emphasis on pharmacokinetic and drug metabolism questions, pharmacologic action can be better understood with beneficial consequences to the design of future therapies. Some of his main scientific contributions as a graduate student at Brown included the development of novel mass spectrometric approaches for the quantification of the intermediates of fatty acid metabolism. The methodology was applied towards the establishment of Acyl-CoA profiles in patient fibroblasts with inherited metabolic diseases, in collaborative studies with the Children's Hospital in the University of Pennsylvania.During his seven years at Merck Dr. Tamvakopoulos collaborated with synthetic chemists, biologists, pharmacologists in many new drug discovery programs in the therapeutic areas of metabolic disorders (obesity, diabetes), inflammation (arthritis) and atherosclerosis and actively participated towards the advancement of new leads in the various drug discovery programs. Some of those leads have now advanced to phases of clinical development by Merck. In the pharmaceutical industry, Dr. Tamvakopoulos, his group and colleagues contributed to the research and development work (execution of clinical pharmacokinetic and drug metabolism studies) that lead to the approval of successful new drugs to the market for the treatment of pain and type-II diabetes.

Selected publications/presentations

1.) Trivedi P, Jiang M, **Tamvakopoulos C**, Shen X, Yu H, Mock S, Fenyk-Melody J, Van der Ploeg LH, Guan XM. (2003) Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain Res. 977, 221-230.

2.) Zhu L**, Tamvakopoulos C**, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, Schmidt K, Bagchi A, Griffin PR, Thornberry NA, Sinha Roy R. (2003) The role of dipeptidyl peptidase IV (DP-IV) in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide [1-38]. J Biol Chem. 278 (25), 22418-23.

3.) **Tamvakopoulos C**, Dimas K, Sophianos ZD, Han Z, Wyche JH, Pantazis P. The Curcumin Analogue, Dimethoxycurcumin: Apoptosis Induction of Cultured Human Colon Cancer Cells, Metabolism in Liver Microsomes, Stability in Cultured Cells, and Plasma Concentrations in Mice. Clin Cancer Res. 13(4):1269-77.

4.) **Tamvakopoulos C.** (2007) Mass spectrometry for the quantification of bioactive peptides in biological fluids. Mass Spectrom Reviews, 26 (3): 389-402.

5.) Hatziieremia S, Kostomitsopoulos N, Balafas V, **Tamvakopoulos C.** (2007) A liquid chromatographic/tandem mass spectroscopic method for quantification of the cyclic peptide melanotan-II. Plasma and brain tissue concentrations following administration in mice. Rapid Commun Mass Spectrom. 21, 2431-2438.

PARTNER 1B. PHARMACOLOGY GROUP

Dr. Spiros D. Garbis received his BSc degree in Chemistry from the University of Illinois in 1989. As a research chemist he worked at Honeywell Zellweger Analytics in the area of environmental toxicology using remote sensing molecular spectroscopy technologies from 1990-1995. He later worked as a forensic scientist at the Animal Forensic Toxicology Laboratory of the University of Illinois, Department of Biopharmaceutical Sciences from 1994 – 1998 where he developed and applied methodologies based on bioanalytical mass spectrometry (MS) techniques in the determination of xenobiotic substances and their metabolites in biological fluids and tissues. His exposure in the area analytical toxicology prompted him to pursue doctoral training under the mentorship of Prof. Dr. Richard B. van Breemen at the University of Illinois, Department of Medicinal Chemistry and Pharmacognosy from 1998 – 2003 where he received his PhD in 2003 in the area of Molecular and Biochemical Toxicology. His studies involved the use of MS based proteomic and metabonomic approaches to the study of the bioavailability, biotransformation and bioequivalence properties of folate species in humans. As a tenure track research chemist at IIBEAA, Center for Basic Research, Biotechnology Division, Dr. Spiros D. Garbis is involved in the development and application of novel liquid chromatography – tandem mass spectrometry (LC-MS) techniques in the characterization of peptides and proteins in biological samples. In order to accurately address complex biological processes, he is currently involved in the method development and application of methods combining the use of multiplex stable isotope labeling techniques (i.e. iTRAQ, SILAC, and others) and multi-dimensional LC-MS platforms in the discovery and characterization of novel, mechanism-based protein biomarkers with prognostic and diagnostic potential in prostate cancer treatment (including the proteomic evaluation of natural product chemical analogs both as chemotherapeutic-chemopreventive agents and as «chemical probes» for biomarker effectiveness). As such, he has established in-house capabilities for the preparation of custom capillary columns utilizing advanced

chromatographic chemistries to be used in combination with various MS architectures including nano-electrospray-quadrupole time-of-flight, ion trap and matrix assisted laser desorption tandem time-of-flight instrumentation. In addition, he is currently involved in the design and application of integrated lab-on-a-chip devices in collaboration with Democritos. Such devices hold promise in increasing analysis throughput and sensitivity for the MS based determination of low abundance biomolecules in complex biological matrices.

Selected Publications

1. **Garbis S.,** Lubec G., Fountoulakis M. (2005). Limitations of current proteomics technologies. J. of Chromatogr. A 1077, 1-18.
2. Kouyianou K., **Garbis S.D.,** Boulias K., Dimitraki P., Talianidis I., Fountoulakis M., Tsiotis G. (2006) Proteomic analysis of liver from transgenic mice overexpressing small heterodimer partner. Cancer Genomics and Proteomics.
3, 119-126.3. Tsangaris G.T., Karamessinis P., Kolialexi A., **Garbis S.D.,** Antsaklis A., Mavrou A., Fountoulakis M. (2006) Proteomic analysis of amniotic fluid in pregnancies with Down syndrome. Proteomics. 6, 4410-4419.
4. Giannopoulou E.G**., Garbis S.D.,** Vlahou A., Kossida S., Lepouras G., Manolakos I. (2007) Proteomics Feature Maps Using Spheres. Proteomics. Submitted-manuscript: proteo-2007-00352.
5. **Garbis S.D.** et al (2007). Quantitative proteomic determination of potential cancer biomarkers in prostate tissue derived from a human pilot clinical study. J. of Prot. Res. Manuscript in preparation.

PARTNER 1C: IMMUNOLOGY GROUP

Dr Evangelos Andreakos received his PhD from Imperial College London and went on to do postdoctoral research and then take up a Research Fellow (Lecturer A' scale) position at the Kennedy Institute Division of Imperial College London. Now he is a faculty member of the Centre for Immunology and Transplantations of FBR. E. Andreakos has been the co-author of 30 articles in peer-reviewed journals and 4 book chapters. He is often invited to talk to international conferences and has given consultancy lectures to the pharmaceutical companies Abbott Laboratories (MA, USA) and Pharmacia/Pfizer (IL, USA). He is a member of various professional organizations such as the British Society of Immunology, the Federation of American Societies of Experimental Biology and the International Cytokine Society, and he is acting as a regular referee for articles of several journals that include Blood, Journal of Immunology, Human Gene Therapy and International Immunology. Finally, he has acted as an international reviewer of grants for the Catalonian Health and Technology Agency (Spain), the Eli and Edythe L. Broad Foundation (CA, USA) the Wellcome Trust and the Arthritis and Rheumatism Campaign (UK), and he has been a member of the grants panel of the Catalonian Health and Technology Agency (Spain) for 2003 and 2004. E. Andreakos studies are focusing at present on unravelling the molecular control of myeloid and plasmacytoid dendritic cell antigen presenting function leading to either immune or tolerance induction. Key tools employed include amphoteric liposomes for in vivo siRNA delivery and recombinant adenoviruses expressing activators or inhibitors of antigen presentation. This work offers the prospect of developing new methods to control the immune system by enhancing or silencing its function in an antigen or disease specific manner.

Selected publications

1. **Andreakos E**, Williams RO, Wales J, Foxwell B and Feldmann M. Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. (2006) Proceedings of the National Academy of Sciences of USA 103(39):14459-64
2. **Andreakos E**, Foxwell B and Feldmann M. Is targeting toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? (2004) Immunological Reviews 202:250-65
3. Monaco C, **Andreakos E**, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, Cheshire N, Paleolog E, Feldmann M (2004). The canonical pathway of NF-kappaB activation selectively regulates pro-inflammatory and pro-thrombotic responses in human atherosclerosis. Proceedings of the National Academy of Sciences of USA 101(15):5634-5639
4. **Andreakos E**, Sacre S, Smith C, Lundberg A, Kiriakidis S, Stonehouse T, Monaco C, Feldmann M and Foxwell BM. Distinct pathways of LPS-induced NF-kappaB activation and cytokine production in human myeloid and non-myeloid cells defined by selective utilization of MyD88 and Mal/TIRAP (2004). Blood, 103(6):2229-2237
5. **Andreakos E**, Smith C, Monaco C, Foxwell BM, Brennan FM and Feldmann M. IκB kinase 2 but not NF-κB-inducing kinase is essential for effective antigen presentation in the allogeneic mixed lymphocyte reaction (2003). Blood 101(3):983-991.

Project budget (for the running projects)		**Budget reserved for SMEs**	

Per informazioni contattare: Valentina Tegas *tegas@apre.it*

Reference n.: **HEALTH-EU-SMCP-7**

Deadline: **31/12/2007**

Programme: COOPERATION- HEALTH

Project Title: CerviStudy- Study for Cervical Cancer Origins in Latin America

Financial Scheme:

Description: Priorities' Main Research Areas
We have been involved in several EC and National projects, four of them in the area of medical applications: Lifelinger - development of new ICT-based diagnosis procedure and toolset for early detection of cervix cancer; Heartronic - development of an innovative system of prevention and early warning of heart conditions based on a wearable monitoring device with mobile communications, capable to recognize cardiovascular anomalies and to alert doctors and Hospitals in real time; Troy - development of an ultrasound endoscope capsule (where we are coordinator); and Netcare - Wireless telemetry for continuous health care.

Project description
Our goal is to test and validate a new cervix cancer early diagnosis procedure, based on the integration of advanced statistical analysis with IT networking capabilities and making intelligent use of quantitative non destructive characterisation (QNDC) data for on-line help on early detection of cervical carcinoma.

Keywords
cervix; cervical cancer; latin america; screening; imaging; cytology; Papanicolaou

RESEARCH TOPIC:
- HEALTH-2007-2.4.1-14: Studying cancer aetiology in Latin America.

Organisation Type: Impresa

Partner Sought: Profile of SME sought

Role:
research

Country /region:
EU and Latin America
Start of partnership:
start-up phase

Expertise required:
European Medical Universities - specialised in gynecology with transfer protocols with Latin America medical institutions

Medical Institutions (clinics, hospitals …) with experience in studies about cervix
cancer

Per informazioni contattare: Valentina Tegas - *tegas@apre.it*

Riferimento: HEALTH-EU-LCP-1

Data Scadenza: **31/12/2007**

Titolo: Researches to design a method and an equipment to survey and correct the walking energetic expenditure at patients with osteoarthritis of lower limbs and lumbar spine

Descrizione: The project concept consists in development of a mathematic model for computing energetic expenditure during walking, based on the measurement of ground vertical reaction forces, instantaneous coordinates of their resultant applied point, steps number and the application of thismathematic model for:
• elaborating a new method for monitoring and correcting the energetic expenditure during walking at patients with osteoarthritis of the lower limbs and lumbar spine;
• achievement of a portable computerized electronic equipment for monitoring and correcting the energetic expenditure during walking at patients with osteoarthritis of the lower limbs and lumbar spine;
• achievement of a specialized software with functions for monitoring and interactive training by visual and audio biofeedback for correcting the monitorized parameters.

Tipo Ente: Centro di Ricerca>

Partner richiesto: • Politechnic University/ Bioengineering Faculty and/or

• University of Medicine/ Clinics specialized in osteoarthritis

Per informazioni: Valentina Tegas - *tegas@apre.it*

Riferimento: HEALTH-EU-SMCP-4

Data Scadenza: **12/12/2007**

Titolo: Nutrition and Bioefficacy- NUBI

Descrizione: Summary:
Personalized Nutrition and bioefficacy (NUBI) is a project which will establish the correlation of specific nutritional compounds and gene expression including metabolism of disease specific genes and biomarker for obesity and sequels, under the vision of diagnostic technologies including new IT solutions.
Vision From Nutrigenomic Science to Personalized Nutrition "As from Research Laboratory to Dinning Room"
Nutrigenomics is the scientific investigation of the way specific genes' respond to given nutrients – in other words, the relationship of what we eat with the way our genes function. The goal is to promote human health through optimal nutrition. This is the study of nutrigenomics.
Personalized nutrition (PN) is the application by individuals of their knowledge of nutrigenomics to their everyday decisions about nutrition. The goal is to maximize their own and their family's long-term health based on their knowledge of nutrition and their unique genetic makeup. By active scientific work of researchers consumers will learn about their genetics in at least two important ways: (i) either directly, by means of genetic testing, or (ii) indirectly, based on family history or personal experience.
A variety of players must participate to fulfill this vision. At the discovery end of the value added chain, which is where most of the emphasis in the field is today, society relies on nutritional scientists to advance our understanding of food and nutrition, and on molecular biologists and genomics experts to decipher the meaning of the human genome. Scientists from these disciplines, interacting and sharing their methodologies, will generate new discoveries in the nascent field of nutrigenomics.
Aims of NUBI at a glance
1. Treatment of NASH, Type 2 Diabetes Mellitus (T2DM) and liver metabolism pathology by disease-specific optimized nutritional products
2. Establishments of new insights and expertise in field of personalized nutrition (disease-nutrient correlation)
3. Development of methods for the assessment of the health effects from mixtures products of food additives
4. Qualification and validation of new diagnostic and IT tools e.g. „Cell-chips", databank, data mining
5. Prevention of well known obesity sequels by identification and characterization of gene specific optimized nutrition
SUMMARY
Using facilities and expertise at MUG and addressing the existing scientific questions for PN, we have developed a project construction. Our project (NUBI) plans to have two nutritional sub-areas:
(A) Gene expression on lipids and obesity:
1. Diet induced changes in the components of energy expenditure: resting metabolic rate, thermal effect of food, and energy cost of physical activity; Effects of CHO/FAT ratio in the diet op gene expression in adipose tissue before and during a weight reduction. (Genome scan, SNP-analyses, proteomics in adipocyte)
2. Essential fatty acid metabolism and energy balance. Identification of dietary response genes controlling plasma lipid levels in mice and humans: analysis of the response of plasma lipids on nutritional enrichment with PUFAs.
3. Fat cell differentiation and its genetic determinants; Relevance of genetic predisposition and nutrition factors in the pathogenesis of type 2 diabetes mellitus and cardiovascular complications. (Nano)
4. Folic acid, homocysteine and prevention of atherosclerosis. (Nano)
5. Energy metabolism and diabetes mellitus.
(B) Liver metabolism:
1. Inborn enzyme deficit of liver and possibility of establishment of

special nutritional compounds for preventing the expressed clinical picture. Hepatoprotective effects of dietary enrichment of phosphatidile choline and Vitamin E.
2. NASH, a disease that is in our point of view highly effectible with right nutritional approach. If succeeded in this part, we will find out the exact nutriceutical mixture to act disease and biomarkers espression.
3. Beneficial effects of nutritional stimulation of bilirubin clearance in hyperbilirubinaemie: Modulation of target genes.
4. Protective effect of methionin - tryptophan enriched diet on liver metabolism: expression and depression of target tissue specific CoAs.(Nano)

Tipo Ente: Università>

Partner richiesto: SMEs or/and researchers.
Expertise required:
Technology development in food and pharma industry, quality management in food and pharma industry, safety management in food and pharma industry, production in food and pharma industry, encapsulation and particle development

1.

Date 2007 02 27 Deadline 2007 09 18

Below the Data of a partner who wants to a.) join a consortium b.) coordinate a project and searches for suitable partners or c.) the data of a Consortium which is in need of additional partners with certain expertise / equipment is given.

CONTACT

Organisation	Fraunhofer-Institute of Toxicology and Experimental Medicine (ITEM)	**Department**	Molecular Medicine & Molecular Biotechnology
Contact person	Prof. Dr. Jürgen Borlak	**Male/female**	male
Address	Nikolai-Fuchs Strasse 1	**Email**	borlak@item.fraunhofer.de
Postcode	30625	**Telephone**	+49 511 5350 559
City	Hannover	**Fax**	+49 511 5350 573
Country	Germany	**Website**	http://www.item.fraunhofer.de

Are you familiar with the European Framework Programme?	x☐ YES	☐ NO
Have you participated in a former European FP?	x☐ YES	☐ NO
If yes please indicate the project or activity:		

Project

Title	**Acronym**

Project type	☐ Large Collaborative Project	x☐ Small or medium Collaborative Project	☐ Network of Excellence	☐ Other: _____
Planned to participate as	x☐ **partner**	☐ **coordinator**		
Call identifier	Health-2007-2.4.2-7 Integrating pharmacogenomic approaches in the treatment of CVD			
Workprogramme Topic you are interested in	Theme 1 ☐	Theme 2 ☐		

Your main research areas / Description of research activities

The Center of Molecular Medicine and Medical Biotechnology of Fraunhofer-ITEM of which I serve as Director was founded in 1998 and now consists of 11 postdoctoral fellows (3 males, 8 females), 6 doctoral fellows (3 males, 3 females) and 11 research technicians (3 males, 8 females). In this Center, a wide range of systems are available which enable problem solving and a mechanistic approach in pharmacology, toxicology and cancer. Alongside routine tests in molecular dosimetry, biochemical toxicology, xenobiochemistry, and some specialized studies in endocrine toxicology, gene expression patterns are also investigated in pathology and pharmacological and toxicological assessments using advanced molecular biology techniques. The Fraunhofer-(ITEM) and the Center of Molecular Medicine and Medical Biotechnology are certified for molecular toxicology according to the OECD Principles of Good Laboratory Practice - GLP (German Chemicals Law Â§ 19a, Appendix 1, BGBl pp. 2119-2129, June 28, 2002).
The department has gained in-depth diligence in the fields of genomics (Affymetrix station for the transcriptome-wide gene expression analysis and cDNA arrays, RT-PCR, DNA sequencing, gene polymorphisms), proteomics (Proteomics workstation

	for investigating differentially regulated proteins, EMSA protein/DNA interactions, genomic footprinting, MALDI-TOF/TOF for protein identification and gene polymorphism analyses), metabonomics (600 MHz high resolution nuclear magnetic resonance spectrometer (NMR) coupled with HPLC and MS), cell culture (primary cell and tissue cultures (human and animal) and bioinformatics (in silico analyses of 'omics' data). The experimental verification of the results of in silico approaches is usually performed in our lab using the following methods: EMSA protein/DNA interactions, genomic footprinting, promoter functional assays by reporter gene constructs.

Expertise / Commitment offered:

Description of the know-how/expertise and equipment you can provide	We can participate in the analysis of genetics variations in drug metabolism and/or gene expression. Detection or confirmation of genetic variations can be carried out through Affymetrix microarray systems (e.g. GeneChip® Mapping 100K Set), denaturing high-performance liquid chromatography (dHPLC, Transgenomic), Applied Biosystems 3100 capillary genetic analyzer, Taq Man assays (Applied Biosystems 7500), fluorescence resonance energy transfer (FRET, Light Cycler), and PCR-RFLP assays. Furthermore, comparative sequencing analysis can be undertaken by the following softwares: Lasergene 7.0, Vector NTI 10, and SeqScape 2.0. The work will be carried out by a team of experienced molecular biologists/geneticists, bioinfomaticians and research technicians. Relevant publications 1. Borlak J, Reamon-Buettner SM. N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients. BMC Med Genet 2006; 7:58. 2. Borlak J, Reamon-Buettner SM. N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson's disease. BMC Med Genet 2006; 7:30. 3. Schulte I, Bektas H, Klempnauer J, Borlak J. Vitamin E in heart transplantation: effects on cardiac gene expression. Transplantation 2006; 81(5):736-745. 4. Hermann R, Borlak J, Munzel U, Niebch G, Fuhr U, Maus J, Erb K. The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine. Pharmacogenomics J 2006; 6(3):211-219. 5. Zwadlo C, Borlak J. Disease-associated changes in the expression of ion channels, ion receptors, ion exchangers and Ca(2+)-handling proteins in heart hypertrophy. Toxicol Appl Pharmacol 2005; 207(3):244-256. 6. Borlak J, Zwadlo C. The myosin ATPase inhibitor 2,3-butanedione monoxime dictates transcriptional activation of ion channels and Ca(2+)-handling proteins. Mol Pharmacol 2004; 66(3):708-717. 7. Jetter A, Kinzig-Schippers M, Illauer M, Hermann R, Erb K, Borlak J, Wolf H, Smith G, Cascorbi I, Sorgel F, Fuhr U. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. Eur J Clin Pharmacol 2004; 60(1):17-21. 8. Borlak J, Hermann R, Erb K, Thum T. A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol. Metabolism 2003; 52(11):1439-1443. 9. Borlak J, Zwadlo C. Expression of drug-metabolizing enzymes, nuclear transcription factors and ABC transporters in Caco-2 cells. Xenobiotica 2003; 33(9):927-943. 10. Borlak J, Thum T. Hallmarks of ion channel gene expression in end-stage heart failure. FASEB J 2003; 17(12):1592-1608. 11. Borlak J, Thum T. PCBs alter gene expression of nuclear transcription factors and other heart-specific genes in cultures of primary cardiomyocytes: possible implications for cardiotoxicity. Xenobiotica 2002; 32(12):1173-1183. 12. Thum T, Borlak J. Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 2002; 16(12):1537-1549. 13. Walles M, Thum T, Levsen K, Borlak J. Verapamil: new insight into the molecular mechanism of drug oxidation in the human heart. J Chromatogr A 2002; 970(1-2):117-130. 14. Thum T, Borlak J. Butanedione monoxime increases the viability and yield of adult cardiomyocytes in primary cultures. Cardiovasc Toxicol 2001; 1(1):61-72. 15. Borlak J, Thum T. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis. Clin Chem 2002; 48(9):1592-1594. 16. Borlak J, Dangers M, Thum T. Aroclor 1254 modulates gene expression of nuclear transcription factors: implications for albumin gene transcription and

protein synthesis in rat hepatocyte cultures. Toxicol Appl Pharmacol 2002; 181(2):79-88.
17. Walles M, Thum T, Levsen K, Borlak J. Verapamil metabolism in distinct regions of the heart and in cultures of cardiomyocytes of adult rats. Drug Metab Dispos 2001; 29(5):761-768.
18. Thum T, Borlak J. Reprogramming of gene expression in cultured cardiomyocytes and in explanted hearts by the myosin ATPase inhibitor butanedione monoxime. Transplantation 2001; 71(4):543-552.
19. Thum T, Borlak J. Isolation and cultivation of Ca2+ tolerant cardiomyocytes from the adult rat: improvements and applications. Xenobiotica 2000; 30(11):1063-1077.
20. Pethig K, Heublein B, Hoffmann A, Borlak J, Wahlers T, Haverich A. ACE-gene polymorphism is associated with the development of allograft vascular disease in heart transplant recipients. J Heart Lung Transplant 2000; 19(12):1175-1182.
21. Borlak J, Thum T, Landt O, Erb K, Hermann R. Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert's syndrome) in healthy subjects. Hepatology 2000; 32(4 Pt 1):792-795.
22. Thum T, Borlak J. Gene expression in distinct regions of the heart. Lancet 2000; 355(9208):979-983.

Keywords specifying your expertise	pharmacogenetics, molecular markers, DNA-based assays

Have you already identified Partners for projects you are interested in?	☐ Yes x☐ No	**Have you already contacted other partners?**	☐ Yes x☐ No

If you want to coordinate / build a consortium or have already formed a consortium, you may need additional partners. To identify suitable partners please state what expertise / equipment is required:

Profile of Partner(s) sought

Expected Commitment	☐ technology development	☐ research	☐ training
	☐ dissemination	☐ demonstration	☐ other _____
Country /region			
Expected expertise / know-how and equipment which the partner should contribute to the project(s)			

Data submission to	Public databases	☐ Yes ☐ No
	NKS affiliated organisations in Europe and third countries	☐ Yes ☐ No
	Consortia	☐ Yes ☐ No

Interested Consortia and Partners should directly get in touch with the contact person given on page one.

2.

Date 2007 07 12 Valid until: 2014 12 31

CONTACT DETAILS

Organisation	University of Haifa	**Department**	Biology
Contact person	Amiram Ariel	**Male/female**	M
Address	Room 79, Binian Rav Tahliti	**Email**	Amiram@research.haifa.ac.il
Postcode	31905	**Fax**	972-4-8288763
City	Haifa	**Telephone**	972-4-8288771
Country	Israel	**Website**	

ORGANISATION TYPE

Research organisation type	☒ Research Organisation ☐ Company ☐ Other	**Is your company a Small and Medium Sized Enterprise (SME*)?** **Number of employees:**	☐ YES ☒ NO

* Your enterprise is an SME if:

-it has **less than 250 employees**
-it has either an **annual turnover not exceeding €50M**, **or an annual balance sheet total not over €43M**
-it is **less than 25% owned by a non SME** (unless these are financial investors, such as banks or venture capitalists

Description of research activity: My current research focuses on elucidating and characterizing novel events in the resolution of inflammation as well as determining novel actions for pro-resolving lipid mediators on the acquired immune response. These include the following projects:
(a) Understanding the role of 15-Lipoxygenase and its lipid products in human T_H2 polarization and in the functional antagonism of T_H1-based autoimmunity in animal models.
(b) Reveal novel roles for chemokines and their receptors in the termination of the inflammatory process.
(c) Explore novel roles for apoptotic leukocytes in the resolution of inflammation, and new pathways in their communication with the phagocytes that clear them.

Former participation in an FP European project?	☐ YES ☒ NO
Project title / Acronym:	
Activities performed:	

FP7 PROJECT

Title:	**Acronym:**

Project type	☒ Large Collaborative Project	☐ Network of Excellence	☐ Small Collaborative Project	☐ Other:
Status	☒ **planned for submission**	☐ **running EU project**		
Call references	**FP7-HEALTH-2007-B**			

Priorities' Main Research Areas	**2. Translating research for human health** **2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES** **2.4.5. Other chronic diseases**
Workprogramme Topic	**HEALTH-2007-2.4.5-12**: Early processes in the pathogenesis of chronic inflammatory diseases

EXPERTISE/COMMITMENT OFFERED

Keywords specifying the expertise:	Inflammation and its resolution Chemokines and their receptors apoptosis engulfment by macrophages peritonitis autoimmunity omega-3 PUFA
Description of the expertise:	Our studies, using lipid mediator informatics employing LC-MS-MS, revealed that lipid mediators generated during the resolution of inflammation (*i.e.* Lipoxins and protectins) inhibit T cell pro-inflammatory functions (Ariel et al. *J. Immunol.,* 170:6266*),* and can serve as regulators in T helper cell polarization (Ariel et al. *J. Biol. Chem.,* 280:43079). These results demonstrate novel roles for lipoxins and protectins in the regulation of T cell-mediated responses relevant in inflammation and its resolution. Moreover, they provide potential counter-regulatory signals in communication(s) between the innate and acquired immune systems and between T_H1 and T_H2 differentiation pathways. In addition, we found that apoptotic PMNs serve as chemokine scavengers during murine peritonitis by expressing chemokine receptors on their surface (Ariel et al. *Nat. Immunol.,* 7:1209). These results characterize a novel role for apoptotic leukocytes within the resolution of inflammation.
Commitment offered	☒ Research ☐ Demonstration ☐ Training ☐ Technology ☐ Dissemination ☐ Other:
Term commitment	☐ Short (< 1 year) ☐ Medium (1 to 3 years) ☒ Long (more than 3 years)

3.

Partnership

Call line: HEALTH-2007-2.4.1-10: Role of inflammation in tumour initiation and progression.
The programme will aim at translating knowledge on the molecular machinery underpinning inflammatory processes driving tumour initiation and progression in various cancers, into functional, validated therapeutic anti-cancer approaches. Funding scheme:
Collaborative project (Large-scale integrating project).
Deadline : 19/09/07

Lab : Centre d'Immunologie de Marseille-Luminy INSERM, CNRS, Université de la Méditerranée
Web site of the CIML: *http://www.ciml.univ-mrs.fr/index.htm#*
Web site of the involved team : *http://www.ciml.univ-mrs.fr/Lab/Naquet.htm*

Team :
P Naquet, Professor (Team leader), *naquet@ciml.univ-mrs.fr*
F Galland, Professor
V Millet, Technician
C Roisin-Bouffay, postdoc
A Clément, PhD student
L Hubert, master student

Contact:
- CIML : *naquet@ciml.univ-mrs.fr*
- Université de la Méditerranée : *celine.damon@univmed.fr*

Proposed expertise :
We have identified the Vnn gene family. Vnn1 is a novel epithelial regulator of intestinal inflammation. Using engineered mouse mutant models, we demonstrated that the absence of this molecule controls the development of colitis, regulates intestinal homeostasis and prevents the development of colon cancer on an inflammatory ground.
We are currently following two axis of research: **i) cellular and molecular analysis of the protection; ii) exploration of Vnn expression and function in human tumors.**

Keywords
Inflammation, immunity, colorectal cancer, epithelium, tumor microenvironment

Specific Equipment:
Our team belongs to a large research institute with all the facilities for fundamental research in immunology including work on mouse models, cytometry, microscopy, proteomics

Selected publications on this subject:
- Aurrand-Lions, M., Galland, F., Bazin, H., Zakharyev, V., Imhof, B. A., and Naquet, P. (1996). Vanin-1, a novel GPI-linked perivascular molecule involved in thymus homing. Immunity 5, 391-405.
- Galland, F., Malergue, F., Bazin, H., Mattei, M. G., Aurrand-Lions, M., Theillet, C., and Naquet, P. (1998). Two human genes related to murine vanin-1 are located on the long arm of human chromosome 6. Genomics 53, 203-13
- Pitari, G. , Malergue, F. , Martin, F., Philippe, J.M., Massucci, M.T., Chabret, C., Maras, B., Duprè, S., Naquet, P. and Galland, F. (2000). Pantetheinase activity of membrane-bound Vanin-1 and secreted Vanin-3: lack of free cysteamine in tissues of Vanin-1 deficient mice. FEBS Letters 483, 149-154
- Martin F, Penet MF , Malergue F, Galland F, , Dessein A, de Reggi M, Naquet P*, Gharib B*. (2004) Vanin-1-/- mice show decreased NSAID- and Schistosoma-induced intestinal inflammation associated with higher glutathione stores. J Clin Invest., 113: 591-597. (* co-senior authors)
- Berruyer C, Pouyet L, Millet V, Martin FM, Legoffic A, Canonici A, Garcia S, Bagnis C, Naquet P*, Galland F*. Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor{gamma} activity. J Exp Med. 2006 Dec 25;203(13):2817-27. 2006 Dec 4. (* co-senior authors)

4.

Organization Name:
Fundação Oswaldo Cruz - Fiocruz
Contact:
Cristina Henriques (Ph.D)
Manager, Research and Technology Development.
henriques@fiocruz.br
Tel:+55-21-25903545
Fax:+ 55-21- 25607011
FP7 Call or thematic area:

FP7- HEALTH; FP7-PEOPLE; TECHNOLOGY PLATFORMS; INFRA STRUCTURE

Proposal title:
Technology platforms to produce highly innovative research and new technologies applicable to human neglected diseases.

Proposal Abstract:
Technology platforms, at the Instituto Oswaldo Cruz (IOC), Rio de Janeiro, is a pioneer initiative in Brazil supported and fomented by the Ministry of Health and the Ministry of Science and Technology to overcome the gaps between science and technology, and create innovative solutions for endemic health problems that afflict million of people in developing countries.
IOC is the main research unit of Fundação Oswaldo Cruz, which is also composed by vaccine and drug facilities ensuring that the knowledge generated in the laboratories is transformed into products. The platforms policy is aligned with intellectual property process, ethical and biosecurity legal aspects.
The purpose of our platform developing schedule is to provide infrastructure for research combined with technological development and provide service for laboratories. Five main platforms (Genomics; Proteomics; Cytomics; Microscopy and Biosecurity) are giving support to 66 research laboratories, most of them working with neglected diseases, such as Chagas disease, Leishmaniasis, Malaria, Lymphatic filariasis, Schistosomiasis, Onchocerciasis, Tuberculosis, Leprosy, Leptospirosis and Dengue. Some technological platforms are already well structured, with different levels of access and mechanisms of management, monitoring its efficiency and performance.
“Microscopy and Image” is the oldest platform, originally composed by two transmission electron microcroscopes (Zeiss EM10C and 902) and a scanning electron microscope (Zeiss DSM 940). The image archive is composed of around 40,000 negatives, a source of valuable information, which should be catalogued and stored appropriately. Presently, the microscopy center is being amplified, with the acquisition **SCN Quadra 2, Bloco A, Ed. Corporate Financial Center, 11º andar, Sala 1102, CEP 70712-900 Brasília, DF – Brazil Tel (5561) 3424 9600, Fax (5561) 3424 9659**
of three modern microscopes (Jeol JEM-1011, Jeol JSM-6701F and JSM-6390LV/LGS) and the creation of an Image database center.

Target Partners: 1- Expertise in management of technological platforms, experience in patent process and transformation of research discoveries in biotechnology products.

2- Novel targets for drugs and vaccines development are continuously identified in our Institution, in a manner that some technological platforms should be expanded and new platforms created. 2.1- Based on the relevant number of phyto- and bio-product derivatives already identified that should go to trials, we are seeking for partners with experience in drug screening and early stages of drug development.

2.2- Implementation of Technology Platforms in the field of immuno-therapy and vaccine development, for production of monoclonal antibody and immunogenicity testing, before its production in larger scale.

3- In summary, we are seeking for partnership with small and medium enterprises (SME), Research and/or Biotechnology Institutes, Regulatory offices, Centers of microscopy and images, Universities and Industry

PROFILO 1

Actar AB –
Your Tool for Developing Your Medical Research into Clinical Drugs

Actar AB, a small/medium size Swedish biotechnology company, performs drug development in collaboration with academic researchers at European Universities. Together with the research group we identify and validate compounds active against the drug target discovered by the research group. Through high-throughput screening of chemical libraries, in innovative and relevant model systems, lead compounds are identified. The lead compounds are thereafter transferred to the pharmaceutical industry for further development into candidate drugs.

We have vast experience in collaborating with academic research groups, thus Actar AB is an ideal partner in FP7 calls where academic results should transfer into a drug development project. As the academic researcher provides scientific knowledge to each project, Actar AB's activities are applicable to all fields of medicine involving development of small molecules active against a target.

Actar AB facilitate the first critical steps in drug development for the researcher

Actar's operations enable the key steps needed to attain Proof-of-Concept for a project initiated by an academic researcher by:

► Focus on molecules with chemical characteristics suitable for early drug development

► Conduct high quality laboratory operations within method development, chemical design, and high-throughput screening of in-house chemical libraries.

Actar provides key success factors to the project:

► Screening facilities including compound libraries, robotics and analysis software

► Competence in medicinal chemistry, screening technologies and project management

► Financial resources

More information is available on our website www.actar.se.

Best regards,

Mikael Hanson
Actar AB
Mobil: +46 (0)733 48 48 02
Fax: +46 (0)8 524 84 800
E-mail: mikael.hanson@actar.se
Web: www.actar.se

PROFILO 2

PARTNER is looking for a Project

1.) PARTNER OFFERED

Organisation	SISTEMAS GENÓMICOS S.L.	Type of organisation (IND, SME, RES, HE, others)	SME
Contact person	David Garcia		
Email	*david.garcia@sistemasgenomicos.com*		
Telephone	+34 902 364 669		
Postcode, city	46980, Paterna, VALENCIA		
Country	SPAIN		
Website	www.sistemasgenomicos.com		

Role in desired project	technology development : X	research : X	training :
	dissemination :	demonstration : X	other : X
Expertise offered and what I would like to do	Sistemas Genomicos SL **is a biotechnology company specialised in genetic testing and genome research. The company is the largest one providing DNA analysis in Spain and the only that has taken part in international genome sequencing projects.** **In the** biomedical **field, we provide an extensive range of genetic diagnostics, including many rare diseases. We perform as well Preimplantation Genetic Diagnosis (diagnosis on one cell from an embryo) as assistance to reproduction genetics, amongst other similar and complementary techniques.** **We are nowadays carrying several research projects regarding pathogenic** alternative splicing **events aiming to understand disease progression and to find new therapeutic targets.** **Within the** agri-food **area, we provide services for the industry such as pathogen, GMO and allergens detection, genetic authentification of products, traceability services, etc.** **We participated in the sequencing of *Arabidopsis thaliana*, and nowadays we are involved in the** international consortium sequencing tomato genome**.** **We offer our expertise in the analysis of splicing events and PCR-based test. We offer as well our sequencing capabilities to assist in any project related to molecular biology.**		

I am familiar with the European Framework Programme:

YES X	NO

2.) COORDINATOR / PROJECT sought after **(for proposal submission only)**

WP topic : HEALTH-2007, KBBE-2007 and SME-2007-1

Project type

Large scale integrating collaborative project	X
Small or medium-scale focussed research project	X
Collaborative projects targeted to SMEs	X
CA or SSA	
Network of Excellence	X

Keywords of project:	Genome, transcriptome, splicing, GMO, cancer, molecular diagnostics, drug targets, therapeutic targets, molecular epidemiology, metagenome, cell free DNA, massive sequencing, rare diseases

I AGREE WITH THE PUBLICATION OF MY DATA

PLEASE FILL IN THE PROFILE FORM AND RETURN IT TO:
david.garcia@sistemasgenomicos.com

PROFILO 1

Contact:
Lic. Marcela Olano Gossweiler
Proyect Officer
Ministry of Education and Culture,
Reconquista 535,
11000 Montevideo, Uruguay
Tel/Fax: ++5982 916 1016 and 915 1045

Colaborative proposal

Our aim is to develop effective vaccines for liver fluke disease, a major health problem of livestock caused by the trematode parasite *Fasciola hepatica*, widespread in Europe, America and Oceania. On the other hand, *F. hepatica* causes significant human disease in developed countries affecting 4m people, with 180m people at risk of infection.

We propose an integrated strategy to provide new knowledge in key areas of the host-*F. hepatica* relationship that will assist the development of vaccines for fasciolosis. Studies on host immunity to fasciolosis suggest a complex host-parasite interaction which determines whether infection leads to chronic infection or acquired immunity. Evidence suggests that differences between host immune responses influence the host-parasite relationship. We have shown the feasibility of experimental vaccination of ruminants to control fasciolosis but this approach is constrained by the fact that subsets of animals do not respond to vaccination and understanding the molecular basis of this non responsiveness in ruminants is needed.

General Objectives

We will compare the RNA/protein signatures associated with natural acquired immunity in susceptible sheep and compare these with signatures in vaccinated sheep to study variations in vaccine-induced protective immunity.

We will define the ESTs and proteome of the juvenile stages of both *Fasciola hepatica*, and compare these datasets to identify cDNAs/proteins expressed which may contribute to immune evasion mechanisms of *Fasciola*: such molecules represent novel vaccine or drug targets.

Novel and existing candidate vaccines developed in our laboratory such as leucine aminopeptidase (LAP) and thiredoxin glutathione reductase (TGR) will be further validated, optimised and tested in sheep and cattle: mucosal delivery of vaccines in live vectors will be assessed.

Recent publications

Piacenza, L., Acosta, D., Basmadjian, I., Dalton, J.P., Carmona, C. (1999) Vaccination with cathepsin L proteinases and with leucine aminopeptidase induces high levels of protection against fascioliasis in sheep. Infection and Immunity 67, 1954-1961.

Berasain, P., Carmona, C., Frangione, B., Dalton, J., Goñi, F. (2000) Interaction of *Fasciola hepatica* proteases with human IgG subclasses. Basis of parasite subversion of the humoral immune response. Experimental Parasitology 94, 99-110.

Torgerson, P. R., Carmona, C. and Bonifacino, R. (2000) Estimating the economic effects of echinococcosis: Uruguay an upper middle income developing country. Annals of Tropical Medicine and Parasitology, 94, 703-713

Alvarez, D., Medeiros, A., Míguez, M., Casaravilla, C., Malgor, R., Carmona, C., Nieto, A. Osinaga, E. (2001) O-glycosylation in *Echinococcus granulosus*: Identification and characterisation of the carcinoma associated Tn antigen. Experimental Parasitology, 98, 100-109.

Carnevale, S., Rodríguez, M., Guarnera, E., Carmona, C., Tanos, T. Angel, S. (2001) Inmunodiagnosis of fasciolosis using recombinant procathepsin L cysteine proteinase. Diagnositic Microbiology and Infectious Disease, 41:43-49.

Touz, C., Nores, M., Slavin, I., Carmona, C., Conrad, J., Mowatt, M., Nash, T., Coronel., C., Lujan, H. (2002) The activity of a developmentally regulated cysteine proteinase is required for cyst wall formation in the primitive eukaryote *Giardia lamblia*, Journal of Biological Chemistry 277, 8474-8481.

Touz, C., Nores, M., Slavin, I., Piacenza, L., Acosta, D., Carmona, C., Luján, H. (2002) A membrane-associated dipeptidyl peptidase IV-homolog is involved in encystation-specific gene expression during *Giardia* differentiation. The Biochemical Journal 364, 703-710.

Bentancor, A, Piacenza, L., Carmona, C. (2002) Immunization with cathepsin L proteinases CL1 y CL2 secreted by *Fasciola hepatica* elicit a preferential type 1 response based on IgG2a antibodies in rats. Journal of Helminthology 76, 199-207.

Freire, T., Casaravilla, C., Carmona, C., Osinaga, E. (2002) Mucin type *O*-glycosylation in *Fasciola hepatica*: characterization of carcinoma associated Tn and sialyl-Tn antigens and evaluation of UDP-GalNAc:polypeptide-acetylgalactosaminyltransferase activity. International Journal for Parasitology 33, 47-56.

Freire, T., Robello, C., Casaravilla, C., Medeiros, A., Carmona, C., Osinaga, E. (2002) Antígenos mucínicos de *O*-glicolisación simple: nuevas similitudes moleculares entre células cancerosas y parásitos. Actas de Fisiología de la Facultad de Medicina, 8, 89-107.

Casaravilla, C., Malgor, R., Carmona, C. (2003) Characterization of carbohydrates of adult* Echinococcus granulosus *by lectin binding analysis. Journal of Parasitology. 89, 57-61.

Casaravilla, C., Freire, T., Malgor, R., Medeiros, A., Osinaga, E, Carmona, C. (2003) Mucin-type *O*--glycosylation in helminth parasites from major taxonomic groups: evidence for widespread distribution of the tn antigen (GalNAc-Ser/Thr) and identification of UDP-GalNAc:polypeptide n-acetylgalactosaminyltransferase activity. Journal of Parasitology. 89, 709-714.

Berasain, P., Carmona, C., Frangione, B., Cazzulo, J.J., Goñi, F. (2003) Specific cleavage sites on human IgG subclasses by cruzipain, the major cysteine proteinase from *Trypanosoma cruzi*. Molecular and Biochemical Parasitology 130, 23-29.

Moreno, M., Benavídez, U., Carol, H., Rosenkranz, C., Welle, M., Carmona, C., Nieto., A., Chabalgoity, J.A. (2004) Local and systemic immune responses to *Echinococcus granulosus* in experimentally infected dogs. Veterinary Parasitology 119, 37-50.

Cancela, M., Carmona, C., Rossi, S., Goñi, F., Berasain, P. (2004) Purification, characterization and immunolocalization of paramyosin from the adult stage of *Fasciola hepatica*. Parasitology Research 92, 441-448.

Maggioli, G., Piacenza, L., Carámbula, B., Carmona, C. (2004) Purification and characterisation of a thioredoxin reductase from *Fasciola hepatica*. Journal of Parasitology 90, 205-211.

Oku, Y., Malgor, R., Benavidez, U., Carmona, C., Kamiya, M. (2004) Control program against hydatidosis and the decreased prevalence in Uruguay. International Congress Series 1267, 98-104.

Casaravilla, C., Malgor, R., Rossi, A., Sakai, H., Nonaka, N., Kamiya, M., Carmona, C. (2005) Production and characterization of monoclonal antibodies against excretory / secretory products of adult *Echinococcus granulosus*, and their application to coproantigen detection. Parasitology International 54, 43-49.

Bessonart, M. E., Macedo, N., Carmona, C. (2005) High resolution B-scan ultrasound of hypertrophic scars. Skin Research and Technology 11; 185-188.

Ubillos, L., Medeiros, A., Cancela, M., Casaravilla, C., Saldaña, Y., Domínguez , L., Carmona, C., Le Pendu, J. ,Eduardo Osinaga. (2007) Characterisation of the carcinoma associated Tk antigen in helminth parasites. Experimental Parasitology. Doi.10.1016/jexppara.2006.12.009.

PROFILO 2

- Presentation of ACF International

Action Contre la Faim (Action Against Hunger) is a humanitarian non-profit organisation which focuses on assisting the most vulnerable populations with nutrition, health, food security, water and sanitation programmes. Advocacy is also carried out in support of people's right to food, health care, water and other transversal thematic. ACF is an international network with head offices in Paris, London, Madrid, New York and Montreal.

- ACF International has operations in 40 countries.
- ACF France in figures (2005):
    - 288 international staff
    - 3400 national staff
    - 18 countries of operations in Africa, Asia and the Caribbean
    - 1 854 000 beneficiaries
    - Budget: 69 million Euros

ACF intervenes in emergency situation (conflicts and disasters) as well as in post crisis situations. ACF works in coordination with other actors. ACF focuses on operational projects, support to civil society, research and publications.

- Areas of work and technical research:

- Nutrition: nutrition surveys, treatment for severe and moderate malnutrition, feeding products, innovation.

- Medical: outpatient care; health and hygiene education; immunization; anti malaria prevention; psychosocial care.

- Water, Sanitation and Hygiene: water resource investigation, water supply, sanitation and hygiene promotion, community based management,

- Food security: food aid, agriculture support, surveillance, community organization, cattle raising.

- Examples of current research projects :

- Nutrition:
- Psychosocial profile of beneficiaries admitted to TFCs (Therapeutic Feeding Centres) and specificities linked to difficulties in breastfeeding (Afghanistan).
- Comparative study of the effectiveness of therapeutic milk products in the treatment of severe acute malnutrition in children under six months of age.
- Improving the quality of the distributed ration by implementing micronutrient supplementation with the family ration distributions.

- Water, Sanitation and Hygiene:
- Improving the sustainability of water and sanitation ACF IN projects and techniques for disengagement.

- Food security:
- ACF Capitalisation on Cash-based Interventions (Paris).

- Contact :
Myriam Aït-Aïssa
Research Assistant

Tel : + 00 33 (0)1 43 35 88 58
Email : *maitaissa@actioncontrelafaim.org*

Action Contre la Faim
4 rue Niepce
75662 PARIS Cedex 14
FRANCE
http://www.actioncontrelafaim.org
Fax : +00 33 (0)1 43 35 88 00

1.

INSTITUTE OF PUBLIC HEALTH

Rruga: "Aleksander Moisiu", Nr 80, Tirana, Albania.
Tel: +355 4374756, Fax 355 43 70058

Instituti i Shëndetit Publik

FP7 Coordinator; Alban Ylli

Email: albanylli@yahoo.co.uk
Tel/fax: +355 4 372962
Mob: +355692378236

Institute of Public health (IPH) is interested to identify partners in the following calls
HEALTH-2007- 3.5-1: epidemiological investigation into long-term trends of population health as consequence of socio-economic transitions, including lifestyle
HEALTH-2007-2.2.1-10: Childhood and adolescent mental disorders
HEALTH-2007-3.5-3: Health care intervention research – optimizing hospital care
HEALTH-2007- 4.1-8: Promotion and facilitation of international cooperation – health policy research

---

We offer:

- Relevant experience in
    - Population surveys; epidemiology, biostatistics
    - Child/adolescent monitoring
    - Health care surveys; health facility or community based
    - Policy analysis
    - Access to hospitals and primary health care
    - Central position in a transition (demographic and social) country health system.

.

2.

Centre for Personal Development

Coordinator 1
AGACHI Ioana
Email: *ioanagachi@yahoo.com*
Mobile: + (40) 744 831 508
Website: *www.cdppsi.ro*

Coordinator 2
DEACONU Diana
Email: *deaconu2001ro@yahoo.com*
Mobile: + (40) 740 155 143

We are interested in finding partners for the following calls:
HEALTH-2007-2.2.1-10: Childhood and adolescent mental disorders
HEALTH-2007-3.1-6: Continuity of clinical care
HEALTH-2007-3.1-7: Patient self-management of chronic disease
HEALTH-2007-4.1-5: Science communication actions

We **OFFER**:

- Relevant **experience** in
    - Organizing *support*, *personal development* and *psychotherapy groups*.
    - Organizing *workshops* and *training* sessions on a wide range of topics that cover psychological practice.
    - Editing *scientific publications*.
    - The application and interpretation of *psychological tests*.
- Appropriate **web-space** for project promotion, as well as for article publication.

We **REQUIRE**:

- **Material resources**
    - Psychological *tests*
    - Access to *articles* and scientific *publications*.
- **Experience** in the *clinical* field
- Access to **mental health institutions**

3.

PARTNER PROFILE FORM

Date:	09-03-2007
Deadline:	2007
Call identifier:	

CONTACT INFORMATION			
Organisation Name	Institute for Biomedical Research	Contact person	Skiriutė Daina
Type of organization	☒ Research institute ☐ University ☐ **SME*** ☐ Industry ☐ Other		
Department	Laboratory of Neuroscience	Telephone	Tel. +370 37 795482
Address	Eiveniu str. 4, LT-50009 Kaunas Lithuania	Fax	Fax. +370 37 302959
Web site	http://www.kmu.lt/index.php?cid=1753	E-mail	d.skiriute@gmail.com

* Your enterprise is an SME if:

-it has **less than 250 employees**
-it has either an **annual turnover not exceeding €50M**, **or an annual balance sheet total not over €43M**
-it is **less than 25% owned by a non SME** (unless these are financial investors, such as banks or venture capitalists

EXPERTISE OFFERED	
Keywords specifying the expertise	Brain tumours; genomics; gene alterations in cell cycle and apoptosis signalling pathways; homozygous deletions and promoter methylation of tumour suppressors.
Description of the expertise	Our group has an expertise in the molecular characterisation of brain tumour tissue. We are successful together with neurosurgeons in tissue banking of brain tumours; we have experience in cancer cell culturing; extracting DNA, RNA from fresh and snap-frozen tumour tissue, whole blood and cultured cancer cells; gene promoter methylation studies and homozygous deletion of tumor supressors are based on MsPCR and dPCR reactions.
Main researchers and expertise (name, surname, academic degree)	Daina Skiriute, Ph D, research assistant in Biomedicine Paulina Vaitkiene, Ph D student, junior research assistant in Biomedicine Arimantas Tamašauskas, M.D., Ph D, professor (Neurosurgery) Vytenis Deltuva, M.D., Ph D, associated professor (Neurosurgery) Kęstutis Skauminas, M.D., Ph D, (Neurosurgery)
Experience in international cooperation and partnership (SMEs, universities, research institutes)	Daina Skiriute – Two months fellowship (04.09.2006 – 04.11.2006), Institute of Anatomy, Kiel University, Germany. Paulina Vaitkiene - Five months fellowship "Erasmus", supplied by the European Community (From 01.04.2006 until 01.09.2006) in the Institute of Neurophatology, Charite, Humboldt University, Germany.
International projects (last 5 years - Title of project, source of funds, duration) Please, indicate if you were/are coordinator, partner or subcontractor	

EXPECTATIONS	
Target consortium Please, indicate the topic	HEALTH-2007-2.1.1-1: Networking biobanking initiatives across Europe: developing standards and norms for existing and future human

title from the work programme	sample biobanks. HEALTH-2007-2.1.2-5: Multidisiplinary fundamental genomics and molecular biology approaches to study basic biological processes relevant to health and desease (*deadline 18 September 2007*) HEALTH-2007-2.4.1-2: Translating clinical 'omics'-technology (genomics, proteomics, metabolomics) into innovative cancer biomarkers aiding in early diagnosis, prognosis and treatment selection of cancer patients. HEALTH-2007-2.4.1-3: Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer. HEATH2007-2.4.1-4: Novel cancer screening methods

4.

PARTNER PROFILE FORM

INFORMATION OF ORGANIZATION	
Name of organization	Institute of Atomic Physics and Spectroscopy, University of Latvia
Organization type	☐ Consultancy x☐ Research x☐ Education ☐ Industry ☐ Technology Transfer ☐ Non-Commercial ☐ Other ☐ SME ☐ Owned by non-SME
Organization Size (employees)	☐ < 10 ☐ 10-49 x☐ 50-99 ☐ 100-199 ☐ 200-249 ☐ >250
Short description of organization (main research activities)	The institute (*http://home.lanet.lv/~asi/en/index.htm*) is aiming at multi-disciplinary research, including development of new optical technologies for clinical applications, carried out at the Bio-optics and Fibre Optics laboratory headed by Prof. Janis Spigulis (*www.lanet.lv/~spigulis*).
Expertise offered	New optical methods and equipment for medical diagnostics and monitoring, including parallel multi-channel and multi-laser photoplethysmography for cardiovascular and dermatological applications, wireless health monitoring systems and novel spectrometry methods (based on laser fluorescence and diffuse reflectance) for human skin assessment.
Target partner (expertise)	**Consortia preparing proposal on topic HEALTH-2007.1.2.-2** Novel optical methodologies for detection, diagnosis and monitoring of disease or disease related processes.
International cooperation and partnership (SMEs, universities, research institutes)	Linkoping University, Sweden Lund University, Sweden Columbia University, USA

International projects (last 5 years - Title of project, source of funds, duration) Please, indicate if you were/are coordinator, partner or subcontractors	1. "Studies of ALA-based laser photodynamic therapy", EC Programme "Improving Human Potential – Access to Research Infrastructures", project # HPRI-CT-1999-00041, Lund Laser Centre, 2001. 2. "Biomedical Physics in vocational training at different levels: targeting distance education", EC LEONARDO DA VINCI project # LT/00/B/F/PP-137.024, 2001-2002. 3. „AOMD-3" – EC FP5 Project # ICA1- 2001- 60041, 2002. 4. "Optoelectronic equipment and methodology for cardio-vascular monitoring during the training process", LMES Grant # TOP 02-13, 2002 - 2003. 5. Institute of Atomic Physics and Spectroscopy – Centre of Excellence for Basic Research in Nanoscale Physics and Applications, EC FP5 # G1MA-CT-2002-04063, 2003-2005. 6. "CLEAR – Clinical Research Physician", EC LEONARDO DA VINCI project # 2003-A/03/B/F/PP-158.023, 2003 – 2006. 7. "Optical methods for "*in vivo*" control of bio-processes", LSC Grant # 04.283, 2004 – 2007. 8. "Development of optical methods for functional diagnostics", Scientific Exchange Program between Latvia and USA (Columbia University), 2004. 9. "Methods and devices for optical cardio-vascular monitoring", University of Latvia research project, 2004 - 2006. 10. "Perspective biomaterials and medical technologies", Latvian state research project, 2005-2008. 11. "New methods and technologies for production and application of optical fibres", ERDF project #VPD1/ERAF/CFLA/05/APK/2.5.1./000047/023, 2006-2008. 12. "Information technologies for optical cardio-vascular monitoring", ERDF project # VPD1/ERAF/CFLA/05/APK/2.5.1./000044/022, 2006-2008

CONTACT DETAILS	
Name, Surname:	Janis Spigulis
Address:	University of Latvia, IAPS, Raina Blvd. 19, Riga, LV-1586, Latvia
Phone:	+371 7228249 ; +371 29485347
Fax:	+ 371 7228249
e-mail:	janispi@latnet.lv
Web site:	www.lanet.lv/~spigulis

PARTNER PROFILE FORM

Date:	15/03/2007
Deadline:	31/12/2007
Call identifier:	**HEALTH-2007-**

CONTACT INFORMATION			
Organization Name	**The Institute of Experimental and Clinical medicine at Vilnius University**	Contact person	**Gintautas Mereckas**
Type of organization	☒ Research institute ☐ University ☐ **SME*** ☐ Industry ☐Other		
Department	**The Gerontology Rehabilitation Centre**	Telephone	**+3705 2777745**
Address	**Kalvariju-323, Vilnius, Lithuania**	Fax	**+3705 2700538**
Web site	***http://www.ekmi.vu.lt/en/index.htm***	E-mail	***ginmerec@ktl.mii.lt***

* Your enterprise is an SME if:

-it has **less than 250 employees**
-it has either an **annual turnover not exceeding €50M**, **or an annual balance sheet total not over €43M**
-it is **less than 25% owned by a non SME** (unless these are financial investors, such as banks or venture capitalists

EXPERTISE OFFERED	
Keywords specifying the expertise	**Urinary incontinence, prevalence, quality of life, aged males and females**
Description of the expertise	Our centre contributes to the solution of social problems, reducing disablement and improving the prophylaxis of social health of elderly people. Our research group is majoring in urinary incontinence problems of elderly people. During the year 2005-2006, our group carried out the epidemiology study on urinary incontinence in elderly population in Vilnius city, specializing in nursing homes. The short description on the results of the study can be found on internet magazine:*http://www.gerontologija.lt/en/2006nr4/4.htm*
Main researchers and expertise (name, surname, academic degree)	Associated prof. Vidmantas Alekna Gintautas Mereckas
International projects (last 5 years - Title of project, source of funds, duration) Please, indicate if you were/are coordinator, partner or subcontractor	1) Leonardo da Vinci (2005-2006) - coordinator 2) 5th Framework: • ***Cross-national determinants of quality of life and health services for the elderly*** **(**CLESA); • ***The measurement of quality of life in older adults and its relationship to healthy ageing*** (WHOQOL-OLD); 2002-2004 (partner); 3) 6th Framework: **Better care and social inclusion for people with disabilities (**DIS-QOL); 2005-2008 (partner).

EXPECTATIONS	
Target consortium Please, indicate the topic title from the work	We would like to join consortium working on the topic **HEALTH-2007-2.4.5-11: Translational research aiming for a treatment of urinary incontinence**

programme	

6.
PARTNER PROFILE FORM

Date:
14.03 2007

INFORMATION OF ORGANIZATION	
Name of organization	**Faculty of Medicine, University of Latvia**
Organization type	☒ Research ☒ Education ☐ Industry ☐ Technology Transfer ☐ Consultancy ☐ Other
Organization Size (employees)	☐ < 10 ☐ 10-49 ☐ 50-99 ☒ 100-199 ☐ 200-249 ☐ >250
Short description of organization (main research activities)	The main research activities of Biochemistry team of Faculty of Medicine are connected with: -) Gene polymorphism studies, -) Genetic basis of metabolic and autoimmune disease -) Mechanism of action of cardiovascular and antitumour drugs -) Role of NO in pathology and drug action. -) Chromatin, nuclear matrix.
Expertise offered	Collections of DNA samples. Novel substances as prospective drugs. Molecular biology methods. Biochemical methods. Immunocytochemistry
Target partner	*Consortia preparing proposal on topics:* *1st call* *HEALTH-2007—2.4.1.-1 Translating the knowledge on non-coding RNAs linking to the aetiology of cancer into novel diagnosis and therapy strategies.* *2nd call* *HEALTH-2007-2.4.1.-12 Translating the hypoxic tumour microenvironment*

CONTACT DETAILS	
Name, Surname:	Nikolajs Sjakste
Address:	Sharlotes 1a, Riga LV1001, Latvia
Phone:	371-7038120
Fax:	371-7366306
e-mail:	Nikolajs.Sjakste@lu.lv
Web site:	www.lu.lv

7.

CONTACT DETAILS

Organisation name	LiteThru Ltd	**Contact person - name**	Darren Andrews
Department	CLIK	**Gender**	M
Address	Daresbury Laboratory	**Email**	*darren.andrews@litethru.com*
Postcode	WA4 4AD	**Tel:**	01925603747
City	Warrington	**E-mail**	
Country	UK		
www address	www.clikbiz.co.uk		

ORGANISATION TYPE

Research organisation type	Company	**Is you company an SME?** **Number of employees**	Yes

Description of expertise offered.

Former participation in a Framework project? **Project title/acronym** **Activities performed**	No

Your enterprise is an SME if: it has less then 250 employees. It has an annual turnover not exceeding 50m€ or an annual balance sheet not exceeding 43m€.

EXPERTISE/COMMITMENT OFFERED

Keywords specifying the expertise:	Raman, cancer, non-invasive, spectroscopy, diagnosis, safe

Description of the expertise	Tissue measurement and diagnosis using Raman spectroscopy of materials at depths of up to 50mm, e.g., bone beneath skin, calcifications inside soft tissue

Commitment offered	Research:	X	Training	
	Demonstration		Dissemination	

	Technology	X	Other

Interested in participation in Project types	☐ Large-scale integrating collaborative project	X Small or medium-scale focused research collaborative project	☐Targeted to SMEs	☐ Other (Marie Curie Actions, ERA-NET…):
	☐ Coordination and Support Action	☐ Network of Excellence	☐Research for the benefit of SMEs	
Call references	X**1st Call**	☐ **2nd Call**		

Main Research Topics :

First call:
Health-2007-1.2-2: Novel optical methodologies for detection, diagnosis and monitoring of disease or disease-related processes**.**

EXPECTATIONS

Term of commitment	Short (<1 year) Medium (1-3 years) Long (more than 3 years)

Expected results for your organisation	Successful demonstration of our technology's superiority in medical diagnostics

8.

Date: 21/ 3/ 2007	Deadline:

Contact

Organization	National Research Centre	**Department**	Molecular Genetics & Enzymology
Contact person	Ibtessam M. Ramzi Hussein		
Email	*ibtessamr@yahoo.com*; *ibtessamr@hotmail.com*		
Address	Tahrir St., Dokki, Giza		
Postcode	12622	**City** Giza	
Country	Egypt		
Telephone	202 010 66 00 127	**Fax**	202 33 70 931
Website			

Familiar with the European Framework Programme? ☐ ***YES*** ☐ ***NO***

PROJECT

Title: Development of new diagnostic tools in Thalassemia and sickle cell anemia	**Acronym:**

Funding Scheme	☐ **Large-scale integrating collaborative project** X **Small or medium-scale focused research collaborative project** ☐ **Targeted to SMEs** ☐ **Network of Excellence** ☐ **Coordination and Support Action** ☐ **Research for the benefit of SMEs** ☐ **Other (Marie Curie Actions, ERA-NET…)**
Status	**X Planned for submission** ☐ **Running project**
Call references	**X 1st Call** ☐ **2nd Call**

Priorities' Main Research Areas (Topics from Workprogramme)	**HEALTH-2007-1.2-6:** High throughput diagnostics in individual patients for genetic diseases with heterogeneous clinical presentation
Keywords	Hemoglobinopathies, thalassemia, sickle cell anemia
Commitment/Work to be offered	Thalassemias and sickle cell anemia are common health problems in the Mediterranean region. Prevention through carrier detection and prenatal diagnosis should require sensitive, fast and reliable techniques. Knowledge of the molecular basis of the disease is mandatory to provide the basis for development of an accurate diagnostic technique. The development of new molecular diagnostic techniques such as microarray should allow the screening of large number of mutations in several samples in short time. Genotypic and phenotypic heterogeneity was also observed among patients with thalassemia in Egypt as well as other countries. Further studies are needed to explore the role of modifier genes or gene/ environment interaction on the severity of these disorders. Work to be offered: Collection of samples, clinical and hematological examination, and screening for most common mutations, molecular studies for detection of unknown or rare mutations. Development of a screening procedure for the molecular diagnosis of these diseases.
Partners already involved	

Profile of Partner Sought

Role	☐ **technology development** **X research** **X training** **X dissemination** ☐ **demonstration** ☐ **other**

If another role expected, please specify it here

Country /region	
Start of partnership	**X start-up phase** ☐ **mid-term** ☐ **end-phase**
Expertise required	Hematologists Clinical Geneticists Molecular geneticists

9.

Date: 22/ 3/ 2007	Deadline:

Contact

Organization	National Research Centre	**Department**	Molecular Genetics & Enzymology
Contact person	Dr. Ibtessam M. Ramzi Hussein		
Email	ibtessamr@yahoo.com , ibtessamr@hotmail.com		
Address	National Research Centre, Tahrir St., Dokki,		
Postcode	12622	**City**	Giza
Country	Egypt		
Telephone	202 010 66 00 127	**Fax**	202 33 70 931
Website			

Familiar with the European Framework Programme? ☐ ***YES*** ☒ ***NO***

PROJECT

Title: Congenital Heart Defects	**Acronym:**

Project type	☐ **Large-scale integrating collaborative project**	**X Small or medium-scale focused research collaborative project**
	☐ **Targeted to SMEs**	☐ **Network of Excellence**
	☐ **Coordination and Support Action**	☐ **Research for the benefit of SMEs**
	☐ **Other (Marie Curie Actions, ERA-NET…)**	
Status	**X Planned for submission** ☐ **Running project**	
Call references	☐ **1st Call** **X 2nd Call**	

Priorities' Main Research Areas (Topics from Workprogramme)	Health- 2007- 2.4.2-4: Congenital pathologies affecting the heart. Collaborative project (small or medium scale focused research projects).
Keywords	Congenital heart defects, genetics, transcription factors, genes
Commitment/Work to be offered	Congenital heart defects are among the most common congenital defects in the Egyptian population. The work will focus on studying genetic basis of congenital heart disease, structure and function of transcription factor genes. Epidemiological studies in the Egyptian population will be done to explore the role of environmental factors and their interaction with candidate genes in the development of heart defects. The research group will collect affected cases including familial and sporadic patients, epidemiological studies including assessment of consanguinity and other environmental factors will be evaluated with other partners in the collaborating research groups. Chromosomal analysis, FISH, and molecular studies of the transcription factors will be offered and evaluated with the results from other groups.
Partners already involved	
Project budget (for the running projects)	

Profile of Partner Sought

Role	**X technology development X research X training** **dissemination demonstration other**

If another role expected, please specify it here

Country /region	
Start of partnership	**X start-up phase mid-term end-phase**
Expertise required	Epidemiologists Molecular Biologists Molecular Cytogenetics.

10.

Date: 20/03/2007	Deadline:

Contact

Organization	Faculty of Medicine – Cairo University	**Department**	Tropical Medicine
Contact person	Dr. Naglaa Ali Zayed		
Email	naglaazayed@yahoo.com		
Address	Tropical Medicine Department Kasr Alainy Faculty of Medicine - Cairo University		
Postcode	12111	**City**	Cairo
Country	Egypt		
Telephone	0020101460366	**Fax**	(+202) 5326543
Website	www.cairoemd.org		

Familiar with the European Framework Programme? ☐ ***YES*** ☐ ***NO***

PROJECT

Title:	**Acronym:**

Project type	☐ **Large-scale integrating collaborative project**	⊙ **Small or medium-scale focused research collaborative project**
	☐ **Targeted to SMEs**	☐ **Network of Excellence**
	☐ **Coordination and Support Action**	☐ **Research for the benefit of SMEs**
	☐ **Other (Marie Curie Actions, ERA-NET…)**	
Status	⊙ **Planned for submission**	☐ **Running project**
Call references	⊙ **1st Call**	☐ **2nd Call**

Priorities' Main Research Areas (Topics from Workprogramme)	HEALTH-2007-2.4.1-1: Translating the knowledge on non-coding RNAs linked to the aetiology of cancer into novel diagnosis and therapy strategies.
Keywords	Hepatocellular carcinoma,microarray,c DNA

Commitment/Work to be offered	Study the expression of certain genes among patients with Hepatocellular Carcinoma (HCC) which is a international health problem and is responsible for a major number of deaths recorded annually. cDNA microarray technology enables investigators to measure the expression of thousands of mRNA simultaneously in a biological specimen and therefore may provide comprehensive information for diagnosis and therapeutic interventions of tumors in ne future. Microarray technology now allows scientists and clinicians to identify qualitative changes at RNA level in the development and progress of cancer .
Partners already involved	None till now.

Profile of Partner Sought

Role	⊙ **technology development** ☐ **research** ⊙ **training** ☐ **dissemination** ⊙ **demonstration** ☐ **other**

If another role expected, please specify it here

Coordinator and partners

Country /region	
Start of partnership	⊙ **start-up phase** ☐ **mid-term** ☐ **end-phase**
Expertise required	Expertise in genetic study and microarray assay for HCC tissues samples. Training for personnel Application of the recognized genes in diagnosis,prognosis and may be treatment of HCC

11.

The Shareholder Association NIFARMA´98 was established in the early 1998 by a group of specialists, who had worked for many years in the field of the pharmaceutical science and pharmaceutical technology, as heads of the main departments in the Chemical Pharmaceutical Research Institute (NIHFI) – Sofia, part of the former Pharmachim structure.

NIFARMA employs leading specialists in the field of:

- bioavailability studies;

- quality control of drug substances and final products;
- development of technologies and technological and chemical pharmaceutical documentation for manufacture and registration of dosage forms;
- GMP;
- standardization and registration of drug substances and final products;
- synthesis of active substances, isolation and purification of natural products;

Main activities of the company:

- Preparation of DMFs and registration of dosage forms and substances in the country and abroad;
- Development of technologies and technological documentation for manufacture of drug substances and dosage forms and introducing the above technologies in production of the ordering or purchasing company;
- Development of validated methods of quality control of drug substances and final products;
- Quantitation of drug substances in biological liquids for evaluation of bioavailability/bioequivalence;
- Training pharmaceutical companies' staff in the requirements of GMP of WHO and EC. This activity includes also performance of GMP audits, as well as consultant services in the introduction of GMP rules in the pharmaceutical manufacturing companies.

For its nine years existing in NIFARMA are developed for Bulgarian and foreign companies manufacture technologies for more than ten generic and several new dosage forms.

There are prepared and submitted for registration in Bulgaria more than 25 DMFs including these for foreign companies. For all of the submitted documentations, drugs approvals for manufacture and sale are already obtained.

There are prepared more than 20 DMFs for registration in other countries for Bulgarian and foreign companies and most of them are already approved.

More than 60 bioequivalence studies on dosage forms owned by Bulgarian and foreign companies are performed. There are no objections received till now from Bulgaria or another country concerning the studies carried out.

The company possesses:

- ***Laboratory for dosage forms***

  The laboratory has available all necessary equipment for development, characterization and creation of dosage forms – tablets, sustained release tablets and coated tablets, and checking the technologies in pilot plant scale.

  Head of the laboratory is Prof. Mag. Pharm. Evtimia Velikova

- ***Bioavailability/bioequivalence Testing Laboratory***

  The laboratory is accredited to perform testing of finished pharmaceutical products for bioavailability/ bioequivalence by quantitative determination of drugs concentration in biological liquids according to BDS EN ISO/IEC 17025:2006

  Head of the laboratory is Assoc. Prof. Dr. Nadezhda Tyutyulkova Medical Dr.

- ***Laboratory for analysis of drug substances and dosage forms***

  The laboratory possesses up-date equipment for analysis of drug substances and dosage forms and has contracts with many Bulgarian pharmaceutical companies for analytical control on their final production.

  Head of the laboratory and QA is Assoc. Prof. Dr. Eng. Rumen Vodenicharov

- ***Bureau for preparation of technological documentation and DMFs for registration in the country and abroad***

  Head of the bureau is Res. Fellow Eng. Kina Konstantinava

The company works in laboratories on the territory of Bulgarian Academy of Sciences (BAN).

Chairman of the Board and Executive Director of The Shareholder Association NIFARMA´98 is Assoc. Prof. Dr. Eng. Kiril Ninov

For correspondence and contacts:
1113 Sofia, Akad. G. Bonchev str., Bl.108, Complex BAN, BULGARIA
Tel: +359 2 870 5213; +359 2 870 4132; Tel/Fax +359 2 870 3501
E-mail: nifarma98sa@mbox.contact.bg

12.

Date:	08.03.2007
Deadline:	
Call identifier:	

CONTACT INFORMATION			
Organisation Name	Vilnius University, Institute of Experimental and Clinical Mrdicine	Contact person	Irena Butrimiene
Type of organization	☒ Research institute ☒ University ☐ **SME*** ☐ Industry ☐Other		
Department	Department of Rheumatology	Telephone	+370-5-236-53-02
Address	Vilnius University Institute of Experimental and Clinical Medicine, Zygimantu 9 Vilnius, Lithuania	Fax:	+370-5-236-53-02
Web site		E-mail	Irena.Butrimiene@santa.lt

* Your enterprise is an SME if:

-it has **less than 250 employees**
-it has either an **annual turnover not exceeding €50M**, **or an annual balance sheet total not over €43M**
-it is **less than 25% owned by a non SME** (unless these are financial investors, such as banks or venture capitalists

EXPERTISE OFFERED	
Keywords specifying the expertise	Rheumatoid arthritis, reactive arthritis, chronic inflammatory disease, molecular mechanisms of pathogenesis, genetic and epigenetic changes
Description of the expertise	Our group has a long-standing expertise in the analysis of molecular and immune mechanisms of pathogenesis in chronic inflammatory arthritic diseases **Expertise.** Our group have participated in the studies of molecular mechanisms of immune response in reactive and rheumatoid arthritis. Recently, the study of genetic and epigenetic changes in synovial tissues is initiated. **Specific interest.** Molecular mechanisms of pathogenesis of reactive arthritis; occurrence of genetic and epigenetic changes in inflamed synovium. **Infrastructure.** We have a wide range of techniques established in our labs including immunohistochemistry, FISH and Comet analysis, chromosome aberration and micronucleus tests, DNA mutation

	analysis, DNA hypermethylation assay, gene expression analysis by TaqMan assay. Biobank of samples (synovial tissues, blood cells) from patients with rheumatoid and reactive arthritis is recently initiated in our institute.
Main researchers and expertise (name, surname, academic degree)	Irena Butrimiene, MD Gailute Kirdaite, MD Sonata Jarmalaite, PhD **Relevant publications**: ▪ **Jarmalaite S, Mierauskiene J, Beitas K, Ranceva E, Lazutka JR and Butrimiene I. Sister chromatid exchanges and cell proliferative abilities in cultured peripheral blood lymphocytes of patients with rheumatoid and reactive arthritis. Clin Exp Rheumatol. 2006 Nov-Dec; 24(6): 677-82.** ▪ Butrimiene I, Ranceva J, Griskevicius A. Potential triggering infections of reactive arthritis. Scand J Rheumatol. 2006 Nov-Dec; 35(6): 459-62. ▪ Ploski R, Butrimiene I, Kaminska E, Valiukiene K, Sliwinska P, Kubasiewicz E et al. Rheumatoid arthritis in Poland and Lithuania: different clinical course and HLA associations despite similar genetic background. Ann Rheum Dis 2005;64:165-166. ▪ Bagdonas S, Kirdaite G, Streckyte G, Graziene V, Leonaviciene L, Bradunaite R, Venalis A, Rotomskis R. Spectroscopic study of ALA-induced endogenous porphyrins in arthritic knee tissues: targeting rheumatoid arthritis PDT. Photochem Photobiol Sci. 2005 Jul;4(7): 497-502. ▪ Kvien TK, Gaston JS, Bardin T, Butrimiene I, Dijkmans BA, Leirisalo-Repo M, Solakov P, Altwegg M, Mowinckel P, Plan PA, Vischer T; EULAR. Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis. 2004 Sep; 63(9): 1113-9. ▪ Butrimiene I, Jarmalaite S, Ranceva J, Venalis A, Jasiuleviciute L and Zvirbliene A. Different cytokine profiles in patients with chronic and acute reactive arthritis. Rheumatology . 2004, 43(10): 1300-4.
Experience in international cooperation and partnership (SMEs, universities, research institutes)	Multicentral EULAR studies in Reactive arthritis. Genetic studies in Ankylosing Spondylitis and Reactive Arthritis with Nuffield Department of Orthopaedic Surgery Nuffield Orthopaedic Centre, Oxford UK Genetic and epigenetic studies in collaboration with Finnish Institute of Occupational Health.
International projects (last 5 years - Title of project, source of funds, duration) Please, indicate if you were/are coordinator, partner or subcontractor	Partner of project “Genetics of RA in Lithuanian and Polish populations” with Institute of Rheumatology, Warsaw, Poland and Human Molecular Genetics Laboratory, Medical University, Warsaw, Poland.

EXPECTATIONS	
Target consortium Please, indicate the topic title from the work programme	**HEALTH-2007-2.1.2-5** Multidisciplinary fundamental genomics and molecular biology approaches to study basic biological processes relevant to health and disease **HEALTH-2007-2.4.5-12** Early processes in the pathogenesis of chronic inflammatory diseases

13.

Beacon Tech commenced activity in 2003 upon the common vision of its owners - bringing skills and experience concepts and methods to the world of technology-oriented innovation management, by mixing business and technology knowledge and understanding.

The expertise of the company personnel includes Project and Business Management for various projects such as, European Union projects, M&A projects for public and private corporations, R&D Financing consulting, Analysis and Evaluation of R&D activities, Establishment of R&D operations, Product Management, Product design, etc.

Beacon Tech Ltd. *www.beacontech.eu*

Yoram Lev-Yehudi
Managing Director

23, Jacob Meridor St.
Tel Aviv, Israel 69411
Tel 972-3-648 1698
Fax 972-3-629 0599
Mob 972-5-22249264
yly@beacontech.eu

14.

Date:	Deadline:

Contact

Organization	National Research Centre	**Department**	Genetic Immunology; Division: Human Genetics and Genome
Contact person	Dr. Waheba .A. Zarouk		
Email	W_zarouk@yahoo.com		
Address	NRC;El-Tahrir Street eldokki		
Postcode	12211	**City**	cairo
Country	Egypt		
Telephone		**Fax**	3370931
Website			

Familiar with the European Framework Programme? ☐ ***YES*** ☐ ***NO***

PROJECT

Title:	**Acronym:**

Project type	☐ **Large-scale integrating collaborative project** * **Small or medium-scale focused research collaborative project** ☐ **Targeted to SMEs** ☐ **Network of Excellence** ☐ **Coordination and Support Action** ☐ **Research for the benefit of SMEs** ☐ **Other (Marie Curie Actions, ERA-NET…)**
Status	***Planned for submission** ☐ **Running project**
Call references	* **1st Call** ☐ **2nd Call**

Priorities' Main Research Areas (Topics from Workprogramme)	Health -2007-2.4.3-1 Early processes in the pathogenesis of type 1 diabetes and strategies for early prevention.
Keywords	Diabetes-Genes-Sequence-HLA-Auto Antibodies-virus-Pancreatic islets-Molecular genetics-Immunology-PCR-Elisa.
Commitment/Work to be offered	The project focuses on large scale genetic studies on human samples from European and Egyptian and other Arab populations using innovative and standardized methodologies as well as generation of new idea in the interest of developed sensitive and specific techniques with lower cost to specify markers for prediction of susceptibility to type one diabetes to prevent complete destruction of beta cells at diagnosis and prevent late complications of diabetes based on gene sequence and/or HLAD ,virus studies(environmental),pancreatic function.
Partners already involved	No

15.

Contact

Organization	National Research Centre; Egypt	**Department**	Genetic Immunology
Contact person	Waheba Zarouk		
Email	W_zarouk@yahoo.com		

Address	NRC; El-Tahrir St. Dokki;Egypt;Cairo		
Postcode	12211	**City**	Cairo
Country	Egypt		
Telephone		**Fax**	
Website			

Familiar with the European Framework Programme? ☐ ***YES*** ☐ ***NO***

PROJECT

Title:	**Acronym:**

Project type	☐ **Large-scale integrating collaborative project**	* **Small or medium-scale focused research collaborative project**
	☐ **Targeted to SMEs**	☐ **Network of Excellence**
	☐ **Coordination and Support Action**	☐ **Research for the benefit of SMEs**
	☐ **Other (Marie Curie Actions, ERA-NET…)**	
Status	***Planned for submission** ☐ **Running project**	
Call references	* **1st Call** ☐ **2nd Call**	

Priorities' Main Research Areas (Topics from Work programme)	Health-2007-2.4.3-3: Insulin resistance as a key factor in the development of diabetes and metabolic syndrome.
Keywords	Diabetes – Insulin resistance- Gene sequence- virus infection- - metabolism- enzymes.
Commitment/Work to be offered	Gene sequence to identify if susceptible loci are included, enzymes related to metabolic defects leading to insulin resistance in glucose and fatty acid cycles will be determined and also identification of receptors involved in the path physiology of the disease
Partners already involved	No

Proposal for Health -2007- 3.3-5: Improve vaccination coverage

---

Title of the action: Project to study effectiveness and cost-effectiveness of vaccination programmes and to harmonize vaccination coverage assessment.

Background: Vaccines constitute the instrument with higher potential of prevention of the transmissible diseases and the only one that allows to achieve its elimination in a community or country. At present high efficacious vaccines are available, but their effectiveness in the protection of the population depends on the coverage of the programs of vaccination.

In order to reduce the incidence of vaccine preventable diseases an assessment of vaccination programmes has been carried out , being vaccination coverage is a good indicator for this purpose This indicator allows the follow-up of the programs of systematic vaccination or specific campaigns, and permits to describe the re-adequacy of strategies of access to the target population and periodically to evaluate the immunization policies. In Europe different policies have been observed, and methodologies for calculating the coverage are different.

As of today , assessment of vaccination coverage in Europe is not carried out by means of a standardized method. Efficacy estimates and cost-effectiveness of a programme are different from one country to another.

Furthermore, the calculation of vaccination coverage differs according to the method used. Specially interesting for assessing the vaccine coverage are the population surveys, but to be able to obtain correct indicators at European level it is necessary to harmonize this kind of methodology.

Outline of the Action

A unified vaccination coverage indicator for systematic immunization is to be obtained by means of a standardized method for its evaluation to be used by participating countries. This indicator is to make vaccination coverage calculation easier from the data available in each country.

Parting from a sample population, per example adolescent population, it would be appropriate to conduct a project made up of different phases:

1- Seroprevalence study of the antibodies generated by some of the vaccines included in the systematic immunization schedule;
2- Calculation of vaccination coverage for this population by means of a query based on data from vaccination certificates;
3- Calculation of vaccination coverage of systematic vaccines through the number of doses distributed and population data from each countries health authorities.

Because of the large cost and burden that conducting a seroprevalence study for all immunization antibodies implies, only two vaccines will be assessed : Td and hepatitis b vaccines.

To study vaccine preventable disease incidence in vaccinated and non-vaccinated population is proposed to determine the effectiveness of immunization progremmes.

Association between effectiveness of this programme with costs (the cost of vaccinating vs costs derived from not vaccinating) is studied to determine cost-effectiveness. The idea is to encourage participants to use the same methodology and calculations.

To determine the sample a probabilistic random sampling taking the classroom or school as the sampling unit is suggested. The project started out on a first phase with adolescents, with the possibility to expand this study to other segments of the population. Due to methodological handicaps it is suggested that this project be set , in the beginning, in large cities or in a large region within each participating country.
From the results obtained , there will be team work to improve immunization policies and coverage in each country.

The CIBER groups which present this proposal are the following: Department of Health of the Generalitat of Catalonia (Infectious Diseases and International Health Group). Other CIBER groups interested in this project are the Public Health Agency of Barcelona (Policy and Health Services Assessment Group) and the Public Health Institute of Navarra (Policy and Health Services Assessment Group)

The CIBER group from the department of Health of the Generalitat of Catalonia has experience in effectiveness and cost-effectiveness of Immunization programmes as well as in studies to determine vaccination coverage as can be seen through the list of publications attached in Annex 1.
Anexo 1

Navas E , Salleras L, Dominguez A, Ibanez D, et al. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives. Vaccine 2007 (en prensa).

Domínguez A, Plans P, Costa J, Espuñes J, Cardeñosa N, Salleras L, Plasència A. The seroepidemiology of tetanus in Catalonia, Spain.
Medical Microbiology and Immunology 2007 (en prensa)

Salleras L, Domínguez A, Pumarola T, Prat A, Marcos MA, Artigas R, et al. Effectiveness of virosomal subunit influenza vaccine in preventing influenza related illnesses ant its social and economic consequences in children aged 3-14 years: a prospective cohort study. Vaccine 2006; 24:6638-6642

Navas E, Salleras L, Gispert R, Domínguez A, Prat A, Timoner E, Ibáñez D. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain). Vaccine 2005; 23: 2342-2348

Plans P, Rabella, N, Otegui M, Espuñes J, Domínguez A, Plasència A. Evaluación del grado de protección inmunitaria conseguida con la vacuna oral antipoliomielítica en la población infantil de 6-12 años de Cataluña. Medicina Clínica 2006; 127: 612-614

Navas E, Salleras L, Gispert R, Domínguez A, Prat A, Rodríguez G, Galí N. Efficiency of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the hepatitis B vacination programme of preadolescents in schools. Vaccine 2005; 23: 2185-2189.

Salleras L, Domínguez A, Cardeñosa N. Dramatic decline of meningococcal serogroup C disease incidence in Catalonia (Spain) after a mass vaccination with meningococcal C conjugated vaccine. Vaccine 2003; 21: 729-733

Domínguez A, Salleras L, Carmona G, Batalla J. Effectiveness of a program of mass hepatitis A vaccination in preadolescents. Vaccine 2003; 21: 698-701

Salleras L, Domínguez A, Cardeñosa N. Impact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in Spain. Vaccine 2003; 21: 725-728

Salleras L, Taberner JL, Batalla J, Urbitzondo L, Rodríguez G, Plans P, Domínguez A, Carmona G, Vidal J, Costa J. Enfermedades prevenibles mediante vacunaciones sistemáticas. Evaluación de los objetivos del Plan de Salud de Cataluña para el año 2000. Medicina Clínica (Barc) 2003; 121 (Supl 1):748

Salleras L, Bruguera M, Taberner JL, Domínguez A, Batalla J, Buti M et al. Efectividad del programa masivo de vacunación antihepatitis B de los preadolescentes en las escuelas de Cataluña. Medicina Clínica (Barc) 2003; 121 (Supl 1): 79-82

Salleras L, Domínguez A, Prats G, Parrón I, Muñoz P. Dramatic decline of serogrup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people. Journal of Epidemiology and Community Health 2001: 55: 283-287.

Salleras L, Domínguez A, Navas E. Eficacia, efectividad y eficiencia de la vacuna de la varicela. Vacunas 2001; 2 (Supl. 1):12-15.

Lopalco PL, Salleras L, Barbuti S, Germinario C, Bruguera M, Buti M, Domínguez A. Hepatitis A and B in children and adolescents – What can we learn from Puglia (Italy) and Catalonia (Spain)?. Vaccine 2001; 19: 478-482.

Salleras L, Plans P, Vidal J, Domínguez A, Navas E, Urbitzondo L, Espuñes J, Batalla J, Bruguera M. Serological evaluation of the universal hepatitis B vaccination programme of pre-adolescents in Catalonia (Spain). Vacunas 2000; 1: 3-6.

Navas E, Domínguez A, Tresseras R, Gali N, Tarín G, Salleras L. Cost-effectiveness analysis of four alternative strategies of tetanus vaccination of the adult population of Catalonia. Vacunas 2000; 1: 65-69

Salleras L, Domínguez A, Prats G. Control of serogroup C meningococcal disease by mass-vaccination in Catalonia (Spain). Vaccine 1999; 17: S56-S60.

Godoy P, Domínguez A, Salleras L. Measles: effect of a two dose vaccination programme in Catalonia (Spain). Bulletin of the World Health Organization 1999; 77: 132-137

2.

CONTACT

Organisation	University Clinic of Respiratory Diseases and Allergy Golnik
Department/group…	NRL for Mycobacteria, NTB Ward, NTB Registry
Contact person	Damijan Erzen, Manca Zolnir-Dovc PhD,
e-mail	damjan.erzen@klinika-golnik.si; manca.zolnir@klinika-golnik.si;
Phone	+38642569301, +38642569408
Address	Golnik 36
City/code	4204 Golnik
Country	Slovenia

PROJECT

Project type:	☒ Collaborative projects	☐ Networks of Excellence	☐ Coordination and Support Actions
Planned to participate as:	☒ Partner	☐ Coordinator	
Call identifier : Topics:	FP7-HEALTH-2007-2.3.2-10 European network for study and clinical management of TB drug resistance		
Other work programme topics you are interested in:			

Your main research areas / Description of research activities	We are interested to join to consortia preparing proposals for 7th Framework programme on the topic European network for study and clinical management of MDR-TB. We are performing research work in the field of tuberculosis on the national level utilising well established network of laboratories, hospital wards and outpatient departments covering the whole country. Since the population of Slovenia is around 2 millions this could serve as a regional model how to run a good interplay of facilities to achieve the maximum benefit. Our team joined Molecular surveillance of multi-drug resistant tuberculosis project implemented by EuroTB and RVIM in 2005 as providers of information and correspondents from Slovenia. A part of our research is also collaboration with states of former Yugoslavia for control of multi-drug resistant tuberculosis. So far collaboration with Serbia, Kosovo and Macedonia was established helping those countries to perform drug sensitivity testing and genotyping of resistant strains. Further collaboration with those countries can help providing information to identify international molecular clusters of MDR-TB strains over time in Europe connected to the cases from the Balkans in order to take coordinated control actions.

Expertise / Commitment offered:

NRL for Mycobacteria is performing more then 9.000 cultures yearly, both liquid and solid media for identification and DRS, PCR diagnostic, QFT testing and genotyping (RFLP, Spoligo) of all strains in Slovenia since 2001. The performance of NRL is submitted to external QC system both commercial and WHO supranational, and was accredited with ISO 9001:2000 standard. It can serve as a provider of reliable data on MDR-TB and genotyping for most Balkan states.

NTP for TB in Slovenia achieved accelerated decline in last 10 years. In 1997 case notification rate was 24.3 per 100.000 population and in 2006 case notification rate was 10.5 (ie. 210 registered cases) in 2005 the rate was 14,1. Slovenia is one of 26 countries fulfilling WHO targets for 2005 of treatment success over 85% and DOTS detection rate over 70%. The National TB Registry is well established, all relevant data about TB cases are recorded, and also contact tracing and treatment of latent TB infection is recorded at the level of the Registry. The structure of the recording and reporting system can serve as a model for district level of larger countries.

The experience with MED-TB in Slovenia is limited by the low proportion of drug resistance (total between 3 and

5 % depending on the year) in the country. All strains are routinely tested for drug resistance. The level of MDR-TB is 0,5%, so each year one or two cases are treated. Treatment is performed in National TB Ward. Since 1995 18 cases were treated. Treatment success in MDR cases is 62% overall and is improving in the last years. Experiences and clinical data on MDR-TB patients can be utilised in further research of clinical management of resistant tuberculosis in Europe.

3.

Activery Biotech is seeking to join a research proposal as a partner on the following theme:
HEALTH-2007-2.4.1-7: Improving targeted drug delivery to cancer cells for cancer therapeutics other than gene therapy (in coordination with NMP-2007-4.0-4 in Theme 4)
Theme: Bioavailability and permeability enhancement of antineoplastic drugs through supercritical fluid technology.
Objective: Activery envisages playing a significant role in the research, development and production of drug nanoparticles or the generation of stable amorphous drug/excipient powders in treatment of cancer. The use of stable nanoparticulate drugs crystalline or amorphous in their solid state could allow enhanced solubility and permeability of these usually poorly bioavailable drugs.
Competency: Activery (www.activery.com) is a leading company in the use and development of supercritical fluid technology for drug particle engineering. Development of nanoparticulate drugs or drug/polymer co-formulations by using a proprietary supercritical fluid precipitation process. Production of batches at laboratory and pilot scale for the use in animal trials.
Context: Cancer drugs frequently display very low aqueous solubility often coupled with low permeability leading to high drug doses to reach minimal plasma levels. This could lead to increased side effects and toxicity when undergoing therapy. It is therefore desirable that improved drug delivery vehicles for these drugs are found and utilized. Currently, drug powders are milled with or without surfactants to achieve small drug particles. However, milling is highly undesirable for these potent drugs due to the generation of substantial amounts of undesired fines together with a fraction of large particles which have escaped the milling process. Alternatively, the powder is suspended in irritating or sensitizing vehicles, e.g. Cremophor.
Alternatively, the in-vitro and in-vivo solubility of many antineoplastic drugs could be enhanced using a supercritical fluid technique for particle size reduction or solid state alteration. Both steps can be performed simultaneously using our proprietary supercritical fluid technology without the drawbacks of current methodologies. Supercritical fluid produced pure drug nanoparticles or drug/excipient co-formulates are physically and chemically stable and the amorphous state provides the highest possible solubility.
It can be envisaged that supercritical fluid engineered particles would provide better drugs with improved solubility and permeability. Formulated into nano-medicines this would generate better drugs with effectively lower doses with reduced side effects during treatment through more precise targeting leading to significant patient benefits.
Activery Biotech S.L.
www.activery.com

Contact: Carles Ventosa, CEO of Activery Biotech S.L.
Centre d'Empreses de Noves Tecnologies
Parc Technològic del Vallès
08290 Cerdanyola del Vallès
Tel.: +34 93 582 01 52
Email: ftp7@activery.com

EU Funded Research Project
Partner Search Form

Date:	Deadline:

Contact

Organization	Pediatric Cardiology, Children Hospital, Cairo University	**Department**	Pediatrics, Cairo University
Contact person	Hala Mounir Agha		
Email	Agha.hala@gmail.com		
Address	12 Mohamed Morsy Street, El Haram		
Postcode	12111	**City**	Giza
Country	Egypt		
Telephone	+202-5856985 +202-0101113284	**Fax**	
Website			

Familiar with the European Framework Programme? ♦ ***YES*** ☐ ***NO***

PROJECT

Title: Collaborative multicenter study of risk factors for CHD	**Acronym:** CMSRFCHD

Project type	☐ **Large-scale integrating collaborative project**	♦ **Small or medium-scale focused research collaborative project**
	☐ **Targeted to SMEs**	☐ **Network of Excellence**
	☐ **Coordination and Support Action**	☐ **Research for the benefit of SMEs**
	☐ **Other (Marie Curie Actions, ERA-NET…)**	
Status	☐ **Planned for submission**	
Call references	♦ **2nd Call**	

Priorities' Main Research Areas (Topics from Workprogramme)	Health-2007-2.4.2-4: Congenital pathologies affecting the heart

Idea of The project And Commitment to be offered	**Background:** Cardiac abnormalities occur with an incidence of 1 per 100 live births represent 25% of all congenital malformations, and are the leading cause of death in the first year of life. CHD is the most common birth defect, carries significant and life long personal& social costs. More children die from CHD each year than are diagnosed with childhood cancer. The etiologies of congenital heart disease (CHD) include consanguinity, environmental factors, teratogens and genetic mutations. Yet, 90% of all CHD cases dont not have any known etiology. It has been reported that approximately 5 to 8% of patients with CHD have a gross chromosomal defect, usually trisomy 21, 13, 18 and Turner s syndrome. Most non syndromic CHD are caused by a complex interaction between maternal life style factors, environmental exposures and maternal and fetal variants. The complexity of heart formation, which integrates different structures and cell types, involves a network of genes regulated by transcription factors. The molecular causes of most CHDs remain unknown, although numerous cardiac regulatory factors have recently been described. Understandably, parents of patients, and increasingly patients themselves, are interested in the risk that future offspring will be affected. Improved understanding f the causes and prevention of CHD depends on studies in large population. Yet, these studies are complicated because CHD encompass different anatomical lesions and clinical manifestations & have various causes & because children with CHD are difficult to ascertain, diagnosis and classify within a population . This incomplete ascertainment limits investigators s ability to evaluate the incidence of disease and to identify risk factors in a population. Having a complete understanding of the risk factors for CHD may lead to effective interventions to prevent them. **Multicenter collaborative study** is important because no single center has sufficient resources to answer a research question. Collaboration will resolve the question more authoritatively and will speed the resolution of the research question. **The magnitude of the problem in Pediatric Cardiology Unit, Children Hospital, Cairo University:** Cairo University, Children Hospital (CUCH) is the largest tertiary hospital affiliated to the university in Egypt. This specialized hospital received 113070 cases in outpatient clinics in last Year 2006. The sites visited mostly by patients with congenital heart disease are the pediatric cardiology clinic (7496 cases (16%), cardiac catheterization clinic (2407 cases (5%), cardiothoracic surgical clinic (4337 cases (7%). Echocardiography was performed for 4806 cases; including congenital and acquired heart diseases. Diagnostic and interventional cardiac catheterization were done for 430 cases and open and closed cardiac surgical procedures were performed for 556 cases this last year (2006). The majority of the cases referred to catheterization clinics and surgical clinics were referred from the outpatient clinic or echocardiography laboratory. The majority of these patients are properly managed as CUCH is the biggest tertiary center for pediatric cardiology service in Egypt. **Genetic causes***:* As whole genomic sequencing &single nucleotide polymorphism data become available. Identification of genetic mutations predisposing to CHD may allow preventive measures by modulation of secondary genetic or environmental factors. Consanguinity has been a long standing social habit among Egyptian. The estimates of consanguinity ratios in different parts of Egypt ranged from 29 to 50%. **Environmental factors***:* Investigations of environmental impact on the developing cardiovascular system are essential to provide the knowledge necessary for an evidence-based approach to treating and preventing congenital heart disease. The main problem in studying the environmental risk factors on CVS is that many risks factors are not clear or quantified and there is a need for a longitudinal study of effects of environmental exposures (broadly defined). The study concepts should include longitudinal study of children, families and environment. It should be national in scope, hypothesis driven. Environment defined broadly to include chemical, physical, behavioral, social and cultural factors. Exposure period begins in pregnancy.
Keywords	

Main goal : Prevention of Congenital heart disease in our community

Prevention of theses disorders is a big issue. Research into genetic and environmental risk factors is therefore critical in identifying clues to causation and prevention.
The increase number of patients with CHD, the presence of families having more than one affected child with psychological and financial burden which could be impacted on the family as well as the enormous portion of the national income which is spent in the treatment of these patients. These expenses could be spared by establishing a proper strategy and plan for prevention of these disorders.

Our proposal came into being from our continuous daily work in the division of the pediatric cardiology for about 15years. We are challenged with a tremendous number of CHD patients, properly diagnosed and managed, but unable to predict the recurrence risk for families of children with CHD due to deficiency in the molecular genetic study and other risk factors.

Requirement tools:
This proposal has been prepared by the collaborative (conjoint) work of staff members working in different medical fields serving the cardiac child. The working groups will include staff members in pediatric cardiology, epidemiology in Cairo University, human genetic in National research center, Egypt.
Presentation of the consortium:
Egypt: Pediatric Cardiology Division, Children Hospital, CUCH)Cairo University,
Public Health Department, Cairo University
National Research Center

Study population design:
Case control study based on prospectively collected data. ; The study will include all-live born cases of CHD diagnosed in the first year of life between 2008 and 2010 presented to CUCH , the largest tertiary center in Egypt. A random sample of unaffected infants controls matched by year and hospital of births.
After a written consent had been obtained. The protocol for informed consent was reviewed and approved by the institutional review board of pediatric department, Cairo University.
Study population :
Consisted of liveborn CHD cases and their parents:
*Complete triads (case and both parents)
*Incomplete triads (case with only one participating parent) were included in the study.
Cases were identified and ascertained as outpatient or inpatient cases in pediatric cardiology division, CUCH.
Inclusion criteria:
-Residence of both parents in (upper , lower Egypt) at the time of the completion of index pregnancy and at the time of enrolment in the study.
-A physician diagnosis of a syndromic & non syndromic CHD that was confirmed by postnatal echocardiogram or surgery.
-Single gene disorder; chromosomal abnormality, syndromic cases are included.
-All congenital CHD are included ; septal, conotruncal, right or left obstructive CHD.
Exclusion criteria:
-Residence of the parents outside Egypt before completion of index pregnancy
-Dependence on antenatal diagnosis of CHD are excluded.

Role of Pediatric Cardiology Division, CUCH in the project:
Carry out all the clinic work including:

1- Proper selection of patients through expertise clinical assessment from the pediatric cardiology outpatient clinic, echocardiography lab, catheterization laboratory, inpatient wards including ICU and cardiothoracic surgical division.
2- Registration of all the clinical data of the patient in files, taking photomicrography for the patients.
3- Screening of the sibs of the proband case for detection of asymptomatic cases through echocardiographic examination.
4- Describe full report of echocardiographic examination for proper diagnosis of the cases.
5- Perform catheterization if needed for proper delineation of the lesion and its complexity, hemodynamic sequelae.
6- Extraction of DNA from blood samples from the proband and his parents.

Role of Human genetic Department, NRC in the project:

1-Registration of all the clinical data of the patient in files, taking photomicrography for the patients.
2-Constructing family pedigree in order to know all affected members and bringing them to clinical attention.

	Role of Public Health, Cairo University: Anticipated exposure measures include: -Environmental samples from air , dust, water -Biomarkers for chemicals: blood, breast milk. -Interview & history -Serology and medical data -Housing and living characteristics -Family and social experiences. -Neighborhood & community characteristics
Keywords	Congenital heart disease/ syndromic/non-syndromic/right-left heart obstructive lesions/conotruncal anomalies/shunt lesions/cyanotic/non-cyanotic heart diseases/echpcardiography/catheterization/environmental impact/genetic basis/human genetic/family degree/consanguinity/

Profile of Partner Sought

Role	☐ **technology development** ☑ **research** ☑ **training** ☑ **dissemination** ☑ **demonstration** ☐ **other**

If another role expected, please specify it here

Coordinator and Partners	
Country /region	All country
Start of partnership	◉ **start-up phase** ○ **mid-term** ○ **end-phase**
Expertise required	Molecular genetic field specially for congenital heart disease Epidemiologist interested in the field of pediatric cardiology

I agree with the publication of my data
Please fill-in and return it to:
Egyptian National Scientific & Technical Information Network (ENSTINET)
By email to: *fp7@sti.sci.eg*
By fax. To: (+202) 7947807

EU Funded Research Project
Organization/SME Profile Form

I. ORGANIZATION DETAILS:

Organization	Pediatric Cardiology	**Department**	Pediatrics, Cairo University, Egypt
Contact person	Hala Mounir Agha		
Email	Agha.hala@gmail.com		
Address	12 Mohamed Morsy street, El Haram, Giza		
Postcode	12111	**City**	Giza
Country	Egypt		
Telephone	+202-5856985	**Fax**	
Website			

Description of Research activity:

Activities Performed:

The Division of Cardiology has active research programs in numerous clinical research areas. Active clinical investigation is ongoing in several areas with trial for extramural funding. These areas of interest are including:

-The Molecular and Genetic Cardiology Program; the purpose of this program is to have an important impact on the understanding of the etiologies of cardiac malformations for early diagnosis and treatment of pediatric cardiovascular disorders in the future. This program aims to translate molecular science to the field of clinical Pediatric Cardiology.

- The Preventive Cardiology Program; it focuses on the factors that increase the risk of developing heart disease, not only as children, but also in adults. Many adults who develop heart disease are at risk for this because of problems identifiable in childhood. Modification of these risk factors in childhood may have the most significant impact on changing the chances for developing cardiac problems as adults. The clinical programs include the rheumatic fever and rheumatic heart disease clinic, congenital heart diseases clinic, cardiomyopathy clinic, electrophysiology clinic and the hypertension clinic.

Research priority:

-Genetic basis of cardiovascular malformations

-Preventive aspects of pediatric cardiological problems ; congenital and acquired heart diseases specially rheumatic heart diseases.

-Epidemiological backgrounds; morbidity and mortality in cardiac disorders including preoperative and postoperative cases.

-Recent therapeutic modalities for cardiovascular problems; either pharmacological, interventional catheterization, surgical procedures or hybrid techniques

Expected results for your organization: Prevention of theses disorders is a big issue. Research into genetic and environmental risk factors is therefore critical in identifying clues to causation and prevention. The increase number of patients with CHD, the presence of families having more than one affected child with psychological and financial burden which could be impacted on the family as well as the enormous portion of the national income which is spent in the treatment of these patients. These expenses could be spared by establishing a proper strategy and plan for prevention of these disorders

I agree with the publication of my data
Please fill-in and return it to:
Egyptian National Scientific & Technical Information Network (ENSTINET)
By email to: *fp7@sti.sci.eg*
By fax. To: (+202) 7947807

1.

PARTNER is looking for a Project

1.) PARTNER OFFERED

Organisation	FUNDACIÓN GAIKER	Type of organisation (IND, SME, RES, HE, others)	RTD
Contact person	EMELINE POSTIGO		
Email	POSTIGO@GAIKER.ES		
Telephone	(0034) 94-600-23-23		
Postcode, city	48190		
Country	SPAIN		
Website	WWW.GAIKER.ES		

Role in desired project	technology development :	research : x	training :
	dissemination :	demonstration :	other :
Expertise offered and what I would like to do	In vitro diagnostics, general diagnostics		

I am familiar with the European Framework Programme :

YES	NO

2.) COORDINATOR / PROJECT sought after **(for proposal submission only)**

WP topic : 1.2-5;Standarisation and improvement of preanalytical procedures for in vitro diagnostics.

Project type

Large scale integrating collaborative project	X
Small or medium-scale focussed research project	
Collaborative projects targeted to SMEs	
CA or SSA	
Network of Excellence	

Keywords of project:	

I AGREE WITH THE PUBLICATION OF MY DATA

PARTNER is looking for a Project

1.) PARTNER OFFERED

Organisation	FUNDACIÓN GAIKER	Type of organisation (IND, SME, RES, HE, others)	RTD
Contact person	EMELINE POSTIGO		
Email	POSTIGO@GAIKER.ES		
Telephone	(0034) 94-600-23-23		
Postcode, city	48190		
Country	SPAIN		
Website	WWW.GAIKER.ES		

Role in desired project	technology development :	research : x	training :
	dissemination :	demonstration :	other :
Expertise offered and what I would like to do	Diagnostic		

I am familiar with the European Framework Programme :

YES	NO

2.) COORDINATOR / PROJECT sought after **(for proposal submission only)**

WP topic : 1.2-6: High throughput molecular diagnostics in individual patient for genetic diseases with heterogeneous clinical presentation

Project type		
	Large scale integrating collaborative project	
	Small or medium-scale focussed research project	x
	Collaborative projects targeted to SMEs	
	CA or SSA	
	Network of Excellence	

Keywords of project:	Diagnostic, general diseases, molecular.

I AGREE WITH THE PUBLICATION OF MY DATA

PARTNER is looking for a Project

1.) PARTNER OFFERED

Organisation	FUNDACIÓN GAIKER	Type of organisation (IND, SME, RES, HE, others)	RTD
Contact person	EMELINE POSTIGO		
Email	POSTIGO@GAIKER.ES		
Telephone	(0034) 94-600-23-23		
Postcode, city	48190		
Country	SPAIN		
Website	WWW.GAIKER.ES		

Role in desired project	technology development :	research : x	training :
	dissemination :	demonstration :	other :
Expertise offered and what I would like to do	Diagnostic, genomic and molecular biology.		

I am familiar with the European Framework Programme :

YES	NO

2.) COORDINATOR / PROJECT sought after **(for proposal submission only)**

WP topic : 2.1.2-5 Multidisciplinary fundamental genomics and molecular biology approaches to study basic biological processes relevant to health and diseases.

Project type

Large scale integrating collaborative project	
Small or medium-scale focussed research project	x
Collaborative projects targeted to SMEs	
CA or SSA	
Network of Excellence	

Keywords of project:	Diagnostic, genomics, molecular biology.

I AGREE WITH THE PUBLICATION OF MY DATA

PLEASE FILL IN THE PROFILE FORM AND RETURN IT TO:

4.

1.) PARTNER OFFERED

Organisation	SISTEMAS GENÓMICOS S.L.	Type of organisation (IND,	SME

		SME, RES, HE, others)	
Contact person	David Garcia		
Email	david.garcia@sistemasgenomicos.com		
Telephone	902364669		
Postcode, city	46980 Paterna		
Country	SPAIN		
Website	www.sistemasgenomicos.com		

Role in desired project	technology development : X	research : X	training : X
	dissemination :	demonstration : X	other : X
Expertise offered and what I would like to do	Sistemas Genómicos SL is a biotech company specialised in genetic testing and genome research. The company is the largest privately owned organisation providing DNA analysis in Spain and the only one that has taken part in international genome sequencing projects. Our works in the biomedical field include diagnosis of genetic diseases, rare disease and preimplantation genetic diagnosis. Nowadays we are carrying out the project: "New therapeutic approaches for myotonic dystrophy: functional genomics and in vivo drug discovery studies", aiming to discover new therapeutic targets in dystrophia miotonica. In addition we are part of the Tomato Genome Sequencing Consortium. We offer our expertise in genome sequencing and RT-PCR analyses to any project related to molecular biology.		

I am familiar with the European Framework Programme:

YES X	NO

2.) COORDINATOR / PROJECT sought after (for proposal submission only)

WP topic : HEALTH-2007-1.2-6

Project type		
	Large scale integrating collaborative project	X
	Small or medium-scale focussed research project	X
	Collaborative projects targeted to SMEs	X
	CA or SSA	X
	Network of Excellence	

Keywords of project:	Molecular biology, biotechnology, cancer, oncology, rare diseases, genetic diseases, PGD, sequencing, RT-PCR, dystrophia, allergen, GMO, product authentification,

I AGREE WITH THE PUBLICATION OF MY DATA
PLEASE FILL IN THE PROFILE FORM AND RETURN IT TO: velasco_cristina@cdti.es

1.) PARTNER OFFERED

Organisation	SISTEMAS GENÓMICOS S.L.	Type of organisation (IND, SME, RES, HE, others)	SME
Contact person	David Garcia		
Email	david.garcia@sistemasgenomicos.com		
Telephone	902364669		
Postcode, city	46980 Paterna		
Country	SPAIN		
Website	www.sistemasgenomicos.com		

Role in desired project	technology development : X	research : X	training : X
	dissemination :	demonstration : X	other : X
Expertise offered and what I would like to do	Sistemas Genómicos SL is a biotech company specialised in genetic testing and genome research. The company is the largest privately owned organisation providing DNA analysis in Spain and the only one that has taken part in international genome sequencing projects. Our works in the biomedical field include diagnosis of genetic diseases, rare disease and preimplantation genetic diagnosis. Nowadays we are carrying out the project: "New therapeutic approaches for myotonic dystrophy: functional genomics and in vivo drug discovery studies", aiming to discover new therapeutic targets in dystrophia miotonica. In addition we are part of the Tomato Genome Sequencing Consortium. We offer our expertise in genome sequencing and RT-PCR analyses to any project related to molecular biology.		

I am familiar with the European Framework Programme:

YES X	NO

2.) COORDINATOR / PROJECT sought after (for proposal submission only)

WP topic : HEALTH-2007-1.4-6

Project type	Large scale integrating collaborative project	X
	Small or medium-scale focussed research project	X
	Collaborative projects targeted to SMEs	X
	CA or SSA	X
	Network of Excellence	

Keywords of project:	Molecular biology, biotechnology, cancer, oncology, rare diseases, genetic diseases, PGD, sequencing, RT-PCR, dystrophia, allergen, GMO, product authentification,

I AGREE WITH THE PUBLICATION OF MY DATA
PLEASE FILL IN THE PROFILE FORM AND RETURN IT TO: velasco_cristina@cdti.es

PARTNER is looking for a Project

1.) PARTNER OFFERED

Organisation	FUNDACIÓN GAIKER	Type of organisation (IND, SME, RES, HE, others)	RTD
Contact person	EMELINE POSTIGO		
Email	POSTIGO@GAIKER.ES		
Telephone	(0034) 94-600-23-23		
Postcode, city	48190		
Country	SPAIN		
Website	WWW.GAIKER.ES		

Role in desired project	technology development :	research : x	training :
	dissemination :	demonstration :	other :
Expertise offered and what I would like to do	Proteomics, diagnostic.		

I am familiar with the European Framework Programme :

YES	NO

2.) COORDINATOR / PROJECT sought after **(for proposal submission only)**

WP topic : 2.3.1-1: Novel targets for drugs against Gram negative bacteria.

Project type

Large scale integrating collaborative project	
Small or medium-scale focussed research project	x
Collaborative projects targeted to SMEs	
CA or SSA	
Network of Excellence	

Keywords of project:	Gram bacteria. Diagnostic.

I AGREE WITH THE PUBLICATION OF MY DATA

PLEASE FILL IN THE PROFILE FORM AND RETURN IT TO:

PARTNER is looking for a Project

1.) PARTNER OFFERED

Organisation	FUNDACIÓN GAIKER	Type of organisation (IND, SME, RES, HE, others)	RTD
Contact person	EMELINE POSTIGO		
Email	POSTIGO@GAIKER.ES		
Telephone	(0034) 94-600-23-23		
Postcode, city	48190		
Country	SPAIN		
Website	WWW.GAIKER.ES		

Role in desired project	technology development :	research : x	training :
	dissemination :	demonstration :	other :
Expertise offered and what I would like to do	diagnostic. Research,		

I am familiar with the European Framework Programme :

YES	NO

2.) COORDINATOR / PROJECT sought after **(for proposal submission only)**

WP topic : 2.3.1-3: An integrated platform for development and clinical evaluation of point of care diagnostic devices for microbial detection antibiotic susceptibility determination and biomarkers.

Project type

Large scale integrating collaborative project	x
Small or medium-scale focussed research project	
Collaborative projects targeted to SMEs	
CA or SSA	
Network of Excellence	

Keywords of project:	Diagnostic, microbial detection

I AGREE WITH THE PUBLICATION OF MY DATA

Partner Search Form

Date: 17/6/2007	Deadline:

Contact

Organization	Faculty of Medicine for Girls Al-Azhar Univeristy	**Department**	Obstetrics & Gynecology
Contact person	Dr. Monira M. Gad		
Email	monira.gad@gmail.com		
Address	39 Kaboul Street Nasr City		
Postcode		**City**	Cairo
Country	Egypt		
Telephone	+20101401089	**Fax**	
Website	*http://www.fmg-azhar.edu.eg*		

Familiar with the European Framework Programme? ***YES***

PROJECT

Title:	**Acronym:**

Project type	☑ **Large-scale integrating collaborative project**
Status	☑ **Planned for submission**
Call references	☑ **2nd Call**

Priorities' Main Research Areas (Topics from Workprogramme)	- HEALTH-2007-2.4.1-10: Role of inflammation in tumour initiation and progression. - HEALTH-2007-2.4.1-11: Epidemiology of gene-environment interactions involved in carcinogenesis.
Idea of the project	The aim of the project is to study the prevalence of Cervical Intraepithelial Neoplasia and genotype of Human Papillomavirus among Mediterranean females and geno-environmental interaction involved to develop cancer. The study will include prevention techniques.
Keywords	Human Papillomavirus genotype, Cervical Intraepithelial Neoplasia, screening

Commitment/Work to be offered	- Using invasive & non-invasive technique for the detection of CIN with data collection. - Training for detection of CIN - Detection of HPV
Partners already involved	

Profile of Partner Sought

Role	**☑ technology development ☑ research ☑ training ☑ dissemination ☑ demonstration**

If another role expected, please specify it here

Coordinator/Partners

Country /region	All
Start of partnership	☐ **start-up phase** ☐ **mid-term** ☐ **end-phase**
Expertise required	- New genotype detection technology of HPV - Extracting DNA virus from Paraffin blocks - Confirming the genotype detected by sequencing

I agree with the publication of my data

Please fill-in and return it to:
Egyptian National Scientific & Technical Information Network (ENSTINET)
Egypt National Contact Point for Health
By email to: *fp7@sti.sci.eg*
By fax. To: (+202) 7947807